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Abstract 
 
The thesis describes the molecular genetic analysis of fifty low-grade paediatric 
astrocytomas. DNA copy number changes were investigated in paediatric low-grade 
astrocytomas (WHO grade I and II), using array comparative genomic hybridisation and 
Affymetrix 250K and 6.0 SNP arrays. A discrete region of DNA copy number gain was 
identified at chromosome 7q34, primarily although not exclusively in pilocytic 
astrocytomas of the cerebellum. Further analysis of this region, by PCR and sequencing, 
demonstrated the presence of gene fusions between KIAA1549 and BRAF. Five KIAA1549-
BRAF fusion variants were subsequently identified. A further gene fusion between 
SRGAP3 and RAF1 was also found in a single tumour with DNA copy number gain at 
chromosome 3p25. The fusion genes lacked the auto-inhibitory domains of BRAF and 
RAF1. These were replaced in-frame by N-terminal segments of KIAA1549 and SRGAP3, 
respectively, conferring constitutive kinase activity. 
 
Sequencing confirmed the presence of activating mutations in KRAS and BRAF in three 
tumours where gene fusions were not identified. Both gene fusions and activating 
mutations were shown to cause activation of the ERK/MAP kinase pathway by Western 
blotting. Further sequencing was performed of CDKN2A, PTEN and IDH1/2 to assess the 
frequency of abnormalities in paediatric low-grade astrocytoma.  These genes have 
previously been found to contain aberrations within adult high-grade astrocytomas. To 
date, no significant aberrations have been identified in the paediatric astrocytoma samples 
examined. This confirms previous findings in adult and paediatric astrocytomas, which 
appear to show distinct molecular changes depending on patient age. 
 
Gene fusions or activating mutations were identified in 100% pilocytic astrocytomas 
studied and were also found in 28% of grade II astrocytomas. These findings highlight the 
importance of the ERK/MAPK pathway both in the development of paediatric low-grade 
astrocytomas and as a possible therapeutic target. Gene fusions may provide a means of 
molecular classification for pilocytic astrocytomas in the future.   4
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Chapter 1. Introduction 
 
Cancer is a genetic disease, which is globally responsible for one in eight deaths (Stratton 
et al., 2009). Hippocrates (460-370 BC) based the earliest theory on the origins of cancer 
on the accumulation of an excess of ‘black bile’; imbalances of any of the four humours 
were thought to be responsible for all illnesses (reviewed by Weinstein) (Weinstein et al., 
2008). However, this theory was discarded when anatomic dissection during the 
Renaissance failed to identify the existence of ‘black bile’. Further credible theories on the 
origins of cancer did not develop until the nineteenth century, when microscopy enabled 
Virchow to propose that cancer was a disease of cells. Observations of dividing cancer 
cells by von Hansemann and Boveri in the late nineteenth and early twentieth centuries 
linked the presence of chromosomal aberrations to cancer for the first time (Mitelman et 
al., 2007). 
 
The identification of DNA as the molecular basis of inheritance by Avery et al. in 1944, 
and the elucidation of its molecular structure by Watson and Crick in 1953 suggested that 
cancer was caused by mutations arising from DNA damage (Watson et al., 1953, Avery et 
al., 1944). More detailed cytogenetic analysis revealed the presence of specific and 
recurrent genetic aberrations in cancer, such as the Philadelphia translocation between 
chromosomes 9 and 22 in chronic myeloid leukaemia (Rowley, 1973). Normal NIH3T3 
cells were transformed into cancer cells by the introduction of total genomic DNA from 
human cancer cells (Krontiris et al., 1981, Shih et al., 1981). These findings led to the 
discovery of the first activating point mutation to cause human cancer in 1982: the single 
base substitution from guanine to thymine which leads to a substitution of valine for 
glycine in the gene HRAS (Tabin et al., 1982, Reddy et al., 1982).  
 
The field of cancer genetics has grown rapidly over the last thirty years. The search for 
aberrations within genes and molecular pathways in the most common form of childhood 
brain tumour forms the basis for the work presented within this thesis.   19
1.1   Cancer biology – an overview 
 
Cancer is characterised by the progressive growth of neoplastic cells, which have clonally 
expanded to create an abnormal tissue (Croce, 2008, Stratton et al., 2009, Vogelstein et al., 
2004). All cancers contain aberrations that impair normal physiological processes within 
cells, causing them to gain new and pathological abilities to develop malignancy. These 
changes lead to the development of the ‘hallmarks of cancer’ described by Hanahan and 
Weinberg in 2000: where cancer cells display limitless replicative potential, self-
sufficiency in growth signals and insensitivity to signals inhibiting growth, sustained 
angiogenesis, evasion of apoptosis, chromosomal instability and the ability to invade and 
metastasise (Hanahan et al., 2000). Each represents the failure of a cellular surveillance 
system designed to protect against cancer. Several or indeed all of these hallmarks of 
cancer may be accumulated during the development of cancer, and they may occur in any 
order. Some tumours may accrue several changes simultaneously. For example, the loss of 
function of the TP53 tumour suppressor gene may promote angiogenesis and the 
development of chromosomal instability in addition to evading apoptosis (Levine, 1997). 
 
All cancers, however diverse they may be, are thought to share a common evolutionary 
pathway (Cahill et al., 1999, Greaves, 2007). A normal cell is transformed into a cancer 
cell through the accumulation of genetic and/or epigenetic changes. In general these are 
somatic changes, but aberrations may occur in germline DNA, leading to hereditary cancer 
predisposition syndromes such as Li-Fraumeni syndrome, where germline mutations occur 
in the TP53 tumour suppressor gene (Malkin et al., 1990). Cancer cells often display 
genomic instability, allowing the cells to accumulate changes ranging from single point 
mutations, deletions or amplifications, to complex aberrations including translocations or 
whole chromosome gains or losses (Lengauer et al., 1998).  
 
   20
1.2   Genetic and epigenetic changes in cancer – a genomic 
disease 
 
Genetic changes occur often in normal cells, however cellular surveillance systems exist to 
monitor DNA sequence integrity and facilitate repairs to DNA sequence errors or strand 
breakages (Hanahan et al., 2000, Loeb, 1991). The tumour suppressor protein p53 plays a 
vital role here: in response to DNA damage p53 may cause cell cycle arrest to allow repair 
to occur, or may initiate apoptosis leading to cell death if the damage is severe. Loss of 
function of the p53 DNA damage repair pathway has been found in the majority of human 
cancers, highlighting the importance of this pathway in maintaining the integrity of normal 
cells (Levine, 1997). 
 
Cancers result from modifications of the DNA sequence within oncogenes and tumour 
suppressor genes, which can occur by many different mechanisms (Croce, 2008, Mitelman 
et al., 2007). However, cancer may also result from epigenetic modifications affecting 
levels of gene expression where the DNA sequence is not altered (Esteller et al., 2001). 
Hence, it may be more correct to term cancer a genomic and epigenomic disease rather 
than a genetic disease. Epigenetic modifications include DNA methylation and chromatin 
remodelling (Mathews et al., 2009). Non-coding RNAs including microRNAs have also 
been identified as important post-transcriptional regulators since they target specific 
messenger RNAs (mRNAs) for degradation or translational repression, and these may also 
be regulated epigenetically (Saito et al., 2006). 
 
DNA copy number changes can lead to the activation of oncogenes, inactivation of tumour 
suppressor genes (TSGs) and alterations in the levels of microRNAs (Croce, 2008). Boveri 
proposed in 1914 that in every normal cell there was a ‘specific arrangement for inhibiting, 
which allows the process of division to begin only when the inhibition has been overcome’ 
and that ‘cells of tumours with unlimited growth would arise if those inhibiting 
chromosomes were eliminated’ and conversely that cells also contained chromosomes 
which ‘promote division’, thus stimulating cell growth (Boveri, 1914, as reviewed by   21
Knudson, 2001(Knudson, 2001, Boveri, 1914)). This theory anticipated the discovery of 
oncogenes and tumour suppressor genes over 60 years later. 
1.2.1   Oncogenes  
 
Oncogenes were initially thought to be transmissible pieces of viral DNA from 
retroviruses, and were believed to be the underlying cause of all cancer in humans. Rous 
demonstrated that injection of a cell-free extract from chicken tumour cells induced tumour 
formation in healthy chickens (Rous, 1911). This extract was found to contain the Rous 
Sarcoma retrovirus (RSV), which induced the formation of sarcomas in chickens. In fact 
the transmissible agent was not the virus itself, but a nucleotide sequence encoding the 
gene v-src present in RSV and related to nucleotide sequences found in normal chicken 
DNA. This led to the discovery of the first oncogene SRC, identified by Stehelin et al. in 
1976 (Stehelin et al., 1976). Stehelin, Bishop and Varmus discovered that oncogenes were 
normal genes found in many organisms, which are responsible for controlling cell growth 
and division.  
 
Oncogenes encode proteins that regulate cell proliferation and/or apoptosis, and their 
products may be broadly classified into six groups, as reviewed by Croce in 2008 (Croce, 
2008). These are summarised in Table 1.1. Oncogenes may be activated by genetic 
aberrations such as translocations creating novel gene fusions (e.g. EWS-FLI1 and EWS-
ERG)  or by the addition of novel enhancer or promoter regions to a gene region 
(juxtaposition of MYC to the human immunoglobulin heavy chain enhancer regions in 
Burkitt’s lymphoma)(Joos et al., 1992, Delattre et al., 1994). Oncogenes may also become 
activated by gene amplification (MYCN) or by activating mutations (RAF or RAS genes) 
(Schwab et al., 1983, Downward, 2003). Oncogene activation may confer a growth 
advantage and/or survival advantage, leading to cancer development. 
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Category Examples  Role  of  protein 
Transcription factors  JUN 
 
 
EWS 
 
 
MYC 
Forms AP-1 transcription factor as a dimer with Fos transcription protein, increasing proliferation in osteosarcoma, 
liver and skin cancer (Shaulian et al., 2002, Shaulian et al., 2001) 
 
Translocations create fusion genes between EWS and multiple partners; the resulting fusion proteins drive Ewing’s 
sarcoma formation (Delattre et al., 1994) 
 
Involved in translocations with IGH in Burkitt lymphoma and in numerous other malignancies. Amplification of 
MYC is seen in medulloblastoma and neuroblastoma (Joos et al., 1992, Schwab et al., 1983) 
Chromatin remodelling  MLL MLL may fuse with multiple partner genes, creating fusion proteins which modulate nucelosomes and histones and 
deregulate homeobox genes in acute leukaemias (ALL and AML) (Nakamura et al., 2002) 
 
Growth factors  PDGF  Overexpression of platelet derived growth factor (PDGF) induces unregulated cell growth, for example in 
glioblastoma (Hermansson et al., 1988) 
 
Growth factor receptors  EGFR  Deletion  of  the ligand-binding domain or mutations in the epidermal growth factor receptor (EGFR) leads to 
constitutive activation of the receptor, as seen in glioblastoma (Huang et al., 1997) 
 
Signal transduction: 
1) Tyrosine kinases 
 
 
2) Serine/threonine kinases 
 
 
ABL 
 
 
AKT 
 
The ABL-BCR fusion gene in chronic myeloid leukaemia encodes a constitutively activated tyrosine kinase (Lugo et 
al., 1990) 
 
Protein kinases from the AKT family display constitutive activation in many cancers, promoting cellular survival and 
resistance to chemotherapy and radiotherapy (Brunet et al., 1999) 
 
Apoptosis regulation  BCL2 BCL2  is constitutively expressed after forming a fusion gene with the IGH locus in follicular lymphomas. BCL2 
encodes a cytoplasmic protein that inhibits apoptosis, increasing cell survival (Tsujimoto et al., 1984, Tsujimoto et 
al., 1985) 
 
 
Table 1.1 General classification of oncogenes according to the type of protein produced, with examples for each category (adapted from 
Croce, 2008) 23 
1.2.2   Tumour suppressor genes 
 
Knudson first proposed the concept of tumour suppressor genes from studying the 
incidence of retinoblastoma (Knudson, 1971). Hereditary retinoblastoma is an 
autosomal dominant condition, generally leading to bilateral tumour development in the 
retina of children. Sixty percent of retinoblastoma cases are hereditary, and of these 
80% arise bilaterally. Retinoblastoma may also occur de novo; these cases are always 
unilateral. Using incidence data for bilateral and unilateral retinoblastoma, Knudson 
was able to generate models for the number of mutations required to develop disease. 
He predicted that bilateral retinoblastomas (which already contained a germline 
mutation) required one further mutation to arise, and that unilateral retinoblastomas 
required two somatic mutations to occur – thus proposing the ‘two-hit hypothesis’. 
These data were supported by the knowledge that children born to a parent affected by 
retinoblastoma did not always develop retinoblastoma themselves, but could have 
affected children. Hence the concept arose that both alleles of a tumour suppressor gene 
must be inactivated before tumorigenesis can occur. This prediction was confirmed by 
the identification of recessive mutations in the two alleles of the retinoblastoma gene 
(RB), the first tumour suppressor gene to be cloned (Friend et al., 1986). 
 
Inactivation of tumour suppressor genes following the ‘first-hit’ may occur by a variety 
of different genetic methods, as shown in Figure 1.1. Epigenetic changes such as DNA 
hypermethylation may also inactivate tumour suppressor genes. 
 
TP53 was initially identified as a tumour suppressor gene in colorectal cancer. Studies 
using SV40 virus for malignant transformation of cells identified TP53, and analysed 
the coding sequence. Mutations in TP53 were later found in two colorectal carcinomas: 
both of which had deletions at 17p13 and both were shown to express TP53 from the 
remaining allele (Baker et al., 1989). Germline mutations in TP53 are found in patients 
with Li-Fraumeni syndrome, a hereditary syndrome that predisposes to numerous 
tumours including breast, lung, colorectum and brain. The p53 protein acts as a cellular 
checkpoint, integrating responses through the cell cycle and DNA repair processes and 
balancing levels of cell growth and apoptosis in response to internal and external signals 
(reviewed by Finlay in 1989 and Knudson in 2001) (Knudson, 2001, Finlay et al., 
1989). Inactivation of TP53 and RB or inactivation within their genetic pathways has  24
been implicated in the development of the majority of human cancers. TP53 is part of a 
complex cellular surveillance system for monitoring DNA damage, inducing cell cycle 
arrest to enable DNA repair to be completed. If the damage cannot be repaired apoptosis 
is triggered. Absence of TP53, BRCA1 and other so-called “caretaker” genes allows 
DNA damage to accumulate, thus facilitating the multi-step process of tumorigenesis 
(Deng et al., 2003, Jackson et al., 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Mechanisms for tumour suppressor gene inactivation (after Knudson, 
1971).  
 
 
1.3   Epigenetic changes in cancer 
 
Epigenetic changes are changes affecting gene expression which are not due to 
alterations in DNA sequence, but are instead related to modifications to the DNA 
molecule (for example by methylation) or to histone proteins which package the DNA 
within the nucleus (Pogribny et al., 2009, Mathews et al., 2009).  
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1.3.1   DNA hypermethylation  
 
DNA hypermethylation is the most fully characterised epigenetic change in cancer. In 
cancer epigenetics, the relative terms ‘hyper-’ and ‘hypo-methylation’ are used in 
comparison to normal non-malignant tissue. DNA methylation is known to vary 
between different tissue types in humans, and also between the same tissues from 
different mammalian species (Gama-Sosa et al., 1983, Ehrlich et al., 1982). Cultured 
cells from tumours also display distinct and changed methylation profiles from non-
cultured cells (Smiraglia et al., 2001). Therefore, for cancer studies it is most useful to 
compare methylation profiles between tumour and matched tissue-specific controls. 
Where this is not possible comparisons should be made between tumour and a range of 
normal tissues (Ehrlich, 2002).  
 
In DNA methylation, a methyl group is covalently added to the fifth carbon atom in the 
cytosine pyridine ring by the action of DNA methyltransferases, resulting in the 
formation of 5-methylcytosine (Chiang et al., 1996). This only occurs where cytosine 
residues are situated next to a guanine nucleotide; here the dinucleotide is termed CpG 
where ‘p’ denotes a phosphate separating the two bases in the same sequence (unlike 
the complementary base pairing of cytosine to guanine bound by hydrogen bonds in the 
DNA double helix) (Esteller et al., 2002). The majority of CpG dinucleotides are found 
in unexpressed heterochromatin, however large regions of CpGs, or ‘CpG islands’ are 
often found within the 5’ regions of genes, containing the promoter, untranslated region 
and sometimes the first exon (Bird, 1986). Around 75% of gene promoters contain CpG 
islands, comprising ~ 7% of all CpGs in the genome (Rollins et al., 2006). The majority 
of CpG islands are not methylated in normal cells. 
 
CpG island methylation is a method of silencing genes at times when their expression is 
not needed (Esteller et al., 2002). DNA methylation is an essential mechanism used to 
control normal cellular functions and development. For example, DNA 
hypermethylation is used to inactivate the genes on one of the two X chromosomes in 
women (Singer-Sam et al., 1993). In cancer, hypermethylation of CpG islands may 
function in the same way as a tumour suppressor gene, by switching off gene expression 
when the gene should be active. Hypermethylation of CpG islands has been found to 
downregulate genes within the RB and TP53  tumour suppressor gene pathways,  26
including p16
INK4α and p14
ARF (Esteller et al., 2000, Robertson et al., 1998, Sakai et al., 
1991).  
 
Hypermethylation leading to the inactivation of O-6-methylguanine-DNA 
methyltransferase (MGMT), which encodes a DNA repair protein, has important 
therapeutic implications in glioblastoma and may be used as a biomarker to direct 
patient treatment (Nagarajan et al., 2009, Hegi et al., 2005). Reduced expression of 
MGMT  due to  promoter hypermethylation leads to a defect in DNA repair, thus 
increasing the sensitivity of cancer cells to DNA damage by alkylating agents such as 
temozolamide. Newly diagnosed glioblastoma patients with hypermethylation of 
MGMT respond well to treatment with temozolamide and radiotherapy and have been 
shown to derive a survival benefit, which is not seen in patients with unmethylated 
MGMT (Hegi et al., 2005).  
 
1.3.2   DNA hypomethylation in cancer 
 
Global DNA hypomethylation is a common finding in many cancers, where malignant 
cells may contain 20-60% less 5-methylcysteine than normal control tissue (Gama-Sosa 
et al., 1983, Feinberg et al., 1983). The loss of DNA methylation appears to be mainly 
from the coding regions and introns of genes, and regions of repetitive DNA sequence. 
The mechanism for de-methylation in cancer is currently unknown, but it is probable 
that multiple processes are involved. Global hypomethylation has been found in ~ 80% 
human glioblastomas (Cadieux et al., 2006). 
 
Levels of DNA hypomethylation are known to increase progressively with age. DNA 
damage, in particular when caused by oxidative stress or exposure to bioflavinoids, 
alcohol and cigarettes may impair the function of DNA methyltransferases leading to 
DNA hypomethylation (Weitzman et al., 1994, Valinluck et al., 2004, Lee et al., 2005b, 
Liu et al., 2007, Seitz et al., 2007). 
 
The degree of DNA hypomethylation appears to correlate with tumour grade, and has 
been used in some cancers as a prognostic biomarker. Demethylation of DNA is 
apparent during premalignant stages of urothelial and ovarian cancers, and the degree of 
hypomethylation increases as the tumour progresses (Widschwendter et al., 2004,  27
Nakagawa et al., 2005, Watts et al., 2008). Hypomethylation of repetitive satellite 
sequences and hypermethylation of promoter CpG islands has been used to distinguish 
between different grades of ovarian cancer (Watts et al., 2008). These data suggest that 
DNA hypo- and hypermethylation are implicated in the process of tumorigenesis, rather 
than being a result of damage to the cell by malignant transformation.  
 
Hypomethylation may also be implicated in creating a suitable environment for 
genomic instability eventually leading to aneuploidy, a common feature of many 
cancers (Eden et al., 2003).  Hypomethylation affects repetitive segments of DNA, 
found at centromeres, pericentromeric or subtelomeric regions and repetitive elements 
such as L1 (long interspersed nuclear elements) and Alu repeats (Bestor, 2005, Howard 
et al., 2008). Hypomethylation of these regions may favour the formation of 
chromosomal aberrations and has been shown to lead to genomic instability in mice. 
 
Finally, a small number of genes have been identified which show aberrant activation 
due to promoter hypomethylation, and are therefore highly expressed in cancer 
(reviewed by Pogribny (Pogribny et al., 2009)). Melanoma antigen family A-1 (MAGE-
1)  gene expression, from the cancer/testis/melanoma antigen family is silenced in 
normal tissues including the brain; it is usually active only in the testis and placenta (Liu 
et al., 2004, Cadieux et al., 2006). Increased expression of MAGE-1 due to specific 
MAGE-1 promoter hypomethylation has been found in glioblastomas and glioblastoma 
cell lines. These increased expression levels also correlated with overall levels of global 
hypomethylation, but were not associated with increased patient age, indicating that 
promoter hypermethylation is a regulatory mechanism for gene silencing (Cadieux et 
al., 2006).  
 
1.3.3   Post-translational histone modifications 
 
DNA is coiled tightly around nucleosome proteins to form chromatin, a DNA-protein 
complex that enables the entire genome to be packaged within the nucleus (reviewed by 
Mathews and Esteller (Esteller, 2008, Mathews et al., 2009)). Each nucleosome is 
composed of eight core histone molecules, with two from each subtype (H2A, H2B, H3 
and H4) (Kornberg, 1974). The histone octamer forms a globular structure (around 
which DNA is coiled), and a flexible histone tail projects from the surface. This histone  28
tail may be modified by numerous means including methylation, acetylation and 
phosphorylation, causing conformational changes in the histone structure or charge and 
hence the nucleosome structure. The conformational changes following histone 
modifications may allow the chromatin to become highly condensed (heterochromatin) 
where gene transcription is silenced, or more ‘open’ and transcriptionally active 
(euchromatin) (Adkins et al., 2004). Histone modifications have been shown to affect 
DNA repair and gene transcription, and may be a method of storing information 
(Jenuwein et al., 2001). The type and site of the modified residue may also influence 
functional outcome. For example transcriptional activation results from methylation of 
H3 at lysine position 4, while transcriptional repression results from methylation of 
lysines at positions 9 or 27 in H3 (Karpf et al., 2005). These and other observations 
have suggested that a ‘histone code’ may form an additional regulatory level for the 
expression of the genetic code (Jenuwein et al., 2001). 
 
Studies of histone modifications in cancers are in their infancy, however initial findings 
suggest that these may become as significant as genetic alterations in the future. 
Mutations have been found in numerous genes involved in modifying histones, 
including histone deacetylases, methyltrasferases and demethylases in glioblastomas, by 
a recent large-scale sequencing study (Parsons et al., 2008). For example, BMI1 is a 
member of the polycomb complex that regulates histone methylation: deletions and 
amplifications of BMI1 are frequent findings in adult astrocytomas, and deletions of 
BMI1 may be associated with poor prognosis in some patients (Hayry et al., 2008, 
Nagarajan et al., 2009). 
 
1.4   MicroRNAs 
 
MicroRNAs (miRNAs) have recently been recognised as key regulatory factors in 
cancer development (Croce, 2008). Unlike oncogenes and tumour suppressor genes, 
which encode proteins, microRNAs encode single strands of RNA between 17-27 
nucleotides long (Visone et al., 2009). MiRNAs were first identified in C. elegans in the 
early 1990s, where small complementary transcripts of the gene lin-4 were found to 
downregulate the function of lin-14 mRNA via an antisense RNA interaction (Lee et al., 
1993, Wightman et al., 1993). These small transcripts of Lin-4  were subsequently 
revealed to be miRNAs.   29
 
Mature miRNAs are formed from longer primary single-strand RNA transcripts, by 
multiple cleavage steps within the nucleus and cytoplasm (Figure 1.2) (Chang et al., 
2007). A miRNA strand is taken up by the RNA-induced silencing complex (RISC). If 
there is perfect sequence complementarity the miRNA-RISC complex may cause 
cleavage of the target mRNA, if the sequence is partially complementary mRNA 
translation may be repressed or the mRNA may be degraded. There are now estimated 
to be between 700-1000 miRNAs in humans. Bioinformatic approaches have predicted 
that each miRNA may downregulate many hundreds of mRNAs, and estimate that 
~30% of all protein coding mRNAs in humans may be regulated by miRNAs 
(Sethupathy et al., 2006). Aberrant levels of miRNA expression are present in many 
diseases including cancer (Visone et al., 2009). They may have similar effects to 
oncogenes or tumour suppressor genes by targeting the messenger RNAs encoding 
proteins implicated in tumorigenesis.  
 
Over-expression of miR-155 has been found in B cell lymphomas and breast, lung, 
colon and thyroid cancers (Eis et al., 2005, Volinia et al., 2006). Transgenic mice 
overexpressing miR-155 in B cells display rapid polyclonal pre-B cell expansion in 
spleen and bone marrow, and go on to develop pre-B cell ALL and high-grade B-cell 
lymphomas (Costinean et al., 2006). The polyclonal nature of the malignancies 
developed by these mice indicates that expression of miR-155 alone may be sufficient 
for cancer development, hence miR-155  may be acting as an oncogene. Recently, 
promoter hypermethylation has been shown to inactivate genes encoding miRNAs, 
showing that epigenetic modifications and miRNAs may work in tandem to regulate 
gene function (Lujambio et al., 2007). 
 
Recent studies have shown the importance of microRNAs in tumorigenesis, progression 
and metastatic processes in cancer, including brain tumours (reviewed by Nicoloso 
(Nicoloso et al., 2008)). Significant overexpression of miR-21 has been found in 
glioblastoma cell lines and tumour samples when compared with control samples (Chan 
et al., 2005). Knockdown of miR-21 using antisense oligonucleotides and sequence 
specific miRNA inhibitors increased cell death by apoptosis in glioblastoma cell lines, 
suggesting that miR-21 upregulation has an anti-apoptotic effect. 
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It is hoped that microRNAs may also be used therapeutically in the future, by 
selectively targeting miRNAs or anti-miRNAs to alter levels of gene expression (Visone 
et al., 2009). Investigation of the roles played by microRNAs will thus form an 
important part of future cancer studies. 
 
 
 
Figure 1.2 MicroRNA generation and function 
Figure adapted from Chang et al. (Chang et al., 2007) 
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1.5   Chromosomal rearrangements in cancer 
 
Normal human somatic cells contain 46 chromosomes, and are described as diploid 
(Heim et al., 2009). Each cell normally contains two homologues of each chromosome 
and two sex chromosomes, one of maternal and one of paternal origin. The short and 
long arms of chromosomes are termed ‘p’ and ‘q’, respectively. Chromosome 
rearrangements in cancer may involve changes in the numbers of chromosomes, termed 
aneuploidy, or aberrations that change the chromosome structure, for example the 
exchange of genetic material between chromosomes, termed translocations. 
Translocations may occur within the same chromosome or between different 
chromosomes. Chromosome segments may be inserted into new positions, inverted (the 
segment is rotated by 180
o), duplicated or deleted. An isochromosome is formed where 
either the long or short arm of a chromosome is lost, with duplication of the remaining 
arm. Translocations may be un-balanced with gain or loss of genetic material, or 
balanced (reciprocal) where no net change occurs. Amplified chromosomal regions may 
be seen as homogeneously staining regions (HSRs) within a chromosome on imaging, 
or as small chromosomes known as double minutes. 
 
Chromosomal aberrations have been described in over 55,000 cases of cancer so far, 
and are catalogued within the Mitelman Database of Chromosome Aberrations in 
Cancer (http://cgap.nci.nih.gov/Chromosomes/Mitelman). Translocations are common 
in cancer, and are not randomly distributed throughout the genome (Mitelman et al., 
2007). Specific chromosomes, regions or chromosomal bands appear to be 
preferentially involved, and some are highly specific for a particular cancer type (Heim 
et al., 2009). Translocations may initiate cancer formation by joining together segments 
of two different genes at the fusion breakpoint (Figure 1.2). This leads to the 
overexpression of an apparently normal gene at one of the breakpoints, or to the 
creation of a hybrid fusion genes (e.g. ABL-BCR and BCL2-IGH, Table 1.1) reviewed 
by Mitelman (Mitelman et al., 2007). 
 
Fusion genes appear to occur at an early stage in cancer development, as they usually 
correlate closely with specific tumour types. In animal models, insertion of a fusion 
construct has been shown to produce the same malignant diseases found in humans with 
the same fusion, for example insertion of an IGH-MYC fusion into mice led to the 
development of B-cell lymphomas (Adams et al., 1985, Daley et al., 1990). Successful  32
treatment has been shown to correlate with a decrease or absence of detectable fusion 
genes, reflecting a reduction in the cancer cells, as shown by monitoring BCR-ABL in 
chronic myeloid leukaemia (Oehler et al., 2003, Deininger et al., 2005). Finally, 
silencing fusion transcripts, using RNA interference in vitro, for example by targeting 
BCR-ABL and MLL-AF4, has been shown to reduce tumour proliferation and reverse 
tumorigenicity (Scherr et al., 2003, Thomas et al., 2005). 
 
 
 
Figure 1.3 Mechanisms for the creation of fusion genes in cancer. 
Figure adapted from Sheer and Shipley, 2005 (Sheer et al., 2005). 
 
 
The first specific and recurrent translocation to be identified in human cancer was a 
translocation between chromosomes 9 and 22 that was identified by Nowell and 
Hungerford in 1960, as an unusually small chromosome in chronic myeloid leukaemia 
(CML) (Nowell et al., 1960). As the discovery was made in Philadelphia, the small 
chromosome was termed the Philadelphia (Ph) chromosome. It was subsequently shown 
to be derived from a reciprocal translocation between chromosomes 9 and 22 (Rowley, 
1973). This is denoted as t(9;22)(q34;q11), describing the exact position of the 
translocation breakpoint, at chromosome band q34 on chromosome 9, and at 22q11 
(Figure 1.3). 
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Figure 1.4 A translocation between chromosomes 9 and 22 at bands 9q34 and 
22q11 results in the Philadelphia chromosome. 
 
 
Molecular analysis of the breakpoint in the 1980s revealed a fusion between the genes 
ABL (v-abl Abelson murine leukemia viral oncogene homolog 1) on chromosome 9 and 
BCR (breakpoint cluster region) on chromosome 22 (Groffen et al., 1984). ABL encodes 
a nuclear tyrosine kinase, the activity of the protein is negatively regulated by the SH3 
domain. In the BCR-ABL fusion, the first exon of ABL is replaced with the first twelve 
or thirteen exons of BCR,  encoding a chimeric serine tyrosine kinase (Heim et al., 
2009). The SH3 regulatory domain from ABL is retained within the fusion, but remains 
in the inactive form; deregulated kinase activity is encoded by a domain within the first 
exon of BCR (Meyn et al., 2006, Lugo et al., 1990). The BCR-ABL protein is located in 
the cytoplasm, and displays deregulated and constitutive kinase activity leading to 
increased cellular proliferation and leukaemic transformation (Lugo et al., 1990). The 
BCR-ABL fusion alone is sufficient to cause CML, and has been successfully targeted 
by a specific inhibitor of the BCR-ABL tyrosine kinase, imatinib mesylate (Gleevec) 
(Druker et al., 2001, Sawyers, 2004). This was such an outstanding success that 
Imatinib is now used as a paradigm to illustrate how other kinase-driven cancers should 
be treated. Imatinib also targets the kinases KIT and PDGFR in addition to ABL, and is 
additionally used to treat gastro-intestinal stromal tumours. 
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Balanced translocations between the genes EWS and FLI1 are found in 90-95% Ewing’s 
sarcomas and produce novel in-frame fusion proteins containing the N-terminal portion 
from EWS and the DNA-binding C-terminal domain from FLI-1 (Ordonez et al., 2009, 
Arvand et al., 2001). These novel proteins confer increased transcriptional activation in 
multiple signalling pathways critical for cellular growth and proliferation and inhibition 
of apoptosis and senescence, leading to malignant transformation. The presence of 
EWS-FLI1 fusions by FISH or RT-PCR may be used as diagnostic tests for Ewing’s 
sarcomas (Delattre et al., 1994). The presence of specific fusion types may also be used 
to provide prognostic information, for example patients with a fusion between EWS 
exon 7 and FLI-1 exon 6 are reported to have an improved disease-free survival rate 
than patients with different fusion types (reviewed by Riley, (Riley et al., 2003)). These 
fusions are attractive targets for molecularly targeted agents, due to their specificity for 
Ewing’s sarcoma. 
 
The t(8;14)(q24;q32) translocation in Burkitt lymphoma leads to deregulation of the 
oncogene  MYC  (Kuppers, 2005). The fusion causes the first exon of MYC at 
chromosome band 8q24 to be replaced with the regulatory enhancer region for the 
immunoglobulin heavy chain gene (IGH)  at chromosome band 14q32 causing 
constitutive expression of MYC.  This mechanism of gene expression driven by 
immunoglobulin regulatory enhancers is found in over two thirds of mature B-cell 
lymphomas. 
 
The majority of translocations have been identified in leukaemias and sarcomas. This 
has been proposed to be mainly because of the technical difficulties in obtaining 
karyotypes from carcinomas (Heim et al., 2009). However, the balance may shift in the 
future, as new technologies are developed that allow carcinomas to be investigated at 
extremely high resolution. Gene fusions have recently been identified in prostate, lung 
and breast cancers using genome-wide massively parallel sequencing and integrative 
transcriptome sequencing (Ruan et al., 2007, Tomlins et al., 2007, Campbell et al., 
2008). It is possible that all cancers may be found to contain translocations in the future. 
 
Translocations are not always associated with cancers, as they have also been identified 
in individuals without clinical evidence of cancer (Heim et al., 2009). Patients who have 
been successfully treated for leukaemia may retain detectable fusion genes for many 
years without suffering disease relapse. In identical twin studies where one child is  35
affected with leukaemia the concordance rate is ~10% for the second twin, despite both 
being born with the same gene fusion in their lymphocytes (Greaves et al., 2003). TEL-
AML1 and AML1-ETO fusion genes have been identified in the Guthrie blood spots of 
babies, however only around 1% subsequently go on to develop leukaemia (Mori et al., 
2002). These data indicate that the presence of a fusion gene may not be sufficient in 
itself for leukaemia to develop. However, BCR-ABL alone may drive CML as described 
above, and expression of EWS-FLI-1 or the FUS-CHOP fusion proteins alone have been 
shown to transform bone-marrow derived mesenchymal cells into sarcoma-like tumour 
cells in mice (Riggi et al., 2005, Riggi et al., 2006). It appears, therefore, that some 
tumour-specific fusions are sufficient in themselves for the initiation of tumorigenesis. 
An important part of future studies will be to determine which chromosomal aberrations 
are primary ‘drivers’ of the malignant process, conferring a selective advantage, and 
which are acquired as secondary changes or ‘passengers’. 
 
The mechanism(s) by which chromosomal translocations arise are currently unknown, 
however it is likely that DNA double strand breaks occur prior to their formation 
(Mitelman et al., 2007). Chromosomes have been shown to occupy a distinct location 
within interphase nuclei (Cremer et al., 2001, Bolzer et al., 2005). Hence, translocations 
must occur between chromosomes situated near or adjacent to each other. However, the 
nucleus is a dynamic rather than a static structure. It is probable that spatial proximity of 
chromosomes or genomic regions may be related to specific periods of cellular 
proliferation or periods of increased gene expression (Soutoglou et al., 2008). There are 
inherited cancer-predisposition syndromes where DNA has an increased propensity to 
break, including ataxia telangectasia and Nijmegan breakage syndrome, where 
translocations are more likely to occur (Heim et al., 2009).  
 
1.6   Cancer – an accumulation of genetic aberrations 
 
Cancers are thought to arise from the accumulation of genetic aberrations over time, 
following principles of Darwinian evolution (Cahill et al., 1999, Greaves et al., 2003, 
Greaves, 2007). Cells are constantly acquiring genetic changes during their lifetime, and 
natural selection occurs as a result of these genetic changes. Some genetic changes may 
be detrimental to the cell, and undergo repair or bring about apoptosis. However, some 
changes will confer a selective advantage to the cell, and this population will then  36
undergo expansion. Genetic changes can therefore be seen as rate limiting steps within 
the development of a cancer.  
 
Mathematical models, using incidence data based on patient ages, have proposed that 
common epithelial carcinomas seen in adults require between 5-7 genetic changes to 
develop (Armitage et al., 2004, Armitage et al., 1954). Most carcinomas display 
aneuploidy, where cells contain more or fewer than the normal 46 chromosomes (Heim 
et al., 2009). Different cells within the same tumour may also contain different 
chromosome numbers. Some colorectal carcinomas display chromosomal instability 
(CIN), where whole chromosomes may be gained or lost during cell divisions or 
microsatellite instability (MSI), which is associated with inactivations in the DNA 
mismatch repair genes hMLH1 and hMSH2 (Lengauer et al., 1997, Lynch et al., 2003). 
A further subset of colorectal carcinomas contains neither MSI nor CIN (Walther et al., 
2008). MSI is seen in around 15% of colorectal cancers, these tumours usually display 
diploid or near diploid karyotypes. Aneuploidy associated with CIN is found in around 
70% of colorectal cancers, and is associated with a poor prognosis for patients when 
compared to MSI.  
 
Aneuploidy is not always associated with a worse outcome, however. Patient 
stratification according to ploidy is well established in acute lymphoblastic leukaemia, 
and here patients with high hyperdiploidy (51-65 chromosomes) respond better to 
chemotherapy that those with hypodiplody (<46 chromosomes) (Heerema et al., 1999). 
Trisomy 8 is the most common chromosomal aberration found in acute myeloid 
leukaemia (AML), and may be the only change apparent on karyotyping in a small 
subset of patients (Heim et al., 2009). Trisomy 8 may also be found in some cells of 
apparently healthy individuals, not all of whom go on to develop AML (Welborn, 
2004). The significance of aneuplody in cancer remains unclear; deleterious effects are 
not solely due to gene dosage effects. It is uncertain whether aneuploidy represents an 
essential process for the development of some tumours, or whether these are secondary 
changes accrued over time as a result of genetic instability. 
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1.7   Cancer in children – a developmental disease? 
 
Carcinomas comprise the majority of adult cancers, but are rarely seen in children. Over 
50% of childhood cancers are leukaemias and central nervous system tumours (Grovas 
et al., 1997). The accumulation of multiple genetic aberrations over time is a central 
concept within adult cancer biology, proposed to explain the increased incidence of 
cancer with increasing age (Armitage et al., 1954). Children’s cancers develop over a 
much shorter time, and some are even present at birth. It seems likely, therefore, that 
some childhood cancers may require fewer genetic changes to occur, and that some of 
these changes are present within the germ-line or occur in utero (Scotting et al., 2005, 
Knudson, 2001). 
 
Solid tumours in children may arise as a consequence of failures within the normal 
processes of development, and hence cancer may be seen as a ‘developmental disease’ 
in this context. For example, the identification of mutations in the patched gene (PTCH) 
in Gorlin’s syndrome (an autosomal dominant disorder where patients show increased 
risk of nevoid basal cell carcinoma and medulloblastoma) led to the discovery that the 
proliferation of granule cells during normal development of the cerebellum is regulated 
by the sonic hedgehog (SHH) signalling pathway (Hahn et al., 1996, Johnson et al., 
1996, Dahmane et al., 1999). Loss of function mutations in genes within the SHH 
pathway were subsequently discovered in patients with medulloblastoma, including 
PTCH, suppressor of fused (SUFU) and more rarely smoothed (SMO) (Taylor et al., 
2002, Gilbertson, 2004). 
 
Many solid tumours in children are described as ‘embryonal’ as they have an 
undifferentiated histopathological appearance, resembling the corresponding tissue in 
the developing embryo (reviewed by Scotting (Scotting et al., 2005)). These tumours 
may also mimic the biological behaviour of the developing tissue from which they arise. 
In hepatoblastoma, for example, malignant cells secrete α-fetoprotein (AFP), which is 
usually only produced by the fetal yolk sac and developing liver in early fetal 
development, reaching a peak at week 14 of gestation and becoming almost 
undetectable by the age of 1 year (Van Tornout et al., 1997). AFP may be used as a 
diagnostic marker for hepatoblastoma, and as a highly sensitive method of measuring 
tumour response during treatment and follow-up.   38
 
Many childhood tumours have an age-specific incidence; neuroblastoma, 
hepatoblastoma and Wilms’ tumour mainly affect young children aged less than 4 years, 
while Hodgkin’s lymphoma, osteosarcoma and Ewing’s sarcomas are seen more 
commonly in adolescents (Scotting et al., 2005). The peak incidence for bone tumours 
occurs at the same time as the adolescent growth spurt, suggesting that there may be a 
relationship between tumour development and rapid bone growth. Patients with bone 
tumours have generally undergone puberty earlier than their age-matched peers, 
however there are conflicting data on whether these patients are taller than age-matched 
controls (Buckley et al., 1998, Cotterill et al., 2004). 
 
Finally, gene expression studies investigating the profiles from medulloblastoma and 
Wilms’ tumours have shown marked similarities with genes expressed during early fetal 
development of corresponding normal tissues in mice (Dekel, 2003, Kho et al., 2004). 
Taken together, these data appear to suggest that cancers in children may arise from 
defects in the normal processes of growth and development.  
 
1.8   Cancer stem cells 
 
Studies of leukaemias, and more recently of solid tumours suggest that cancer is 
initiated and maintained by a rare fraction of cells with stem cell properties, termed 
cancer stem cells (Singh et al., 2004, Taylor et al., 2005, Singh et al., 2003, Bonnet et 
al., 1997). These cells are phenotypically similar to normal stem cells, but display 
dysfunctional patterns of self-renewal and differentiation. Cancer stem cells were first 
described within acute myeloid leukaemia (AML), where a fraction of CD34
+/CD38
- 
cells were shown to be capable of initiating AML in non-obese diabetic mice with 
severe combined immunodeficiency (NOD-SCID) (Bonnet et al., 1997). These cells 
displayed the same cell surface markers as normal haematopoietic stem cells, 
suggesting that the initiating event in leukaemias occurred in the stem cell compartment.  
 
Similar findings have been made in solid tumours, including paediatric brain tumours. 
Singh et al. established cultures from 14 primary paediatric brain tumours including 
medulloblastomas, pilocytic astrocytomas, grade II astrocytoma, ependymoma and 
ganglioglioma (Singh et al., 2003). Neurospheres formed from a small number of cells  39
(<1%) from all tumour types within 24 to 48 hours. These were found to express the 
surface glycoprotein CD133, which is normally found on neural stem cells. These 
CD133
+ cells displayed properties of self-renewal, proliferation and differentiation and 
were able to recapitulate the original phenotype of the human brain tumours when 
cultured in situ. Furthermore, when CD133
+ cells were selectively sorted from primary 
brain tumours they were able to generate tumours in vivo on transplantation into NOD-
SCID mice and continued to display stem cell properties of self-renewal, proliferation 
and differentiation (Singh et al., 2004). CD133 negative cells stopped proliferating, 
became adherent in culture, and did not form tumours on transplantation into NOD-
SCID mice (Singh et al., 2003, Singh et al., 2004). CD133
+ cells derived from brain 
tumours have been termed brain tumour initiating cells or brain tumour stem cells 
(BTSC). BTSC have also been shown to express nestin, Musashi-1, Sox2 and MELK on 
the cell surface, in addition to CD133 (Sutter et al., 2007). 
 
Brain tumour stem cells isolated from ependymomas have given an insight into the 
possible cell of origin for these tumours. Ependymomas from different sites display 
particular genetic aberrations, suggesting they are molecularly distinct diseases; 
supratentorial ependymomas generally display deletion of CDKN2Aα while spinal 
ependymomas often show deletions at chromosome band 22q12 (Taylor et al., 2005). 
However, gene expression profiles for supratentorial and spinal ependymomas were 
shown to display similar patterns when compared to those from radial glial cells from 
corresponding regions of the developing mouse brain (subventricular zone of the lateral 
ventricles and spinal cord). CD133
+/Nestin
+ tumour cells were subsequently isolated 
from ependymomas. These cells showed similar immunophenotypes to radial glial cells, 
and were able to form tumours with characteristic histopathological features of 
ependymoma when transplanted into NOD-SCID mice. These data suggest that 
ependymomas may arise from radial glia, and hence these may be candidate BTSCs 
found in distinct regions of the central nervous system. 
 
The distinction between CD133
+ brain tumours stem cells and CD133
- cells may not, 
however, be as clear as previously thought. Sequential passage of a pure population of 
CD133
- cells, isolated from primary glioblastomas showed that a small subset of 
CD133
- cells were able to proliferate and produce further neurospheres (Beier et al., 
2007). These contained differentiated cells, showing markers for different neural 
lineages, indicating that some CD133
- cells from tumours may also contain stem cell  40
properties. These observations have been confirmed by further studies performing serial 
passage of glioblastoma xenografts with no detectable CD133 by Western blot analysis 
(Yi et al., 2008). In addition, Yi et al. showed that CD133 is unmethylated in normal 
colon or brain, but is apparently silenced by promoter hypermethylation in some 
colorectal and glioblastoma primary tumours and cell lines, suggesting that CD133 
activity may also be regulated epigenetically. It is therefore possible that some 
glioblastoma cells may not express CD133 due to promoter hypermethylation, but that 
this proportion may be regulated to increase CD133 expression, perhaps during periods 
of rapid tumour growth. Pallini et al. showed that 14/44 glioblastoma tumour samples 
were able to generate BTSC cultures (Pallini et al., 2008). Patients with tumours able to 
generate BTSC cultures had a significantly shorter overall survival than those that did 
not, and higher levels of CD133 and Ki67 expression were also shown to correlate with 
poor patient survival. 
 
1.9   An overview of the mitogen-activated protein kinase 
(MAPK) pathway  
 
An overview of the MAPK pathway is presented here, since work presented in this 
thesis reveals that the RAF protein kinases BRAF and RAF1 within the MAPK pathway 
are critically important in the development of paediatric low-grade astrocytomas. These 
findings will be discussed in detail later.  
 
Protein kinases are enzymes, which are capable of covalently attaching phosphate 
groups to target proteins at particular serine, threonine or tyrosine amino acids.  This 
addition of a phosphate group may affect how the substrate interacts with other proteins, 
alter its propensity for degradation or regulate its enzymatic activity (Johnson et al., 
2002). In the MAPK pathway, many of the substrates are protein kinases, which are 
‘switched on’ by phosphorylation; this in turn allows them to phosphorylate subsequent 
target proteins. 
 
The MAPK pathway is a conserved signalling cascade, which utilizes a series of protein 
kinases to transduce signals from the cell membrane to the nucleus (Figure 1.4). It plays 
a crucial role in mediating a range of biological functions, including cell growth, 
survival and differentiation. The initiating event in MAPK pathway activation occurs  41
when an extra cellular ligand binds to one of several cell-surface receptors. Examples of 
the known cell surface receptors and ligands that may initiate activation of the MAPK 
pathway are shown in Table 1.2. The activated receptor complex then recruits guanine 
nucleotide-exchange factors (GNEFs), such as members of the SOS family. These 
GNEFs displace guanine nucleotides from the membrane-bound RAS proteins, thus 
allowing RAS to bind cytosolic GTP and so adopt its active GTP-bound form (Vetter et 
al., 2001). This process may be reversed by GTPase-activating proteins, such as 
neurofibromin 1 (NF1), which catalyse the conversion of the active GTP-bound form of 
RAS to the inactive GDP-bound form. When RAS is activated, it is capable of 
interacting with more than 20 substrates, including members of the RAF family and 
phosphatidylinositol 3-kinase (PI3K) (Schubbert et al., 2007). This interaction allows 
the three RAF kinases (ARAF, BRAF and RAF1) to phosphorylate MEK1 and MEK2, 
which subsequently activate ERK1 and ERK2. The activated ERK1/2 proteins 
translocate to the nucleus, where they may phosphorylate a number of effector 
molecules such as JUN, ELK1, CREB, TIF-IA and histone H3, which then alter the 
behaviour of the cell (Schubbert et al., 2007, Sharrocks, 2001).  
 
One possible outcome of ERK activation is cell proliferation (Zhao et al., 2003). PI3K, 
which is also activated by RAS proteins, catalyses the phosphorylation of 
phosphatidylinositol-4,5-bisphosphate (PIP2) to generate phosphatidylinositol-3,4,5-
trisphosphate (PIP3). This process is reversed by the 3’-phosphatase PTEN, which 
converts PIP3 back into PIP2. The accumulation of PIP3 leads to the recruitment of 
PDK1 to the membrane where it phosphorylates AKT. Like ERK, AKT can 
phosphorylate a number of different proteins, many of which are involved in cell 
survival (Engelman, 2009). The final target of RAS is RASSF1A, which binds RAS in a 
GTP-dependent manner and primarily mediates apoptosis (Vos et al., 2000). 
 
The MAPK pathway has been found to be constitutively active in a wide range of 
cancers (Mitra et al., 2009, Russo et al., 2009, Espinosa et al., 2007). Most notably, 
alterations in the MAPK pathway have been found in 88% of adult glioblastomas 
(CGARN et al., 2008). Genetic aberrations which contribute to the deregulation of this 
pathway have been found in both the cell-membrane receptors, such as EGFR, ERBB2, 
FGFR1 and PDGFRA, and the downstream cytosolic components NF1, BRAF, HRAS, 
KRAS, NRAS and PTEN (Stratton et al., 2009, Vivanco et al., 2002). This deregulation  42
of the MAPK pathway either occurs as a result of genes with tumour suppressor 
functions being inactivated or oncogenes becoming permanently activated 
 
Figure 1.5 Schematic representation of the MAPK pathway, and the possible 
cellular outcomes from pathway activation. 
 
 
Receptor Ligands  References 
Estrogen receptor  Estradiol 
 
Epidermal growth factor 
(EGF) 
(Migliaccio et al., 1996) 
 
(Bunone et al., 1996) 
Fibroblast growth factor 
receptor 
Fibroblast growth factor  (Muroya et al., 1992) 
Epidermal growth factor 
receptor (EGFR) 
EGF (Heasley et al., 1992) 
E-cadherins  
(cell surface molecules) 
** Ligand independent 
stimulation of EGFR 
(Pece et al., 2000) 
Table 1.2 Examples of cell surface receptors and ligands which may initiate 
activation of the MAPK pathway.  43
1.10   Paediatric brain tumours 
1.10.1   Epidemiology  
 
Brain tumours form the second largest group of childhood cancers after leukaemias in 
children aged 0-14 years. Leukaemias comprise 30% cases, while brain tumours are 
seen in 20-25% cases (Grovas et al., 1997, Peris-Bonet et al., 2006, Arora et al., 2009). 
Overall survival rates have improved markedly for childhood leukaemias over the last 
20 years: 5-year survival rates are now over 80% (Pui et al., 2003). Childhood brain 
tumours have not seen a similar improvement. Hence, brain tumours are the leading 
cause of cancer-related death in children, adolescents and young adults (aged up to 29 
years) (Davis et al., 1998, Baldwin et al., 2004, Geraci et al., 2007).  
 
Arora et al. conducted a recent study on the epidemiology of primary central nervous 
system tumours in England, using national cancer registration data from the Office of 
National Statistics between 1995 and 2003 (Arora et al., 2009). Central nervous system 
(CNS) tumours formed 25% of all tumours seen in children aged 0-14 years, and 9% for 
adolescents and young adults aged between 15-24 years. Primary CNS tumours formed 
2% of all cancers in adults aged 25-84 years.  
 
In young children infratentorial tumours of the posterior fossa predominate, comprising 
around 30% of all CNS tumours seen. The proportion of infratentorial tumours 
decreases with age; the majority of brain tumours in adults and older children arise 
above the tentorium, in and around the cerebral hemispheres (Pollack, 1994, Arora et 
al., 2009). 
 
Astrocytomas are the most common type of brain tumour seen in children. Grovas et al. 
studied incidence data from 2100 hospitals across the United States between 1985-1993, 
estimated to include data from approximately 42% of all childhood cancer patients 
(Grovas et al., 1997). Grovas found 53% of all childhood brain tumours were 
astrocytomas, followed by medulloblastoma (24%) and ependymoma (9%). Arora et al. 
studied incidence data over three different age ranges, and found the prevalence of and 
pathological type of astrocytomas varied with increasing age (Arora et al., 2009). 
Astrocytomas comprised 40% of all CNS tumours in children between 0-14 years; of 
these over 50% were pilocytic astrocytomas (PAs), followed by medulloblastomas  44
(13%) and ependymomas (7%). Astrocytomas formed 30% of CNS tumours in young 
adults aged 15-24 years, of these 25% were PAs. In this age group tumours of the sellar 
region were seen in 16% (the majority of these were pituitary adenomas), 
medulloblastomas and ependymomas together comprised less than 1% of all CNS 
tumours. In adults aged 25-84 years astrocytomas formed 35% of all CNS tumours, the 
majority (67%) were glioblastomas. Metastases to the brain, from primary tumours sited 
elsewhere are very common in adults, seen in 20-40% of cancer patients, however these 
are rarely seen in children (Pollack, 1994, Patchell, 2003). 
 
Overall age-standardized incidence rates (ASR) for paediatric brain tumours are similar 
between Europe and North America, ranging from 29.9 to 35.6 per million person-years 
respectively (Arora et al., 2009, Peris-Bonet et al., 2006). Astrocytoma in children has 
an ASR of 11.8, followed by medulloblastoma (ASR = 6.5) and ependymoma (ASR = 
3.4). The majority of childhood brain tumours occur before the age of 5 years, so 
prenatal factors must be considered important aetiological influences. 
Following this early peak there is a nadir in the incidence of CNS tumours between 15-
19 years, before a further peak in incidence between 75-79 years (Arora et al., 2009). 
These data suggest that genetic factors must play a major role in childhood CNS 
tumours, and that additional genetic and environmental factors may be implicated in the 
development of adult brain tumours.  
 
1.10.2   Aetiological factors 
 
Ionising radiation is the only environmental risk factor to have been clearly implicated 
in childhood brain tumour development. Prenatal exposure to radiation was shown to 
increase the risk of childhood brain tumours (Harvey et al., 1985, Rodvall et al., 1990, 
Doll et al., 1997). Medical practice has changed to avoid the use of X-rays in 
pregnancy, so this aetiology should not be of concern in the future. Children previously 
treated with radiation for cancer have also shown a significant increase (around 22-fold) 
in the incidence of CNS malignancies and a 7-fold increase in all types of secondary 
cancer (Neglia et al., 1991, Meadows et al., 1985). Numerous reviews have been 
performed, considering a wide variety of environmental factors including 
electromagnetic fields, use of mobile telephones and dietary factors, but no additional 
risk factors have been identified to date (Bondy et al., 1994, Baldwin et al., 2004).  45
Families with higher than expected incidence of brain tumours have provided insights 
into the genetic basis of disease. Syndromes including Li-Fraumeni syndrome, tuberous 
sclerosis, Cowden syndrome, Gorlin’s syndrome, Turcot syndrome, and 
neurofibromatosis types I and II are all known to confer an increased risk of childhood 
brain tumours  (Table 1.2) ((Lewis et al., 1983, Blatt et al., 1986, Gorlin, 1987, Li et al., 
1988, Martuza et al., 1988, Miyagi et al., 1995, Gustafson et al., 2007, Napolioni et al., 
2008)). However, these syndromes are rare, and have been estimated to account for less 
than 5% of childhood brain tumours overall (Baldwin et al., 2004, Bondy et al., 1994).  
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Syndrome  Gene  Chromosomal location  Tumour types 
Cowden  PTEN  10q23q31 (Steck et al., 
1997) 
Gangliocytoma  
Hereditary 
retinoblastoma 
Rb  13q14 (Friend et al., 
1986) 
Pineoblastoma, glioma, 
meningioma  
Li-Fraumeni 
 
TP53  17p13.3 (Cogen et al., 
1992) 
PNET, 
medulloblastoma, 
astrocytoma 
Neurofibromatosis 
Type 1 
NF-1  17q11.2 (Ledbetter et al., 
1989) 
Neurofibroma,  
optic nerve glioma, 
astrocytoma 
Neurofibromatosis 
Type 2 
NF-2  22q12.2 (Arai et al., 
1994) 
Schwannoma, 
meningioma,  
spinal ependymoma 
Nevoid basal cell 
carcinoma  
(Gorlin)  
PTCH  9q22.3 (Hahn et al., 
1996) 
Medulloblastoma, 
meningioma 
 
Tuberous sclerosis  TSC1 
 
TSC2 
9q34 (van Slegtenhorst 
et al., 1997) 
16p13.3 (Green et al., 
1994) 
Subependymal giant 
cell astrocytoma 
Turcot  APC 
 
hMLH1 
 
hPMS2 
5q21q22 (Dolan et al., 
1999) 
3p21.3 (Roche et al., 
1996) 
7p22 (Risinger et al., 
1995) 
Medulloblastoma 
astrocytoma, 
ependymoma 
Rubenstein-Taybi  CBP  16p13.3 (Petrij et al., 
1995) 
Medulloblastoma, 
oligodendroglioma, 
meningioma 
 
Table 1.3 Inherited syndromes associated with brain tumours. 
Table adapted from Blaney et al. (Blaney et al., 2006). 
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1.10.3   Early development of the central nervous system 
 
The central nervous system begins to form in the 3
rd week of embryonal development, 
when the ectoderm on the dorsal side of the embryo thickens to form the neural plate 
(Heimer, 1983). The neural plate grows and folds to form the neural tube, which will 
become the brain and spinal cord. As the neural tube closes, cells migrate from the 
lateral portions of the walls to become the neural crest. The two main cell types within 
the brain are derived from the neural crest; neural cells and glial cells. Neural cells 
differentiate into neurons. Glial cells differentiate into four further types of cells: 
astrocytes, oligodendrocytes, ependymal cells and microglia.  
 
Astrocytes supply support and nutrition to neurons and are the most abundant glial cell 
type found in the brain: oligodendrocytes produce the myelin sheath that surrounds 
neurones. Ependymal cells form the lining within the ventricles and the spinal cord, that 
contains cerebrospinal fluid. Microglia are involved in tissue repair and neuronal 
regeneration, and in immune surveillance (Kreutzberg, 1996). They undergo rapid 
proliferation in response to tissue destruction and migrate to the site of injury where 
they phagocytose debris or microorganisms. Microglia promote tissue healing by 
secreting growth factors including IL6 and TGFβ.  
 
The cellular origins for brain tumours have not yet been clearly defined. Astrocytomas 
are thought to be derived from glial cells, specifically astrocytes, which they resemble 
histologically. Similarly oligodendrogliomas are thought to arise from oligodendrocytes 
and ependymomas from ependymal cells (Sanai et al., 2005).  
 
1.10.4   Histopathological classification of paediatric astrocytomas 
 
Astrocytomas are classified into grades I to IV by the World Health Organisation 
(WHO), using defined histopathological and clinical diagnostic criteria reflecting a 
spectrum of biological behaviour (Kleihues et al., 2000, Louis et al., 2007). The WHO 
classification for CNS tumours was first published in 2000 based on the consensus 
recommendations of a working group of experts who met in Lyon in 1999. The fourth 
edition of the WHO classification of tumours of the central nervous system was  48
published in 2007, based on the consensus of 25 pathologists and geneticists (and 
considered additional contributions from a further 70 international experts) (Louis et al., 
2007). These are the standard criteria for the definition of brain tumours throughout the 
world.  
 
The WHO grading is an attempt to predict the behaviour of a tumour; slowly growing 
tumours are graded I or II. Tumours graded III and IV show increased anaplasia, more 
mitotic activity and atypical nuclei, and may contain regions of necrosis reflecting more 
malignant behaviour. All of the work presented in this thesis was conducted on low-
grade (WHO grade I and II) paediatric astrocytomas.  
 
Low-grade astrocytomas (LGAs) are a heterogeneous group of tumours, including 
pilocytic astrocytomas, diffuse astrocytomas (WHO Grade II), pilomyxoid astrocytomas 
(WHO Grade II) and pleomorphic xanthoastrocytomas (WHO Grade II). Pilocytic 
astrocytomas (PAs) are well-circumscribed, slow growing, cystic lesions and are the 
most common type of astrocytoma in children aged 0-19 years (Arora et al., 2009, 
Kleihues et al., 2000). They can arise throughout the brain and spinal cord, but are most 
commonly situated in the cerebellum (Ohgaki et al., 2005b). Pilocytic astrocytomas 
may also arise in the optic pathways (optic pathway gliomas), these tumours are usually 
associated with the tumour predisposition syndrome neurofibromatosis type I (NFI) 
(Rubin et al., 2005, Listernick et al., 2007, Brems et al., 2009). NF1 may be inherited as 
an autosomal dominant disorder or occur following a de novo mutation in the tumour 
suppressor gene NF1, located at chromosome band 17q11.2 (von Deimling et al., 1995). 
NF1 encodes the protein neurofibromin 1, which acts as a negative regulator of the RAS 
signal transduction pathway (Schubbert et al., 2007). Optic pathway gliomas are seen in 
around 15% of patients with NF1, and often behave less aggressively than sporadic 
pilocytic astrocytomas (Listernick et al., 2007).  
 
Subependymal giant cell astrocytoma (SEGA) is also classified as a grade I astrocytoma 
by the WHO. This tumour is associated with tuberous sclerosis, a rare multi-system 
autosomal dominant disease characterised by benign tumours in the brain, kidneys, 
heart, eyes, lungs and skin (Napolioni et al., 2008). Tuberous sclerosis is caused by 
mutations in TSC1  located at chromosome band 9q34 which encodes the protein 
tuberin, or TSC2 located at chromosome band 16p13, encoding hamartin. SEGAs are 
seen in 6-14% patients with tuberous sclerosis, and usually develop in the first two  49
decades of life. SEGAs were excluded from the low-grade astrocytomas included within 
this study. 
 
Diffuse astrocytomas may arise at any site within the central nervous system, but are 
most commonly found in the cerebral hemispheres, particularly the frontal and temporal 
lobes (Kleihues et al., 2000). They are characterised by well-differentiated fibrillary 
astrocytes, showing moderately increased cellularity and occasional nuclear atypia, and 
diffusely infiltrate adjacent normal brain. Diffuse astrocytomas may progress in young 
adults, to form secondary glioblastomas (Ohgaki et al., 2007). 
 
Pilomyxoid astrocytomas were originally described as ‘diencephalic pilocytic 
astrocytoma with clinical onset in infancy’ before being reclassified as a separate entity 
(Janisch et al., 1985). Pilomyxoid gliomas are characterised by myxoid degeneration 
and monomorphic piloid cells (Louis et al., 2007). They are primarily located in the 
hypothalamic/chiasmatic region and appear to have a worse prognosis than pilocytic 
astrocytomas.  
 
Finally, pleomorphic xanthoastrocytomas are typically found in the cerebral 
hemispheres, particularly in the temporal lobe. They may also involve the meninges 
where a cyst may form (Kleihues et al., 2000). These tumours are characterised by large 
xanthomatous cells containing lipid deposits, and generally have a favourable 
prognosis. 
 
1.10.5   Clinical presentation and diagnosis 
 
Brain tumours present in a variety of ways, depending on the age of the child and the 
physical location, type of tumour and the rate of tumour growth (Behrman et al., 1996). 
The most common presenting features are symptoms and signs of raised intracranial 
pressure and focal neurological signs. Tumours situated in the posterior fossa, pineal 
and suprasellar regions are more likely to present with raised intracranial pressure, by 
obstructing the flow of cerebrospinal fluid and producing hydrocephalus (Pollack, 
1994). Tumours situated above the tentorium are more likely to present with focal 
neurological signs and seizures. Most children present with an alteration to their 
personality, they may become irritable, lethargic or forgetful and may perform poorly at  50
school. Many children may also have recurrent episodes of nausea and/or vomiting and 
headaches. 
 
The diagnosis is usually suggested from the patient’s history and by neurological 
examination. Following this, imaging is performed using computerised tomography 
(CT) or magnetic resonance imaging (MRI). CT or MRI appearances may suggest a 
particular tumour type, and will delineate the size and extent of disease. Imaging is also 
important following surgery, where the presence and estimated volume of residual 
disease will direct further treatment decisions. 
 
1.10.6   Treatment 
 
Five-year survival rates for childhood brain tumours range from 64% to 72% across 
Europe and in the United States, respectively (Peris-Bonet et al., 2006). Astrocytomas 
have the best 5-year survival rates for all childhood brain tumours, around 75% (Grovas 
et al., 1997). Low-grade astrocytomas (WHO grades I-II) are less aggressive and more 
responsive to treatment than their high-grade counterparts (WHO grades III-IV). Two-
year progression-free survival rates for children with glioblastoma (WHO grade IV) are 
extremely poor, from 10-30%; 10-year survival rates are >95% for children with 
pilocytic astrocytoma (Broniscer et al., 2004, Burkhard et al., 2003, Gajjar et al., 1997).  
 
The preferred method of treatment for circumscribed low-grade astrocytomas is radical 
surgical excision, and if complete resection is achieved no further therapy is necessary 
(Qaddoumi et al., 2009). However, this may not be possible in cases where the tumour 
is within the brain stem, diencephalon or optic pathways, or where there is a large 
amount of infiltration of adajcent normal tissue. The numerical distinction between 
astrocytomas of grades I-II is not intended to imply that grade II tumours should be 
treated more aggressively. It is often extremely difficult for pathologists to distinguish 
between tumours of grade I and II, particularly as many astrocytomas are 
heterogeneous. 
 
Adjuvant chemotherapy and radiotherapy are used for patients that have unresectable 
tumours and recurrent or metastatic disease. However, these are not always curative, 
and further therapies are needed for such clinical situations. The combination of  51
carboplatin and vincristine is currently the standard approach to treat low-grade 
astrocyotmas in Europe and the United States (Lancaster et al., 2003, Qaddoumi et al., 
2009). Carboplatin allergy is a significant problem with the regimen, and may be seen 
in up to 42% of patients, requiring cessation of treatment with this agent (Lafay-Cousin 
et al., 2008). Alternative chemotherapy regimens include TPCV, comprised of 
thioguanine (T), procarbizine (P), CCNU (lomustine) and vincristine (V), and oral 
temozolamide. There is no apparent difference in the outcome for patients with 
incompletely resected disease treated with TPCV or carboplatin and vincristine (Ater et 
al., 2008). Grade IV astrocytomas (glioblastoma multiforme) are highly malignant, and 
are among the most difficult tumours to treat in children and adults. Changes to 
treatment strategies have made little impact on survival for children with high-grade 
gliomas (HGG) in the last three decades, currently 2-year progression-free survival is 
less than 20% for these patients (Gottardo et al., 2008).  
 
Radiotherapy achieves good tumour response, but is associated with significant neuro-
cognitive and neuroendocrine disabilities, vasculopathy and the risk of second tumours 
(Packer et al., 1987, Packer et al., 2003, Mulhern et al., 2004). Morbidity following 
radiotherapy is particularly prevalent in patients with NF1 (Sharif et al., 2006). In 
general, radiotherapy is delayed until patients are aged > 10 years, or there are signs of 
tumour progression (Pollack, 1994). 
 
1.10.7   Molecular biology of low-grade paediatric astrocytomas 
 
The majority of low-grade astrocytomas appear to display normal karyotypes on 
conventional karyotyping. One hundred and thirteen paediatric pilocytic astrocytomas 
(PAs) and 4 diffuse astrocytomas (DAs) were investigated over eight separate studies 
(Jenkins et al., 1989, Karnes et al., 1992, Agamanolis et al., 1995, Debiec-Rychter et 
al., 1995, White et al., 1995, Bhattacharjee et al., 1997, Bigner et al., 1997, Zattara-
Cannoni et al., 1998). I combined the data from all of these studies: seventy-six PAs 
(67%) and all 4 DAs were found to have apparently normal karyotypes. Thirty PAs 
contained multiple chromosomal aberrations, and 7 contained a single change (usually 
gain of a single chromosome). The most commonly seen aberrations were whole 
chromosome gains of chromosome 7 (16 cases), chromosome 8 (11 cases), chromosome 
11 (10 cases), chromosomes 5 and 6 (5 cases each) and chromosome 12, 15 and 22 (4  52
cases each). Small numbers of chromosome losses were also seen in one or two cases 
for the majority of chromosomes, none were lost with a high prevalence.  
 
Several studies have investigated loss of heterozygosity on chromosome 17 in pilocytic 
astrocytomas from children and young adults. Von Deimling et al. studied 20 PAs, and 
found loss of heterozygosity of loci including NF1 on the long arm of chromosome 17 
in four patients (one patient was known to have NF1) (von Deimling et al., 1993). 
Willert et al. performed mutational analysis for TP53 and studied chromosome arm 17p 
in 8 high-grade astrocytomas and 20 PAs from children (Willert et al., 1995). TP53 
mutations were identified in 1 high-grade astrocytoma and 1 PA. Telomeric losses of 
17p were seen in 6/8 high-grade astrocytomas, and in 2/20PAs. Losses of 17p 
centromeric to TP53 were seen in 3 high-grade astrocytomas and 5 PAs. Four of the 7 
PA patients with 17p deletions suffered disease recurrence within 1-3 years of 
completing treatment, compared to 5/13 PAs without 17p loss. These data suggested 
that genes on 17p might be implicated in disease progression in PAs. Phelan et al. 
conducted mutational analysis for TP53 in 29 paediatric brain tumours, including 7 PAs 
and 2 grade II astrocytomas (Phelan et al., 1995). No mutations were detected in TP35 
for any of the tumours investigated, and no LOH was identified in any of the low-grade 
astrocytomas studied. Finally, Patt et al. conducted mutational analysis for TP53 in 42 
astrocytomas, including 7 PAs and 18 low-grade astrocytomas (Patt et al., 1996). A 
TP53 mutation was found in 1 PA, but this did not lead to a change in the translated 
amino acid sequence. 
 
Sanadou investigated 41 paediatric pilocytic astrocytomas and 7 adult pilocytic 
astrocytomas using comparative genomic hybridisation (Sanoudou et al., 2000). Five of 
the 41 paediatric PAs (12%) showed chromosomal aberrations, all showed gain of a 
single chromosome. Two paediatric PAs showed gains of chromosome 7, the remaining 
three showed gains of chromosomes 5, 6 and 9, respectively. Two of the 7 adult PAs 
(29%) showed multiple chromosomal aberrations. One showed gains of 1p33-pter, 
9q34.1-qter, 17q21.3-ter and whole chromosome gains of 19 and 22. The second 
showed gains of 2p22-pter, 9q31-qter, 12q13.2-q23 and loss of 16q.   
 
Thus, gain of chromosome 7 was the most common copy number aberration found in 
paediatric PAs by conventional cytogenetics and comparative genomic hybridisation. 
These data implied that genes found on chromosome 7 might be involved in the  53
development of paediatric low-grade astroctomas. Studies investigating these tumours 
at higher resolution were required to attempt to identify specific genetic aberrations in 
more detail. 
 
1.11   Astrocytomas in children and adults 
 
Glioblastomas in adults may arise de novo (primary glioblastoma) or evolve from a 
grade II diffuse astrocytoma or grade III anaplastic astrocytoma (secondary 
glioblastoma). The molecular pathways leading to the development of adult primary and 
secondary glioblastomas have been extensively studied and described in detail (Ohgaki 
et al., 2007, CGARN et al., 2008, Parsons et al., 2008). Paediatric high-grade 
astrocytomas are less common than their adult counterparts, and few paediatric high-
grade astrocytomas appear to arise by progression from lower-grade tumours. Less than 
10% paediatric grade II infiltrative astrocytomas undergo malignant transformation to 
high-grade tumours, compared to 50-90% in adult Grade II tumours (Broniscer et al., 
2007).  
 
PTEN mutations and deletions or EGFR amplification, the typical molecular 
characteristics seen in adult high-grade tumours are present in Grade III and IV 
paediatric tumours although they appear to be less common, suggesting that childhood 
tumours may arise via different molecular pathways (Pollack et al., 2006). Similarities 
and differences between the molecular changes found in high- and low-grade adult and 
paediatric astrocytomas will be discussed in detail later. 
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1.12   Aims of this thesis 
 
Despite great technological advances in recent years, little was known about the 
molecular biology of paediatric low-grade astrocytomas at the start of this research, as 
described above. The aims of the research presented in this thesis were: 
 
1)  To identify regions of recurrent DNA copy number gain or loss in low-grade 
paediatric astrocytomas. A detailed genome-wide assessment of grade I and 
II paediatric astrocytomas was performed, initially using array comparative 
genomic hybridisation and later using high resolution single nucleotide 
polymorphism (SNP) arrays. Comparisons were made between pilocytic 
astrocytomas arising in the cerebellum and grade II astrocytomas arising in 
the cerebrum. This work is described in chapter 3 and chapter 4. 
 
2)  To investigate any discrete or recurrent regions of DNA copy number 
change identified, and to determine the significance of genes contained 
within the affected genomic regions. The follow-up of discrete regions of 
copy number gain at chromosome bands 7q34 and 3p25, and the 
identification of specific RAF gene fusions are described in chapter 5. 
 
3)  To investigate candidate genes implicated in adult astrocytoma 
tumorigenesis by mutational analysis. This work is described in chapter 6. 
 
4)  An overview of the findings and their wider significance is discussed in 
chapter 7, and also in the paper ‘Activation of the ERK/MAPK pathway: a 
signature genetic defect in posterior fossa pilocytic astrocytomas’, which is 
bound at the end of the thesis (Forshew et al., 2009). 
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Chapter 2.  Materials and methods 
2.1   Tumour samples 
 
Low-grade astrocytomas (WHO grades I and II) from 50 patients aged 1-20 years were 
obtained from Newcastle General Hospital, United Kingdom and St Jude Children’s 
Research Hospital, Memphis USA in collaboration with Professor David Ellison. 
Access to the tumours and clinical data were in accordance with the Institutional 
Review Board and MREC regulations at all the centres involved in the study: Newcastle 
REC reference number 2002/112; St Jude Children’s Research Hospital reference 
number XPD07-107/IRB and Tissue Resource Request reference number 07-007 and at 
the Institute of Cell and Molecular Science reference number ICMS/PR/09/77.  
 
Thirty-two patients had cerebellar pilocytic astrocytomas (WHO grade I), 11 had 
cerebral diffuse (fibrillary) astrocytomas (WHO grade II), and 5 had midline 
pilomyxoid gliomas. One patient had an infantile hypothalamic pilomyxoid astrocytoma 
(PMA, WHO grade II) and one had a cerebral pleomorphic xanthoastrocytoma (Table 
2.1). All of the patients were negative for Neurofibromatosis type I (NF1) except for the 
infant with a PMA, who had been diagnosed with NF1 on clinical grounds. Tumours 
from the optic pathways were not selected for inclusion in the study, so as to exclude 
optic pathway gliomas occurring secondary to NF1. 
 
All tissue samples were snap frozen in liquid nitrogen at the time of surgical resection, 
and were obtained from patients before any adjuvant therapy was given. Sections (5-
8µm) were prepared from formalin-fixed paraffin-embedded (FFPE) samples of all 
tumours for detailed histopathological review and selected interphase fluorescence in 
situ hybridization (iFISH). 
 
2.2   Control DNA samples 
 
Control DNA was obtained from blood volunteered from fit and healthy co-workers at 
Cancer Research UK London Research Institute. Samples were collected from twenty-
one males and one female.  56
Name Pathology  Site Age    Sex 
PA1 Pilocytic  astrocytoma  Cerebellum  20  F 
PA2 Pilocytic  astrocytoma  Cerebellum  4  M 
PA3 Pilocytic  astrocytoma  Cerebellum  7  M 
PA4 Pilocytic  astrocytoma  Cerebellum  2  M 
PA5 Pilocytic  astrocytoma  Cerebellum  6  F 
PA6 Pilocytic  astrocytoma  Cerebellum  5  M 
PA7 Pilocytic  astrocytoma  Cerebellum  13  M 
PA8 Pilocytic  astrocytoma  Cerebellum  2  M 
PA9 Pilocytic  astrocytoma  Cerebellum  14  F 
PA10 Pilocytic  astrocytoma  Cerebellum  19  M 
PA11 Pilocytic  astrocytoma  Cerebellum  14  M 
PA12 Pilocytic  astrocytoma  Cerebellum  14  M 
PA13 Pilocytic  astrocytoma  Cerebellum  10  M 
PA14 Pilocytic  astrocytoma  Cerebellum  10  M 
PA15 Pilocytic  astrocytoma  Cerebellum  13  M 
PA16 Pilocytic  astrocytoma  Cerebellum  10  M 
PA17 Pilocytic  astrocytoma  Cerebellum  6  M 
PA18 Pilocytic  astrocytoma  Cerebellum  3  M 
PA19 Pilocytic  astrocytoma  Cerebellum  3  M 
PA20 Pilocytic  astrocytoma  Cerebellum  4  M 
PA21 Pilocytic  astrocytoma  Cerebellum  12  F 
PA22 Pilocytic  astrocytoma  Cerebellum  6  F 
PA23 Pilocytic  astrocytoma  Cerebellum  3  F 
PA24 Pilocytic  astrocytoma  Cerebellum  4  F 
PA25 Pilocytic  astrocytoma  Cerebellum  4  F 
PA26 Pilocytic  astrocytoma  Cerebellum  3  F 
PA27 Pilocytic  astrocytoma  Cerebellum  14  F 
PA28 Pilocytic  astrocytoma  Cerebellum  7  M 
PA29 Pilocytic  astrocytoma  Cerebellum  19  M 
PA30 Pilocytic  astrocytoma  Cerebellum  13  F 
PA31 Pilocytic  astrocytoma  Cerebellum  1  F 
PA32  Pilocytic astrocytoma  Brain stem  9  F 
DA1  Diffuse astrocytoma  Cerebral cortex  5  F 
DA2  Diffuse astrocytoma  Cerebral cortex  9  M 
DA3  Diffuse astrocytoma  Cerebral cortex  17  M 
DA4  Diffuse astrocytoma  Cerebral cortex  4  M 
DA5  Diffuse astrocytoma  Cerebral cortex  7  F 
DA6  Diffuse astrocytoma  Cerebral cortex  5  F 
DA7  Diffuse astrocytoma  Cerebral cortex  5  M 
DA8  Diffuse astrocytoma  Cerebral cortex  15  F 
DA9  Diffuse astrocytoma  Cerebral cortex  9  F 
DA10  Diffuse astrocytoma  Cerebral cortex  5  F 
DA11  Diffuse astrocytoma  Cerebral cortex  2  M 
PMA1 Pilomyxoid  astrocytoma  Diencephalon  1  F 
PMG1 Pilomyxoid  glioma  Diencephalon  17  M 
PMG2 Pilomyxoid  glioma  Diencephalon  7  F 
PMG3 Pilomyxoid  glioma  Diencephalon  8  M 
PMG4 Pilomyxoid  glioma  Spinal  cord  12  M 
PMG5 Pilomyxoid  glioma  Spinal  cord  11  F 
PXA1 Pleomorphic 
xanthoastrocytoma 
Cerebral cortex  6  F 
Table 2.1 Summary of clinical and pathological details from 50 patients with low-
grade astrocytomas. Patient ages are shown in years.  57
2.2.1   Control RNA 
 
Total RNA was obtained from normal control brain samples, available commercially 
(BioChain, Hayward, CA).  The samples comprised four fetal brain samples (two from 
cerebellum and two from cerebrum) and 2 adult brain samples (one from cerebellum 
and one from cerebrum)  
2.2.2   Control protein 
 
Total protein was obtained from normal control brain samples, available commercially 
(BioChain, Hayward, CA).  They comprised two fetal brain control samples, one from 
cerebellum and one from cerebrum. 
2.3   Cell lines 
 
Two paediatric medulloblastoma cell lines were obtained from the American Type 
Culture Collection (ATCC). Daoy (HTB186) was originally from a 4 year-old male 
with a posterior fossa medulloblastoma (Jacobsen et al., 1985). HTB-187 (D341) was 
originally from a 3 year-old male with a posterior fossa medulloblastoma (Friedman et 
al., 1988). Cell lines were used as a renewable resource to enable me to optimise 
molecular techniques before using tumour DNA samples. Paediatric medulloblastoma 
lines were selected, as no paediatric astrocytoma cell lines were available. Both cell 
lines were characterised using M-FISH, FISH and array CGH. 
 
2.4   General Methods 
2.4.1   Cell culture 
 
Cells were grown on 75 cm
2  plastic culture flasks, within incubators maintaining a 
temperature of 37
oC and a humidified atmosphere supplemented with 5% CO2. 
 
Daoy and HTB187 are both cultured as monolayers. They were grown in E4 media 
supplemented with 10% fetal calf serum (FCS), 1% 2mM L-glutamine, 1% non-
essential amino acids and 1% 1mM sodium pyruvate, all v/v. Cells were passaged when  58
they reached confluence, usually every 3-4 days. Cells were then washed with 
phosphate-buffered saline (PBS) and detached from the flask by incubating for ~ 3 
minutes with 3ml of a solution containing 0.5% v/v porcine trypsin and EDTA (Gibco, 
Invitrogen) per flask at room temperature. The trypsin digestion was then blocked by 
the addition of excess culture medium containing FCS. Cells were reseeded in two or 
three flasks at ~ 30% confluence, or harvested for the preparation of metaphase spreads 
or extraction of DNA. 
 
2.4.2   Metaphase spread preparation 
 
Prior to the preparation of metaphase spreads from cell lines, 4 drops of colcemid 
(0.05μg/ml, Sigma) were added to each 75cm
2 flask, before returning them to the 
incubator for 1 hour. Colcemid inhibits spindle formation within the cells, so when M-
phase is reached cells are unable to progress further within the cell cycle. Hence, cells 
accumulate in metaphase of mitosis. The duration of exposure to colcemid may be 
varied to alter the length of chromosomes seen within the metaphase spread. For 
example, increased exposure will produce shorter chromosomes. 
 
Cells were detached from the flask with trypsin, re-suspended in 10mls of pre-warmed 
0.075M KCl and incubated at 37
oC for 15 minutes. Following this, the cells were 
centrifuged and the pellet resuspended in 10mls cold 3:1 methanol/glacial acetic acid 
fixative (kept at -20
 oC). This suspension was centrifuged at 1500rpm for 5 minutes  
(ALC centrifuge PK120), and the pellet re-suspended in 1-2 mls of cold fixative. Clean 
glass slides (‘Superfrost’, 1.0mm thick with a frosted end, VWR international) stored in 
100% ethanol were used to make metaphase spreads. Slides were wiped dry of ethanol 
with lint-free tissue paper and then covered with cold 3:1 methanol/glacial acetic acid 
fixative. Following this, 2-3 drops of cell suspension were dropped onto the slide using 
a siliconised glass pipette. Slides were then left to air dry. The quality of the metaphase 
spreads were assessed under a light microscope. The cell suspension was diluted further 
with fixative if the slide had too many overlapping nuclei and metaphase spreads. The 
time of exposure to hypotonic KCl was also adjusted to improve the quality of 
metaphases seen, for example if multiple scattered single chromosomes were seen the 
cells had been exposed to KCl for too long. 
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2.4.3   DNA extraction from blood, cell line and tumour samples 
 
DNA was extracted from blood and frozen tissue samples using the QIAGEN DNA 
mini kit for blood and cell culture (Qiagen, Crawley, UK), following the manufacturer’s 
instructions. This method involves the use of optimised buffer systems for lysis of 
nucleated cells in the presence of an anionic detergent to solubulise cellular fragments. 
Genomic DNA binds to QIAGEN anion-exchange resin within the columns, under 
appropriate low salt and pH conditions. RNA, proteins and low-molecular weight 
impurities are removed by a medium-salt wash. Genomic DNA is finally eluted in 
sterile water, and stored at –20
0C. 
 
2.4.4   DNA extraction to create pooled male control DNA 
 
Pooled control DNA was obtained from blood taken from 21 male volunteers working 
at Cancer Research UK London Research Institute. Genomic DNA was isolated from 
10ml whole blood samples using the Chemagic Magnetic Separation Module I 
(Chemagen AG, Baesweiler, Germany), according to the manufacturer’s instructions. 
Briefly, after lysis of nucleated cells in whole blood, magnetic beads were added that 
specifically bind DNA. The beads and DNA were bound to metal rods magnetised by an 
electromagnet to allow removal of cellular debris by washing. Finally, DNA was 
dissociated into an elution buffer, and the magnetic beads removed using the 
electromagnet, leaving pure DNA in solution. Each 10ml whole blood sample yielded 
1ml of genomic DNA, with concentrations ranging from 171-306 ng/μl. A stock 
solution of control pooled male DNA was created with a final concentration of 
250ng/μl, using 400μl DNA from each of the 21 samples. The pooled male DNA was 
used as control DNA for PCR primer validation, sequencing and array comparative 
genomic hybridisation (array CGH). 
 
2.5   RNA extraction from tumour samples 
 
RNA was extracted from the frozen tissue samples using Trizol (Invitrogen, Paisley, 
UK), initially following the manufacturer’s instructions. Once phase separation was 
complete, the RNA-containing phase was applied to a Qiagen RNeasy spin column  60
(Qiagen, Crawley, UK). RNA thus bound to the spin column was cleaned up using 
buffers RW1 and RPE by centrifugation following the instructions within the RNeasy 
mini kit protocol, and finally eluted into RNAse free water. RNA was stored at –80
0C, 
and repeated removal of RNA was avoided where possible, to avoid recurrent episodes 
of freezing and thawing. 
 
2.6   Protein extraction from tumour samples 
 
Protein was extracted from frozen tissue samples after homogenisation and lysis in 1x 
RIPA buffer containing 1% (v/v) protease inhibitor cocktail (Roche) and phosphatase 
inhibitor cocktail (Roche), according to the manufacturer’s instructions. 
 
2.7   DNA and RNA quantification 
 
Analysis of DNA quantity and purity was performed using a Nanodrop 2000 
spectrophotometer (NanoDrop, ThermoScientific). This instrument measures the light 
absorbance (A) at specific frequencies, within the diluted DNA sample. DNA absorbs 
ultraviolet light at a frequency of 260nm, while protein preferentially absorbs light at 
280nm. A combination of both the 260nm absorbance reading, and the ratio of the 
A260nm/A280nm values allow quantification of DNA and an assessment of its purity to 
be calculated. Pure preparations of DNA will have an absorbance ratio (260nm/280nm) 
of approximately 1.8. Any contaminants, such as protein, within the DNA sample will 
cause a reduction in this value. RNA is considered to be of good quality if the 
absorbance ratio is close to 2.0. 
 
The concentration of nucleic acids may be calculated from the absorbance reading using 
the following formula: 
Nucleic acid  = optical density 260nm x standard coefficient x sample dilution 
  concentration       Pathlength of laser 
 
In general, a 1cm pathlength standard coefficient of 50μg/μl is used for double stranded 
DNA and 40μg/μl for single stranded RNA.   61
2.8   cDNA synthesis 
 
cDNA was synthesized from total RNA using SuperScript First-Strand cDNA synthesis 
system and random hexamers (Invitrogen, Carlsbad, CA), according to the 
manufacturer’s instructions. 
 
2.9   Genomic DNA whole-genome amplification 
 
Genomic DNA was whole genome amplified (WGA) using the REPLI-G whole 
genome amplification kit (Qiagen, Crawley), according to the manufacturer’s 
instructions. 
 
2.10   Fluorescence in situ hybridisation (FISH) 
 
Chromosome paints were used for chromosomes 1, 4, 5, 6, 8, 11, 12, 13, 14, 15, 17, 18 
and 22, and a specific probe for MYC (all from Cambio). For more recent studies clones 
were selected from the Sanger Clone Library to probe a specific region at 7q34, and 
purchased from Geneservice. BAC clone RP11-837G3 was used to target BRAF in 
combination with a control probe to 7p (BAC clones RP11-251I15 + RP11-746C13). 
Here clones were obtained as stabs, and were plated and cultured on agar plates to 
obtain single colonies using a standard protocol. DNA was isolated using the Qiagen 
large construct kit. Clone DNA was labelled by nick-translation with the BioNick kit 
using biotin-14-dATP (Invitrogen) or digoxigenin-11-dUTP (Roche). Each clone was 
initially hybridised to normal human metaphase chromosomes to confirm correct 
localisation. 
 
Prior to hybridisation the chromosomes on each slide were aged with microwave 
irradiation for 2.5 minutes, using a microwave (Sharp Carousel II) set at medium/high 
power. To denature the chromosomes, 90μl of denaturation mixture (70% v/v 
formamide, 2xSSC) was placed on the slide under a 22 x 50 mm coverslip and heated 
on a hot plate at 73
 oC for 3 minutes. The slide was then washed with cool 2xSSC (4 
oC)  62
and dehydrated in an ethanol series (cold 70% then 95% and absolute ethanol, at room 
temperature, each for 2 minutes).  
 
Labelled DNA (300ng) was precipitated with 5μl human Cot-1 DNA (1mg/ml, 
Invitrogen), 2μl salmon sperm DNA (10mg/ml, Invitrogen), 2μl 3M NaAc (Fisher 
Scientific) and 300μl absolute ethanol (final volume 309μl) on dry ice for 30 minutes 
(or -20
oC overnight). The probe was centrifuged at 15,000 rpm for 15 minutes in an 
Eppendorf 5415C microcentrifuge at 4
oC, dried in air and resuspended in 11μl 
hybridisation mixture (50% formamide, 2x SSC and 10% w/v dextran sulphate). The 
probe was denatured on a heating block at 85
 oC for 5 minutes, and then incubated at 37
 
oC for 30 minutes. The slide was then pre-warmed on a heating block at 37
 oC, and the 
denatured probe(s) applied to the selected area of the slide. The hybridisation area was 
sealed under a 22 x 22 mm cover slip with rubber cement, and placed in a moist 
chamber at 37
 oC overnight.  
 
Following hybridisation, the slide was washed three times, by gentle shaking for 5 
minutes, in 50% v/v formamide and 2x SSC at 42
 oC, and a further three times in 1x 
SSC at 60
 oC. The slides were then incubated in 90μl blocking solution containing 4x 
SSC, 0.1% v/v Tween 20 (SSCT) and 5% w/v Marvel skimmed milk powder and 
incubated at 37
 oC for 25 minutes. The blocking solution was drained from the slide, 
and 90μl of the detection antibody (diluted in SSCT) was applied and covered with a 
coverslip. The slides were then incubated with the appropriate antibodies, anti-avidin-
FITC (1:300) or anti-digoxigenin-rhodamine (1:100) at 37
 oC for 45 minutes, followed 
by three washes with 4x SSC and 0.1% v/v Tween 20 at 42
 oC. The chromosomes were 
then counterstained with DAPI (200 ng/ml) in Citifluor antifade solution and stored at 4
 
oC in the dark. 
 
Slides were examined with a Zeiss Axiophot microscope equipped for epifluorescence 
using a Zeiss plan-neofluar 100x objective. Separate grey-scale images were captured 
with a cooled CCD-camera (Hammatsu). Images were then pseudocoloured and 
merged. SmartCapture X software (Digital Scientific, Cambridge) was used for image 
analysis and processing.  
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2.11   Interphase fluorescence in-situ hybridisation (i FISH) 
 
Dual-colour interphase FISH was performed for selected tumour samples by James 
Dalton, at St Jude Children’s Research Hospital, Memphis. Paraffin tissue sections, 5-
8µm thick were used. Probes were derived from BAC clones (Invitrogen, Carlsbad, CA) 
and labelled with either FITC or rhodamine fluorochromes.   
 
The probe mixtures were diluted 1:50 in DenHyb buffer (Insitus Biotechnologies, 
Albuquerque, NM) and co-denatured with the target cells on a slide moat at 90°C for 12 
minutes. Slides were incubated overnight at 37°C on a slide moat and then washed in 
4M urea / 2xSSC at 25°C for 2 minutes. Nuclei were counterstained with DAPI 
(200ng/ml; Vector Labs) for viewing on a Nikon Eclipse E800 fluorescence microscope 
equipped with a 100-watt mercury lamp; FITC, Rhodamine, and DAPI filters; 100X 
PlanApo (1.40) oil objective; and a COHU CCD camera. Images were captured and 
processed with an exposure time ranging from 0.5-1.5 seconds for each fluorochrome 
using Cytovision v3.6 software. 
 
2.12   Multiplex fluorescence in situ hybridization (M-FISH) 
 
M-FISH analysis was performed on metaphase spreads prepared from the 
medulloblastoma cell lines Daoy and HTB187. Slides were pre-treated with 100 μl 
RNase (100μg/ml) under a 22 x 50 mm coverslip at 37
oC for 10 minutes, to remove 
RNA. Slides were washed twice for 5 minutes in 2 x SSC at room temperature, and then 
placed in 0.005% v/v pepsin at 37
oC for 5 minutes, to remove proteins, cellular debris 
and aid permeabilization. Following this, the slide was washed twice for 5 minutes in 
PBS at room temperature, and placed in 1 % formaldehyde fixation solution at room 
temperature for 2 minutes. The slide was again washed twice in PBS for 5 minutes at 
room temperature, and dehydrated in an ethanol series (70%, 95% and absolute ethanol) 
before drying in air. Once dry the slide was placed on a 37
oC hotplate to evaporate any 
remaining ethanol. 
 
The M-FISH Vysis SpectraVysion probe (Abbot Laboratories) was allowed to thaw to 
room temperature (usually stored at -20
 oC), and 10μl of the probe per half-slide was  64
denatured at 72
 oC for 5 minutes. The probe was applied to the slide whilst on the 37
 oC 
hotplate, covered with a 22x22mm coverslip and sealed with rubber cement. The slide 
was placed in a moist warm chamber, and incubated overnight at 37
 oC.  
 
Following hybridisation the slide was washed in 0.4xSSC and 0.3% NP-40 detergent 
(Calbiochem) at 72
 oC for 5 minutes (protecting from light), and then washed in 2x SSC 
and 0.1% NP-40 at room temperature for 3 minutes before leaving to air dry in the dark. 
Forty microlitres of DAPI (42 ng/ml) in Citifluor antifade solution was then applied 
under a fresh 22 x 50 mm coverslip. Images were captured using a Zeiss Axiophot 
microscope equipped for epifluorescence using a cooled CCD-camera (Hamamatsu). 
Image analysis was performed using SmartCapture X software (Digital Scientific). 
 
2.13   Polymerase chain reaction (PCR) 
 
PCR is one of the central techniques used in molecular biology, allowing the 
amplification of DNA from a template using a thermostable DNA polymerase (Mullis et 
al., 1987). Specifically designed oligonucleotide primers allow the amplification of a 
target region to take place. This can occur from as little as one molecule of DNA as a 
starting template. The technique is powerful so it is essential that all reagents are free 
from any contaminating DNA. To confirm this is the case it is always necessary to run a 
negative control, which contains all of the reagents for the PCR reaction except the 
template DNA. Sterile water is used to replace template DNA in the negative control. 
Hence, any amplification signifies that at least one of the reagents is contaminated, and 
must be discarded. 
 
The following reagents are required for PCR: template DNA, PCR buffer, 
deoxyribonucleoside triphosphates (dNTPs), oligonucleotide primers, magnesium 
chloride (MgCl2) and Taq DNA polymerase, or an equivalent enzyme. The correct 
concentration of all components is essential for a PCR reaction to be successful. Each 
PCR reaction must be optimised, by adjusting the PCR cycling conditions, the MgCl2 
concentration or both.  
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2.13.1   Primer design 
 
Primers were designed using Primer3 software, which may be downloaded from the 
following website: 
http://www.broadinstitute.org/genome_software/other/primer3.html 
All oligonucleotide primers were between 18-25bp in length, with an annealing 
temperature (Tm) between 55-65
oC. Tm was estimated using the following formula: 
 
Tm = 59.9 + 0.41 x (%GC) – 600 / length 
 
Primers were analysed for their dimerization capability and secondary structure 
formation. When designing primers for sequencing whole genes, primers were designed 
to amplify each of the coding exons, including the intron-exon boundaries. Fragments 
were restricted to no larger than 500bp. Any exons larger than 500bp were split into 
overlapping fragments. A minimal distance of 35bp was left between the primer and the 
exon/intron boundary. 
 
2.13.2   PCR reactions 
 
All of the PCRs performed throughout the course of the work for this thesis were 
carried out using QIAGEN Fast-cycling PCR reagents. This uses the HotStarTaq Plus 
DNA Polymerase, a modified form of recombinant DNA polymerase originally isolated 
from Thermus Aquaticus and cloned in E.Coli. The enzyme is supplied in an inactive 
state, with no polymerase activity at ambient temperatures. This prevents extension of 
nonspecifically annealed primers and primer–dimers formed at low temperatures during 
the initial stages of setting up the PCR.  
 
Each PCR reaction consisted of 25-50 ng genomic DNA, 0.5μM Forward and Reverse 
primers, QIAGEN Fast Cycling PCR Master Mix (containing dNTPs and magnesium 
chloride) and sterile water to a final volume of 20μl. 
 
The PCR reactions were performed on a Peltier thermal cycler PTC-225 (MJ Research).  
PCR cycling conditions were as follows: initial denatuaration for 3 minutes at 95
oC 
followed by 34 cycles of denaturation at 95
 oC for 30 seconds, annealing at 57
 oC for 30  66
seconds and extension at 72
 oC for 1 minute, followed by final extension at 72
 oC for 10 
minutes. Once complete, the reaction was kept at 4
 oC or on ice. In some reactions the 
annealing temperature and extension times were varied in order to optimise the 
production of clean PCR products. If there was difficulty in obtaining a specific PCR 
product when using certain primers the sterile water was replaced by Q-solution, 
provided within the QIAGEN Fast Cycling PCR kit. This reagent alters the melting 
behaviour of DNA, and may be used to optimise annealing of primers that fail to work 
well under standard conditions. 
 
2.13.3    Agarose gel electrophoresis of DNA 
 
Separation of DNA fragments within a PCR was performed by agarose gel 
electrophoresis. This technique exploits the negative charge of DNA by causing it to 
migrate through an agarose gel towards a positive terminal (anode). The rate of 
progression through the gel decreases as the size of the DNA molecule increases. DNA 
was visualized by the addition of Ethidium bromide to the gel. Ethidium bromide 
intercalates between the bases within the DNA molecule and will fluoresce in the 
presence of ultraviolet light.  
 
One and a half percent agarose gels were prepared, with agarose and 1xTBE. A 
domestic 600W microwave (Sharp Carousel II) was used to melt the agarose, which 
was then allowed to cool to around 50
OC before ethidium bromide was added, to a final 
concentration of ~ 0.5μg/ml. The gel was poured into a casting tray and left to set, 
before being transferred to an electrophoresis tank, and covered with 1xTBE. 
 
DNA samples were mixed with a loading buffer containing OrangeG dye and glycerol 
(see Appendix A 8.1.3 for recipe). These migrate at the same speed as 300-400bp DNA 
fragments, allowing their progress to be followed within the gel. Glycerol increases the 
density of the DNA samples, allowing them to sink into the wells of the gel. Samples 
were loaded into wells and run for ~30 minutes at 120 volts. All gels were run with a 
DNA ladder (Hyperladder I or II, Bioline) in the first and last wells, to allow sizing of 
DNA products. Agarose gels were then visualised on a UV transilluminator (G-Box, 
Syngene) and photographed using Genesnap (Syngene).  
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2.14   DNA purification 
 
Prior to DNA sequencing, PCR products of interest were purified by gel purification or 
by an ExoSap reaction. This is necessary to remove unwanted dNTPs and primers from 
the PCR product, which would otherwise contaminate the sequencing reaction. ExoSap 
was used if the PCR product appeared as a clean band on agarose gel, with no additional 
products or primer dimer seen. Gel purification was used if PCR products additional to 
the band of interest were seen. 
 
2.14.1   ExoSap 
 
The ExoSap-IT PCR product clean-up kit (USB corporation, USA) was used according 
to the manufacturer’s instructions. 
2.14.2   Gel purification 
 
The PCR product of interest was visualised within the gel using a UV-transilluminator, 
and excised from the gel using a sterile scalpel. DNA was then extracted from the gel 
slice using the QIAquick Gel extraction kit (Qiagen) in accordance with the 
manufacturer’s instructions. 
 
2.15   Direct sequencing 
 
Direct sequencing allows the detection of a sequence of nucleotides within a known 
segment of DNA. The most commonly used method for direct sequencing is Sanger 
dideoxy sequencing (Sanger sequencing) (Sanger et al., 1975). Sanger sequencing 
chemistry is based on the use of dideoxynucleotides (ddNTPs). These contain a 
hydrogen on the 3’ carbon, instead of the hydroxyl (OH) group found in 
deoxynucleotides. During the sequencing reaction, a phosphodiester bond cannot form 
between the dideoxynucleotide and the incoming nucleotide. Hence, DNA chain 
synthesis is terminated. Dye-terminator sequencing uses fluorescent labelling, specific 
for each of the four chain terminating dideoxynucleotides (ddATP, ddGTP, ddCTP, or 
ddTTP) within a single reaction. All sequencing reactions were carried out using  68
‘BigDye Terminator Sequencing’ kit version 3 (Applied Biosystems) (Rosenblum et al., 
1997). 
 
DNA target sequences were amplified by PCR, purified by ExoSAP, or by gel 
purification, and then sequenced in both directions using the di-deoxy chain termination 
method. Each 20μl sequencing reaction contained: 8μl BigDye terminator mix, 4-10ng 
template DNA, 3.2μl of primer (either forward or reverse) at a final concentration of 
3.2pmol, and sterile water to a final volume of 20μl.  
 
The thermal cycling conditions were as follows: initial ramp to 96
oC by 2.5
oC per 
second, 96
oC for 1 minute followed by 24 cycles of (96
 oC for 10 seconds, ramp to 
optimum annealing temperature for specific PCR by 1
oC/second then hold annealing 
temperature for 5 seconds, ramp to 60
oC at 1
oC/second followed by 60
oC for 4 
minutes), ending at 12
 oC. 
 
The sequencing reactions were subsequently cleaned up to remove unincorporated dye 
terminators. If there were fewer than 30 samples DyeEx 2.0 spin columns (Qiagen, 
Crawley) were used, for larger numbers of samples DyeEx 96-well cleanup plates 
(Qiagen, Crawley) were used, both according to the manufacturer’s instructions. 
 
Staff at the equipment park within Cancer Research UK London Research Institute 
performed the final sequencing stage, using an ABI 3730 DNA sequencer. Results were 
screened by eye using the Applied Biosystems software packages Sequence Scanner 
version 1.0 and Variant Reporter version 1.0. Mutational analysis was performed by 
eye. 
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Chapter 3.  DNA copy number changes by array CGH 
3.1  Introduction 
 
DNA copy number gains and losses are known to contribute to many genetic syndromes 
and developmental abnormalities. For example, Down’s syndrome is due to the addition 
of a whole or partial copy of chromosome 21 and Cri du chat syndrome is caused by 
partial deletion of chromosome 5p. Changes in DNA copy number occur in most human 
cancers, and deletions and gains of DNA copy number may lead to alterations in the 
expression of tumour suppressor genes and oncogenes, respectively (Hanahan et al., 
2000). It is important to characterise the DNA copy number changes in cancers, in order 
to attempt to understand the pathways and processes involved in tumorigenesis, and 
thereby to improve tumour diagnosis, classification and treatment.  
 
DNA copy number gains and losses were first identified by karyotyping. This technique 
uses dividing cells to produce metaphase chromosome spreads. Cells are dropped onto a 
glass slide, fixed, stained and examined under a microscope. Whole or partial 
chromosome gains and losses may be determined using this technique, but smaller, 
subtle changes may not be identified. It is often difficult to obtain dividing cells in many 
solid cancers, making karyotyping a technical challenge. Furthermore, cancers 
frequently contain extremely complex chromosomal rearrangements, which are almost 
impossible to interpret using conventional karyotyping. Hence, new methods were 
required to investigate DNA copy number alterations in cancer in more detail. 
 
Comparative genomic hybridisation (CGH) was developed in 1992 (Kallioniemi et al., 
1992), and entirely revolutionised the fields of genetics and cancer biology. CGH 
enabled DNA copy number gains and losses to be analysed across an entire genome, in 
a single hybridisation experiment. Equal amounts of DNA from a reference sample 
(control) and a test sample (tumour) are differentially labelled with two fluorochromes, 
and competitively bound to the hybridisation platform. Unlabelled human Cot-1 DNA 
(placental DNA 50-300bp in size, enriched for repetitive DNA sequences) is used to 
block non-specific hybridisation across repetitive sequences within heterochromatin, 
e.g. across centromeric regions (Albertson et al., 2003, Lichter et al., 2000). The 
relative intensities of the two fluorochromes are measured at a given locus. Differences  70
in signal intensity represent regions of gain or loss of DNA sequence in the test sample 
when compared to the reference.  
 
CGH has transformed the study of cancer and inherited conditions, by removing the 
need to culture cells to produce karyotypes. Previously, the majority of investigations 
into the molecular basis of cancer had been based on leukaemias, because of the ease of 
culturing cells and obtaining samples (Mitelman et al., 1997). The few successfully 
characterised solid tumours contained hugely rearranged karyotypes, making the 
interpretation of results difficult. Many solid tumours, however, remained inaccessible 
to detailed study because of an inability to obtain chromosome spreads. 
 
Initially, the CGH technique used human metaphase chromosome spreads as the 
hybridisation platform, and was termed metaphase CGH (Kallioniemi et al., 1992). The 
use of metaphase spreads limited the resolution for CGH to between 3~10Mb (Lichter 
et al., 2000, Beheshti et al., 2003). Subsequently, the technique was replaced by array 
CGH, using mapped fragments of DNA sequence, arrayed on a glass slide. Array 
technology allowed much higher resolution mapping of DNA copy number changes, at 
~1Mb resolution. Three types of array CGH platform are available: the first utilises 
genomic DNA clones from bacterial artificial chromosomes (BAC) and P1 artificial 
chromosomes (PAC) (Pinkel et al., 1998); the second uses complementary DNA 
(cDNA) clones which are generated by reverse transcription of RNA to DNA before 
insertion into a cloning vector (Pollack et al., 1999). Recently a third type of platform 
was developed, using oligonucleotides to perform mapping at higher resolution, for 
example probes may be spaced at 50 or 140bp intervals for a fine-tiling path array to 
investigate a particular chromosomal region of interest (Selzer et al., 2005).  
 
The introduction of metaphase CGH, and then array CGH in 1998 allowed investigation 
of copy number alterations previously beyond the reach of existing technologies to be 
conducted, in large numbers of solid tumours. This groundbreaking technique paved the 
way for numerous discoveries in genetic syndromes and cancer. Associations between 
DNA copy number alterations and prognosis have been identified in many cancers, 
including prostate cancer, breast cancer and lymphomas (Martinez-Climent et al., 2003, 
Paris et al., 2004, Callagy et al., 2005, Rubio-Moscardo et al., 2005, Chin et al., 2006). 
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Knowledge of the copy number variations found in normal individuals is required to 
inform detailed studies of DNA copy number alterations in disease. Array CGH 
technology has also enabled large regions of copy number variation or indels 
(insertion/deletions) to be identified in normal individuals (Iafrate et al., 2004, Sebat et 
al., 2004). These ranged in size from tens of kilobases to megabases. Such large regions 
of copy number variation (CNV) were previously unknown in normal individuals. 
These first two studies identified over 200 large regions of CNV in 75 individuals, and 
led the way for larger studies to identify regions of CNV within the normal population. 
The first of these was the HapMap project, which constructed a CNV map of the human 
genome by investigating 270 individuals from four populations (Redon et al., 2006). 
These comprised parent and offspring trios from Nigeria and Utah, and unrelated 
individuals from Japan and China. Investigations were performed using CGH and 
single-nucleotide polymorphism (SNP) arrays. One thousand four hundred and forty 
seven regions of CNV were identified, covering 360 megabases (around 12% of the 
genome) and containing hundreds of genes. Results from these and later studies are 
freely available to researchers. Common regions of CNV within the genome from 
normal individuals are catalogued, mapped and regularly updated on web-based genome 
browsers such as Ensembl and UCSC.  
 
Paediatric astrocytomas had previously been investigated using conventional 
cytogenetic approaches and metaphase CGH (Raffel, 1996, Schrock et al., 1996, 
Bhattacharjee et al., 1997, Zattara-Cannoni et al., 1998, Sanoudou et al., 2000, Warr et 
al., 2001). High-grade paediatric astrocytomas have been shown to contain some of the 
changes present in adult astrocytomas, including loss of chromosome 10q and the PTEN 
locus, but other changes commonly seen in adult tumours, such as EGFR amplification 
and 17p deletions have not been found at similar frequencies (Rickert et al., 2001, Warr 
et al., 2001). Most low-grade paediatric astrocytomas display balanced karyotypes by 
conventional cytogenetics and metaphase CGH (Raffel, 1996, Bhattacharjee et al., 
1997, Zattara-Cannoni et al., 1998, Sanoudou et al., 2000). Whole chromosome gains 
have been identified in paediatric low-grade astrocytomas, most commonly involving 
chromosomes 5, 7, 19 and 22 (reviewed by Sanoudou) (Sanoudou et al., 2000). The 
majority of these studies were performed using low-resolution techniques. I decided to 
use a higher resolution approach to investigate paediatric low-grade astrocytomas using 
array CGH. Initially the technique was optimised using control normal DNA, and DNA 
from the paediatric medulloblastoma cell lines Daoy and HTB187. Cell lines were used  72
as a renewable resource before using tumour DNA samples. I investigated 20 paediatric 
low-grade astrocytoma samples when I was satisfied with the array CGH optimisation. 
Initially I was blinded to all clinico-pathological details, other than the tumour site, so 
began by comparing tumours from the cerebellum with non-cerebellar tumours. I 
wanted to investigate whether tumours arising from different sites within the brain 
carried distinct or similar molecular aberrations. Any aberrations identified might 
provide an insight into the pathways involved in tumour development, within different 
regions of the brain. When the clinico-pathological details were revealed, it became 
apparent that the group of non-cerebellar tumours contained different pathologies, 
which could not be compared directly as a group with the pilocytic astrocytomas of the 
cerebellum. Hence, the study attempted to identify distinct molecular aberrations within 
the group of cerebellar pilocytic astrocytomas in comparison to the grade II 
astrocytomas which arose outside the cerebellum. 
 
3.2  Aim 
The aim of the work described within this chapter was to investigate genome-wide 
DNA copy number changes in paediatric low-grade astrocytomas using array CGH. 
 
3.3  Array CGH method 
3.3.1  Array CGH slides 
 
Array CGH was performed using slides produced by the Institute of Cancer Research in 
Sutton (Hughes et al., 2005). The slides contained 3,122 bacterial artificial chromosome 
(BAC) and P1 artificial chromosome (PAC) clones. The BAC clones were based on a 
previously reported clone set, produced using modified degenerate oligonucleotide-
primed PCR (DOP-PCR), which allows random amplification of DNA from any source 
(Fiegler et al., 2003). Clones were selected from the Golden Path published in 2001, 
with median separation of 1Mb across the genome (range 500kb-4.5Mb). PAC clones 
were used to cover telomeres, and were selected from a previously described clone set 
(Knight et al., 2000). Chromosome coverage excluded centromeres, where clone 
separation was greater than 1Mb, and the short arms of the acrocentric chromosomes 
(chromosomes 13, 14, 15, 21 and 22). BACs and PACs were spotted in duplicate across  73
CodeLink activated slides. These slides are specifically designed for microarrays, and 
are coated with a hydrophilic polymer which covalently binds amine-modified DNA. 
The slides also had 838 empty spots and 36 spots containing Drosophila DNA, as a 
non-specific hybridisation control. 
 
3.3.2  Random labelling of DNA 
 
DNA from the test sample was labelled with Cy5 and reference control DNA with Cy3 
using a Bioprime labelling kit (Invitrogen). Equal amounts of each DNA sample were 
used, to ensure equality for each sample during the competitive array slide hybridisation 
step. Sixty microlitres (μl) of Random Primer Solution was added to 450ng of DNA, 
and made up to 126μl with distilled water. The solution was then mixed briefly and 
incubated at 100
oC for ten minutes to denature the DNA. The mixture was cooled on ice 
for 2 minutes. Fifteen μl of 10x dCTP mix; 6μl of either Cy3 or Cy5 labelled dCTP and 
3μl of Klenow fragment (5 Units/μl, Applied Biosystems) were then added in sequence 
to give a total volume of 150μl. The solution was mixed gently, and incubated at 37
 oC 
overnight. The reaction was stopped by adding 15μl of EDTA, then put at 100
 oC for 
five minutes before cooling on ice. 
 
Unincorporated labelled nucleotides were removed from the solution using G50 Micro-
spin columns (Amersham) as illustrated below. The columns were prepared by 
vortexing, mixing the liquid within. Each column base was snapped off, and the lid 
opened by a quarter turn before placing in a 1.5ml Eppendorf tube. The columns were 
centrifuged for one minute at 4,000 rpm in an Eppendorf 5415C microcentrifuge, 
creating a gel filtration column. Excess liquid at the base of each column was blotted off 
with clean tissue paper.   
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Figure 3.1 G50 spin column preparation.  
The DNA is cleaned up using a G50 spin column to ensure removal of 
unincorporated labelled nucleotides. Diagram reproduced from G50 spin column 
instruction handbook (Amersham).  
 
 
 
Figure.3.2 Agarose gel image of 12 labelled DNA samples.  
The DNA is run on a 1.5% agarose gel to assess the level of fragmentation achieved 
when compared to the DNA ladder (50-2000bp). The white ‘smear’ for each 
sample trace indicates that adequate fragmentation has been achieved.
 
2000 bp 
1,000bp 
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The columns were placed in fresh 1.5ml Eppendorf tubes, and Cy-dye labelled DNA 
solution was loaded onto the centre of the resin gel column. Three gel columns were 
used per 150μl sample, as the maximum volume for loading each column was 50μl. The 
spin column lids were closed tightly, and then loosened by a quarter turn before being 
centrifuged for two minutes at 4,000 rpm. The eluted DNA was collected into a fresh 
1.5ml Eppendorf tube. An aliquot (5μl) of labelled DNA was run on a 1.5% Agarose 
gel. If adequate fragmentation had occurred, a ‘smear’ of DNA fragments was visible, 
with fragments ranging in size from 50 to 500 base pairs when compared to a 1kb 
ladder (Figure 3.2). 
 
A further 1μl of DNA was analysed using a NanoDrop ND-1000 UV-Vis 
Spectrophotometer (ThermoScientific, UK). The ‘Microarray’ setting was used to 
measure the absorbance of the fluorescent dye, to quantify the concentration of 
Cy3/Cy5 incorporation (pmol/μl) in the labelled DNA. Five pmol/μl was found to be 
the minimum concentration of Cy3 or Cy5 necessary for optimum results when 
scanning the arrays. Samples with fluorescent dye incorporation below this 
concentration were difficult to visualise during scanning. Random labelling was 
repeated for DNA samples that did not reach the 5pmol/μl threshold.  
 
3.3.3  Precipitation of DNA prior to hybridisation 
 
Before hybridisation, it is necessary to block repetitive sequences present in the labelled 
DNA and the array platform clones. Cot-1 DNA was used to block repetitive sequences 
in the labelled DNA on the surface of the array slide, and a combination of Cot-1 and 
Herring Sperm DNA was used.  
 
The pre-hybridisation mixture (80μl Herring Sperm DNA, 135μl human Cot-1DNA, 
23μl 3M NaAc (pH 5.2) and 400μl cold absolute ethanol) and hybridisation mixture 
(180μl Cy3 labelled reference DNA, 180μl Cy5 labelled test DNA, 135μl human Cot-
1DNA, 55μl 3M NaAc (pH 5.2) and 1000μl cold absolute ethanol) was prepared, and 
then precipitated at -20
 oC overnight or at -80
 oC for 1 hour.  
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3.3.4  Preparation of array slide prior to hybridisation 
 
A frame was prepared from thermo-stable adhesive plastic PCR sheets (ABgene, UK). 
This frame allowed both the pre-hybridisation and hybridisation mixtures to be retained 
on the surface of the slide, within the reservoir formed by the frame. Six individual 
adhesive PCR sheets were stuck together, one on top of the other. Great care was taken 
to align the sheets as they were stuck together, and air bubbles were pressed out using a 
plastic slide box to smooth the surface, creating one thick plastic sheet. Any air bubbles 
or irregularities between the sheets would allow the hybridisation mixture to leak out of 
the well during the course of the experiment. The exact dimensions of the array slide 
were drawn on the reverse of the sheet in pencil, including the dimensions of the area 
containing the array spots. The outer edges of the frame were cut to size using a 
guillotine. The inner edges were cut out using a scalpel to create the reservoir. The 
adhesive backing was removed, and the plastic frame placed onto the surface of the 
array slide. Care was taken both to avoid touching the array spots and to leave a clear 
border around them with the plastic frame. The barcode at the base of each slide was 
also left uncovered, to allow reading during the subsequent scanning process. The frame 
was pressed into place and a pair of forceps used to score down each side of the frame, 
to ensure adhesion of the reservoir to the slide surface.  
 
3.3.5   Pre-hybridisation 
 
Three hundred microlitres of hybridisation buffer (Appendix B: Reagents prepared for 
array CGH) was pre-heated to 80
oC in a heat block. A humidity chamber was prepared 
for the hybridisation in a fume hood. Plastic food containers (Lock and Lock) were 
used, as they were both air- and water-tight due to a rubberised seal between the lid and 
container. The containers were covered in opaque tape to ensure they were protected 
from light. Whatman filter paper was used to cover the base of the humidity chamber, 
and drenched in a mixture of 2xSSC and 20% v/v formamide, to ensure humidity within 
the chamber. 
 
The precipitated pre-hybridisation and hybridisation mixtures were spun for 15 minutes 
at 14,000 rpm in an Eppendorf 5415C micro-centrifuge. The supernatant above the 
pellets was removed, and 500μl 80% ethanol was added to each tube before  77
centrifuging at maximum speed for 5 minutes. The ethanol supernatant was removed, 
and the tubes spun for a further minute at maximum speed. Any remaining supernatant 
was removed with a 10μl pipette tip, and the pellet re-spun until dry. 
 
Sixty microlitres of pre-heated hybridisation buffer and 36ng yeast tRNA (Invitrogen, 
diluted in distilled water for 60 minutes to a final concentration of 6ng/μl) was added to 
the hybridisation pellet, which was then resuspended in a heat block at 80
oC for 5 
minutes. The sample was mixed, and heated for a further 10 minutes at 80
oC to allow 
DNA denaturation. The tube was mixed, and incubated in the dark for 60 minutes.  
 
One hundred and sixty microlitres of pre-heated hybridisation buffer was added to the 
pre-hybridisation pellet, and allowed to resuspend in a heat block at 80
oC for 5 minutes. 
The sample was heated for 10 minutes at 80
oC, mixed and given a pulse spin to remove 
air bubbles. The pre-hybridisation mixture was applied to the array slide surface, inside 
the prepared reservoir. Care was taken to avoid touching the array spots with the pipette 
tip, and to ensure even coverage of the slide with the mixture. Any air bubbles were 
removed. The slide containing the pre-hybridisation mixture was sealed in the humidity 
chamber, and placed in a hybridisation oven at 37
 oC, on a rocking platform at 5rpm for 
1 hour.  
3.3.6   Hybridisation 
 
The slide was removed from the humidity chamber. The hybridisation mixture was 
removed from the dark, mixed thoroughly and given a pulse spin in an Eppendorf 
5415C microcentrifuge to remove air bubbles. The hybridisation mixture was then 
applied to the surface of the slide, into the reservoir containing the pre-hybridisation 
mixture. The slide was rocked gently to ensure even coverage and any air bubbles were 
removed. The slide was resealed in the humidity chamber and replaced in the 
hybridisation oven at 37
oC. The slide was rocked gently at 5rpm for 48 hours. The 
humidity chamber was rotated by 90
o after 24 hours, to ensure even coverage of the 
slide surface by the hybridisation mixture. 
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3.3.7   Washing 
 
The slide was removed from the humidity chamber, and placed in 2xSSC and 0.03% 
w/v SDS at room temperature for 1 minute. The slide was then removed, and the plastic 
frame removed with forceps.  The slide was then placed in a Coplin jar containing 
2xSSC/0.03% SDS heated to 65
 oC, wrapped in foil (to protect from light) and shaken 
vigorously on a rocking platform for 5 minutes. The slide was transferred to a glass 
slide holder, open at the base. This was submerged in a large clean container with 1 litre 
0.2xSSC at room temperature, wrapped in foil to protect from light, and shaken 
vigorously for 20 minutes. Three further 20 minute washes were performed in 0.2xSSC, 
using 1 litre of fresh solution each time. After that a further wash was performed in a 
Coplin jar containing room temperature PBS/0.05% Tween20 for 10 minutes. Finally, 
the slide was rinsed in a Coplin jar containing distilled water, and immediately taken for 
drying. 
 
3.3.8   Drying 
 
The wet slide was placed in a slide box with lint-free tissue paper covering the base, and 
dried by centrifugation in a plate centrifuge at 700rpm for 3 minutes at room 
temperature. The slide was stored in a light-proof box until scanning was completed. 
 
3.3.9   Scanning and data acquisition 
 
The slides were scanned using an Axon GenePix 4000B microarray scanner, which uses 
two lasers to scan the slide simultaneously, by excitation of the fluorophores on the 
surface. One laser was optimised to identify Cy3 (green) at a wavelength of 532 nm, the 
other identified Cy5 (red) at 635 nm (Figure 3.3). The intensities of fluorescence at each 
array spot were collected and quantified using GenePix Pro 6.0 software (Axon 
Instruments, USA).  
 
The file containing the GenePix array list (.gal) was loaded into the GenePix software. 
The .gal file describes the size, layout and position of the blocks of spots (known as 
features), and the names and identifiers of the clones printed within each feature. Initial  79
background normalisation was performed using the software auto-balance function to 
even out brightness across the slide. Features were subsequently selected using the 
automatic grid and feature identification functions within the software. The default 
feature diameter was 150μm, although this could be altered on an individual spot-by-
spot basis if the feature diameter was smaller than this. The feature indicator is the 
circle put around each spot, from within which data were collected. The mean, median 
and standard deviation of pixel intensities within each feature indicator were collected 
for each feature. The software parameters for acquisition of data from a feature were set 
as follows. A ‘good’ feature would contain fluorescent signal from either wavelength 
covering >75% of the spot diameter at >2 standard deviations above the background 
signal level. The background signal level was defined as the level of fluorescence in the 
region surrounding each spot (Figure 3.4). Poorly hybridised arrays were rejected after 
visual inspection during the scanning process. 
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Figure 3.3 array CGH scan images  
(A)  Cy 3 image (green)  
(B)  Cy 5 image (red) 
(C)  Combined scan images of Cy 3 and Cy 5 (yellow). 
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Figure 3.4 Definition of the background region by GenePix.  
The black region represents pixels used to calculate the background signal; the 
dark grey represents the pixels used to calculate the feature signal. The pixels 
within the light-grey region are excluded. Figure adapted from GenePix Pro 6.0 
users handbook. 
 
Features where the signal intensity did not fulfil these inclusion criteria were included in 
the data collection, but excluded from the subsequent analysis. The array data were 
acquired as a binary GenePix settings (.gps) file from the feature identifiers surrounding 
each feature signal.  
 
Each block of features was checked by eye to ensure that features flagged as ‘good’ 
were truly representative and were not areas of fluorescent debris. Once all features had 
been checked, the data were saved as GenePix results files (.gpr), which are tab-
delimited text files suitable for further analysis. 
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3.3.10   Data analysis 
 
The .gpr data files were analysed with the assistance of Dr Gavin Kelly at the 
Bioinformatics and Biostatistics group at the London Research Institute, Cancer 
Research UK. Analysis was performed in the same way for all of the array experiments 
using Bioconductor (Gentleman et al., 2004).  
 
An initial background subtraction was performed using GenePix derived values. The 
test (tumour) samples were labelled in red (Cy 5) and the controls were labelled in green 
(Cy3). Background corrected values were calculated for each feature as follows: 
 
Red (R) = Red – local red background signal 
Green (G) = Green – local green background signal 
 
A differential value (M) was then calculated for each feature as follows: 
 
M = log2[R/G)] i.e.  log2 [test signal/control signal] 
 
Any spots with negative values after background correction were deemed to have no 
signal, and were discarded. A log2 scale was used to allow both test and control values 
to be on the same scale, with a predominantly red signal measured from 0 to ∞ and a 
predominantly green signal measured from -∞ to 0. Zero change along the x-axis 
corresponds to no overall gain or loss. Assuming both samples are diploid, gain of 1 
copy of DNA relative to the reference sample (ratio 3:2) is represented as + 0.58 on the 
log2 scale. Gain of 2 copies of DNA, or gain of the X chromosome in a female versus 
male control experiment (ratios 4:2 or 2:1) would be represented as +1 by the log2 scale. 
Losses of 1 or 2 DNA copies relative to the reference sample are represented as –1 and -
∞ respectively. Hence, +1 represents doubling of DNA copy number, and –1 represents 
halving of DNA copy number on the log2 scale. This also makes the assumption that 
there is a linear relationship between DNA copy number and signal intensity. However, 
tumour samples contain varying amounts of non-malignant cells, which affect the ratios 
for DNA copy number gain and loss. For the purposes of this thesis, I defined a single 
copy gain to be ≥0.3 above the X-axis, and a single copy loss to be ≤ -0.5 below the X-
axis.  83
 
Features containing Drosophila DNA were present on the array to be used as non-
specific hybridisation controls. However, many slides were found to contain high 
background signal or fluorescent debris within the spots defined as empty or containing 
Drosophila. It was apparent that these signals were due to non-specific binding of DNA, 
so these features were not used in the analysis. Hence, normalisation was performed 
using data only from the features defined as ‘good’. We did not include data from 
features flagged as ‘bad’, or from features that were empty or contained Drosophila 
DNA.  
 
We used a median normalisation, which results in each slide having the same median 
value (zero) as any other slide, where the median is taken across all the ‘good’ features 
of that slide. This is reasonable under the assumption that no more than 50% of the 
clones across the genome are gained in any particular sample, and that no more than 
50% are lost. Each BAC clone had two replicates on the array slide. The mean M value 
was taken across the two replicates on the array. If one replicate had failed, the 
successful feature value was used. Where multiple array CGH hybridisations were 
performed for the same tumour sample, the mean M value across all the slide replicates 
was calculated, to act as a single measurement per-clone per-tumour. We examined the 
data on both a per-tumour basis and a per-slide basis.  
 
Segmentation (smoothing) of the data was performed using circular binary 
segmentation. Segmentation allows the data to be divided into regions of equal copy 
number, and identifies points of DNA copy number change. This process reduces the 
‘noise’ due to the array CGH method. It is unrealistic to expect adjacent clones to have 
identical aCGH measurements, even when they have identical copy number. 
Segmentation attempts to remedy this. We followed the approach used by Olshen and 
Venkatraman et al (Olshen et al., 2004) using the DNA copy number library by the 
same authors [Venkatraman ES and Olshen A. DNA copy number data analysis. R 
package version 1.18.0.] within Bioconductor (Gentleman et al., 2004). Briefly, this 
recursively attempts to identify the two regions within a chromosome that differ most, 
and then attempts to subdivide these regions, until no further subdivisions are found that 
are statistically significant. We carried out the standard procedure of merging adjacent 
regions that had M values within 0.25 of each other. 
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Tumour samples were further analysed by separating them into two groups; cerebellar 
and non-cerebellar samples. Data were pooled for each group, and the mean value for 
each clone was calculated between all patients in the group (using the per-tumour M 
values). The grouped data then underwent further segmentation. Finally, the segmented 
grouped data from the non-cerebellar samples were subtracted from the cerebellar 
sample grouped data (delta cerebellar group), to identify any significant differences 
present between the two groups.  
 
The average intensity (A) for each feature was calculated as follows; 
 
A = 1/2 x [log2 R + log2 G] 
 
MA plots were calculated for each slide and for each tumour sample using a single 
measurement per-clone per-tumour. The MA plot gives an overview of the raw data, 
under the assumption that the majority of features would contain equal amounts of red 
and green signal. Hence, the majority of data points would be at zero. The MA plot also 
gives an indication of any bias due to excessive amounts of green or red fluorescence 
(possibly due to failure of one fluorochrome), which would skew the plot from the zero 
axis. 
 
All of the data plots shown in this thesis were obtained from Bioconductor, although 
visualisation tools improved over time. Plots obtained later, from the tumour versus 
control studies are displayed in a different way from earlier experiments. However all 
experiments were analysed in the same way as described above. For the early 
experiments involving male versus female and cell line characterisation, large numbers 
of data points were missing from the 23 clone duplicates representing the Y 
chromosome on some of the arrays. This caused problems when using the algorithms; 
hence the Y chromosome was excluded from the earliest analysis. This may have been a 
batch problem, as loss of data from the Y chromosome was not encountered in later 
experiments involving tumour DNA. Information on both the sex chromosomes were 
included in these analyses. 
 
The following weblink provides access to the raw data plots for all tumour samples: 
https://bioinformatics.cancerresearchuk.org/~kelly02/index.php?id=Ruth 
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Data are available for whole karyotype aCGH, MA plots and individual chromosomes. 
Data may be viewed by individual array, by tumour sample and by group. Grouped data 
are available for cerebellar samples, non-cerebellar samples and the delta cerebellar 
group (identifies differences between the two groups). The weblink also contains access 
to the Bioconductor analysis script that generated the visualisations, provided by Gavin 
Kelly.  
 
3.4   Array CGH results 
3.4.1   Male versus female control 
Control aCGH experiments were performed using male versus female and male versus 
male (same/same) DNA from two individuals in the lab. Dye-swaps were performed for 
the male versus female experiments: each DNA was labelled with either Cy5 or Cy3 for 
two replicates to remove any possible competitive advantage due to dye incorporation.  
 
Female versus male aCGH analysis showed relative gain of an additional copy of the X 
chromosome (as expected), but also revealed a number of unexpected small regions of 
gain and loss across all of the chromosomes on the whole genome plot (Figure 3.5). The 
Y chromosome was not included in the earliest analysis using Bioconductor, as 
insufficient data were present.   86
 
 
Figure 3.5 Composite array CGH whole genome data plot. 
A log2 scale is used for each chromosome (1 – 22 and X). The baseline (zero) 
indicates an equal amount of DNA at each point in the test and control samples. 
Green lines above the baseline indicate a gain of DNA relative to the control 
sample. Red lines below the baseline indicate a loss of DNA relative to the control.  
This plot compares female (test) DNA versus male (control) DNA, and clearly 
demonstrates that an additional copy of the X chromosome is present. The plot 
also shows multiple regions of gain and loss across the genome, likely to be due to 
genetic polymorphic differences between the two individuals. 
 
This suggested that the additional regions of gains and losses were probably due to 
genetic polymorphisms between the two normal individuals. The affected clones were 
not found to be mis-assigned after checking on Ensembl, or among the few clones 
known to give unexpected ratios from the experience of other researchers using these 
arrays (Appendix B 8.1 Array CGH clones known to give unexpected ratios). No 
significant differences were noted between the dye-swap replicates, dye swaps were 
therefore not performed for later experiments. 
 
Pooled male DNA from 21 individuals was used as the control DNA for subsequent 
array CGH experiments involving tumour samples, to reduce the possibility of 
identifying copy number changes due to polymorphisms between two individuals.  
 
3.5   Medulloblastoma cell lines versus male control  
Further experiments were performed using cell lines to assess whether the technique 
could correctly identify known regions of DNA copy number gain and loss. Since no 
cell lines derived from paediatric low-grade astrocytomas were available, array CGH 
was performed using two paediatric medulloblastoma cell lines, Daoy (HTB186) and 
HTB187 (D341). Both contained chromosomal aberrations including whole 
chromosome gains, amplifications and deletions.  
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I had previously characterised these cell lines, using M-FISH and FISH as described in 
chapter 2, working with Tania Jones and Radost Vatcheva in the Human Cytogenetics 
laboratory at the London Research Institute. These results are summarised below, with a 
full description of the karyotype for each cell line and representative M-FISH and FISH 
images (Figures 3.6-3.11). 
 
3.5.1   Characterisation of Daoy by M-FISH and FISH 
Daoy is a cell line derived from a medulloblastoma in a four year old male. It contains a 
hypertetraploid modal range of 93-99 chromosomes, two normal X chromosomes, and 
no Y chromosome as is commonly seen in immortalised malignant cell lines. In 
addition this cell line contained multiple complex chromosomal rearrangements.  
 
Whole chromosome changes demonstrated by M-FISH included gain of chromosome 1 
(up to 5 copies, with 3-5 additional marker chromosomes containing chromosome 1 
material), loss of chromosomes 4 (2 copies), 13 (3 copies), and numerous other 
rearrangements  (Figure 3.6). These changes were confirmed using FISH. 
 
3.5.2   Characterisation of Daoy by array CGH 
 
DNA from Daoy was compared to single male control DNA by array CGH in two 
replicates. Array CGH analysis identified the following regions of chromosomal gain 
and loss:  
 
Copy number gain: 1p32-36, 6p12-25, 7p and 7q, 9q22-34, 15q11.1-14, 17p11.1-13, chr 
19, chr 20, chr 21q11.1-22 and chr 22q12.1-13 
Copy number loss: 1q12, 3p12-14, 4q11-32, 8p11.2-23, 8q11.1-21.1, 10 cen, 13p and 
13q11.1-31, 16q11.1-12.2, Xq13-22, and complete loss of Y. 
 
The composite whole genome plot from the array CGH analysis is shown in Figure 3.10 
(A). All of the changes found by FISH and M-FISH were identified by array CGH. 
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3.5.3   Characterisation of cell line HTB187 by M-FISH and FISH 
 
HTB187 is a hyperdiploid line derived from a medulloblastoma in a three year old male. 
It has a modal range of 44-50 chromosomes and one copy of X and Y.  
 
M-FISH analysis showed a male karyotype with the following aberrations: trisomy 6, 
trisomy 8 and trisomy 18, amplification of MYC to form a homogeneously staining 
region (HSR) of chromosome 8 material within a derivative chromosome 11, 
isochromosome 17q, and translocation of 1q onto 22p, producing a derivative 
chromosome 22, der(22)t(1;22)(q12;p12) (Figure 3.7). 
 
These changes were confirmed by FISH: the HSR on chromosome 11 was shown to be 
derived from amplification of MYC using a specific MYC probe, in conjunction with 
chromosome paints for chromosomes 8 and 11. One copy of chromosome 8 did not 
contain the MYC signal; this was translocated to chromosome 11 and was highly 
amplified. Two representative FISH images are shown to demonstrate these findings 
(Figures 3.8-3.9) 
 
3.5.4   Characterisation of HTB187 by array CGH 
 
DNA from HTB187 was compared to DNA from a single male control by array CGH in 
two replicates.  
Array CGH analysis identified the following regions of chromosomal gain: 
Copy number gain: 1q, isochromosome 17q and chromosomes 6, 8 and 18 
Copy number loss: 17p 
 
The composite whole genome plot from the array CGH analysis is shown in Figure 3.10 
(B). Selected smoothed chromosome plots, demonstrating regions of copy number gain 
and loss on individual chromosomes are shown in Figure 3.11. 
All of the copy number changes found by FISH and M-FISH were identified by array 
CGH. 89 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6 M-FISH karyotype of HTB186 (Daoy).  
The cell is hypertetraploid, having amodal range of 93-99 chromosomes with two normal X no Y and multiple rearrangements. 
M-FISH revealed the following karyotype:93-99 X, -(X)(q?), -Y, Y, +(1)(p?), +(1)(q?), t(1;13), +(2)(p?), +(2)(q?), del(3)(p?), +(3)(q?), -4, -4, 
+der(?)t(4:?)(p;?)x2, +(5)(p?), +(5)(q?), +(6)(p?), +(6)(q?), +7, del(8)(pter>q21.1), del(8)(q24.3), del(9)(p?), del(9)(q?), del(10)(p-q), -13, -13, +14, 
del(14)(p11.1), del(14)(p13), +(15)(q12-13),del(15)(p11.2-13), +(16)(p?), del(16)(q?), +(17)(p?), +(17)(q?), del(18)(p?), +19, +20, +(21)(q), +(22)(q?). 4n90 
 
 
Figure 3.7 M-FISH karyotype of cell line HTB187.  
The cell is hyperdiploid, having a modal range of 44-50 chromosomes with 1 copy 
of X and Y. M-FISH analysis showed a male karyotype with the following 
aberrations: 
49, XY, +6, +8, -11, 11(HSR), -17, i(17q), +18, -22, der(22)t(1;22)(q12;p12). 
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Figure 3.8 FISH analysis of HTB187 using chromosome 8 paint (red) and MYC 
probe (green).  
Two normal copies of chromosome 8 and one copy of 8q- (with loss of the MYC 
signal) are visualised. Amplified MYC is translocated to chromosome 11 (see figure 
below). 
 
 
 
 
 
 
 
 
 
Figure 3.9 FISH analysis of HTB187 using chromosome 11 paint (red) and MYC 
probe (green).  
An HSR containing amplified MYC (arrowed) is present on chromosome 11. 
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Figure 3.10 Array CGH whole genome plots for medulloblastoma cell lines Daoy 
and HTB187, obtained using Bioconductor 
 
A) Daoy  (test) versus single male (control). Changes identified in Daoy included 
gained copies of 1p32-36, 9q22-34, whole gain of 7 and 14. Chromosomal losses 
including 8p11-23 and loss of chromosome 16 were identified 
 
B) HTB187  (test) versus single male (control), showing additional copies of 
chromosomes 6, 8 and 18, gain of 1p and 17q and loss of 17p. 
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Figure 3.11 Array CGH plots from individual chromosomes from HTB187 (test) 
compared to male (control), obtained using Bioconductor. Data were smoothed 
following segmentation.   
 
A)  Gain of distal chromosome 1q from 150-245Mb, with additional regions of 
gain on 1p at ~70 and ~100Mb  
 
B)  Trisomy of chromosome 6. The baseline level is consistently above 0, 
indicating gain of a whole copy of the chromosome  
 
C) Amplification  of  MYC on chromosome 8 (arrowed) 
 
D)  Loss of chromosome arm 17p and gain of 17q. 
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3.5.5   Paediatric low-grade astrocytoma versus pooled male control 
 
Array CGH was performed using DNA from 20 paediatric low-grade astrocytoma 
samples. These were provided by Professor David Ellison, as described in chapter 2. 
Information on tumour site alone was available at the time of sample selection. Eleven 
cerebellar and 9 non-cerebellar samples were selected for array CGH according to the 
quality and amount of DNA available. I was blind to all other clinico-pathological 
details, including age, sex and diagnosis at the time the experiments were performed. 
The cohort contained 10 pilocytic astrocytomas (PA) from the cerebellum and 1 PA 
from the brainstem, 5 diffuse astrocytomas (DA), 3 pilomyxoid gliomas (PMG) and 1 
pilomyxoid astrocytoma (PMA), all from non-cerebellar sites, respectively. 
 
Each tumour sample was co-hybridised with pooled normal male control DNA, 
obtained from 21 co-workers as described in chapter 2. Examples of array CGH plots 
obtained for individual samples and for pooled sample groups (cerebellar and non-
cerebellar) are shown in figures 3.12-3.20. 
 
 
3.5.6    Results of array CGH analysis for paediatric low-grade 
astrocytomas 
 
Sex chromosome gains and losses from tumour samples compared with male control 
DNA are shown in table 3.1. Male patients would be expected to display no net gain of 
X or Y chromosome material when compared to male control DNA. Female patients 
should display gain of X and loss of Y material when compared to male control DNA. 
All 20 patients were correctly identified as male or female, with complete agreement for 
the sex chromosome changes identified by array CGH. 
 
Gains and losses, both of discrete genomic regions and whole chromosomes were 
identified in the tumour samples. These results, and details of the clones flanking the 
regions of gain or loss are displayed in Table 3.2.  
 
Three patients had apparently normal karyotypes (PA3, PA15, PA17). A further 6 
patients had apparently normal karyotypes with 1-2 discrete regions of chromosome  95
gain or loss (PA13, PA18, PA23, PMA1, DA7, DA9). Whole chromosome gains were 
identified in 6/20 tumours (range 1-4 whole chromosomes gained). Whole chromosome 
gains were seen for chromosome 6 (gained in 4 samples, respectively), chromosome 5 
(gained in 2 samples) and chromosomes 7, 8, 9, 11, 12, 13 and 21 (gained in 1 sample 
each) (Figures 3.12-3.17). The mean age of patients with whole chromosome gains was 
14.6 years, compared to a mean age of 6.5 years for patients without chromosome gains. 
 
Whole chromosome losses were identified in 5/20 patients (range 1-4 whole 
chromosomes lost). Whole chromosome losses were seen for chromosomes 17 and 22 
(lost in 3 samples each), and chromosomes 19 and 20 (each lost in a single sample).  
 
Smaller regions, involving copy number changes of chromosomal arms, and discrete 
regions of chromosome gains or losses were found in 11 patients. The majority of these 
changes were identified in single samples. However, three regions of chromosomal gain 
or loss were identified involving 2 or more samples, and are described in detail below.  
 
3.5.7   Loss of the terminal end of chromosome 1p 
 
Loss of the terminal end of chromosome 1p was identified in four samples (PA32, 
PMG2, DA2, DA4 (Figure 3.18 (A)). In two samples, PA32 and DA2, the region of 1p 
loss ended at clone RP5-1043G4, at 55Mb, and included over 62 BAC/PAC clones. 
This region includes the genes C1orf175, TTC4, PARS2 and TTC22. The region of 1p 
loss differed in the remaining two samples: DA4 showed 1p loss over 53 clones, ending 
at clone RP11-8J9 (45Mb), which contains the genes ATPAF1, KIAA0494 and a region 
of known copy number variation (CNV). PMG2 showed 1p loss ending at clone RP11-
117D22 (52Mb), and including over 60 clones containing the genes ZYG11B, ECHD2 
and a region of known CNV.  
 
3.5.8   Gain at 2q11.1 
 
Two samples (DA7, DA9) revealed identical regions of copy number gain of 2q11.1 at 
102Mb (Figure 3.18(B)). The gained region covered 1.8Mb, starting at clone RP11-
451C2, ending at clone RP11-451G1, and flanked by RP11-299H21 and RP11-350B7.  96
No genes are contained within the start and end clones, which both contain regions of 
known CNV, however the region gained contains the genes SLC9A2 and TMEM182. 
 
3.5.9   Loss at 7q22.1 
 
Two samples (PA13, DA4) revealed loss of a discrete region at 99Mb on chromosome 
7q22.1 (Figure 3.18 (C)), with a small region of loss common to both. Sample PA13 
showed loss covering 1.5Mb at 7q22.1, starting at clone RP11-506M12 (which contains, 
among others, the genes MCM7 and TAF6) and ending at clone RP5-1059M17, 
containing EMID2. Both of these clones are known to contain regions of CNV. Sample 
DA4 showed a smaller region of loss of 800Kb at 7q22.1. Here, the region of loss began 
at clone RP4-550A13, containing the gene SMURF1, and ended at clone RP11-506M12 
(the starting point for the loss in PA13).  
 
3.5.10   Comparison of cerebellar samples to non-cerebellar samples 
 
Further analysis was performed by separating the tumour samples into two groups, of 
cerebellar and non-cerebellar samples. The cerebellar group was entirely composed of 
pilocytic astrocytomas. The non-cerebellar group contained 5 diffuse astrocytomas 
(DA), 3 pilomyxoid gliomas (PMG), 1 pilomyxoid astrocytoma (PMA), and the single 
pilocytic astrocytoma from the brainstem.  
 
The mean intensity value for each clone was calculated between all patients in the group 
(using the per-tumour M values). The grouped data underwent further segmentation 
before subtracting the non-cerebellar group data from the cerebellar group data to create 
a delta-cerebellar group. This was to identify any significant DNA copy number 
differences present in the cerebellar samples, but not in the non-cerebellar group.  
 
No regions of copy number change were identified in the cerebellar group, compared to 
the non-cerebellar group (Figure 3.19). A single region of gain was identified in the 
non-cerebellar samples at 21q22.2 (~42Mb) when the two groups were compared. This 
group was, however, formed of a number of different tumour types. Individual data 
plots for chromosome 21 are shown (Figure 3.20 (A), (B) and (C)), from cerebellar and 
non-cerebellar groups individually and when compared with each other. The region of  97
21q22.2 gain involved 3 clones and spanned a region of ~2.5Mb. The three clones in the 
gained region were; RP1-128M19 at 40.7Mb, containing BRWDA, HMGN1 and WRB, 
RP1-171F15 at 41.7Mb, containing DSCAM and RP1-265B9 at 42.6-42.7Mb, 
containing BACE2, FAM3B and MX2. Further investigation of the raw data showed the 
regions of gain occurred most frequently in diffuse astrocytomas. RP1-128MG was 
gained in 4 samples (DA3, DA7 and DA9), RP1-171F15 was gained in 4 samples 
(PMA1, DA2, DA4) and RP1-265B9 was gained in 2 samples (DA3 and DA9) 
respectively. However, none of these regions were identified as significant regions of 
gain when examining each sample individually, or within the non-cerebellar group 
alone. 
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Sample 
 
Pathology, 
site 
Age
 
Sex
 
X 
chromosome
Y 
chromosome 
Agrees with 
patient sex 
PA1 Cerebellum  20  F  Gain  Loss  Yes 
PA3  Cerebellum  7  M  No gain  No gain  Yes 
PA11  Cerebellum  14  M  No gain  No gain  Yes 
PA13  Cerebellum  10  M  No gain  No gain  Yes 
PA14   Cerebellum  10  M  No gain  No gain  Yes 
PA15  Cerebellum  13  M  No gain  No gain  Yes 
PA17  Cerebellum  6  M  No gain  No gain  Yes 
PA18  Cerebellum  3  M  No gain  No gain  Yes 
PA20  Cerebellum  4  M  No gain  No gain  Yes 
PA23   Cerebellum 3  F  Gain  Loss  Yes 
PA32 Brain  stem 9 F  Gain  Loss  Yes 
PMA1 Diencephalon  1  F  Gain  Loss  Yes 
DA2  Cerebrum  9  M  No gain  No gain  Yes 
DA3  Cerebrum  17  M  No gain  No gain  Yes 
DA4  Cerebrum  4  M  No gain  No gain  Yes 
DA7  Cerebrum  5  M  No gain  No gain  Yes 
DA9 Cerebrum 9  F  Gain  Loss  Yes 
PMG1  Diencephalon  17  M  No gain  No gain  Yes 
PMG2 Diencephalon  7  F  Gain  Loss  Yes 
PMG5 Spinal  cord 11 F  Gain  Loss  Yes 
Table 3.1  Sex chromosome gains and losses determined by array CGH from 
tumour samples when compared with pooled male control DNA. 
 Male patients should display no net gain of X or Y, and female patients should 
display gain of X and loss of Y. There was 100% concordance between patient sex 
and the gains and losses in the sex chromosomes identified by array CGH. PA 
(pilocytic astrocytoma), DA (diffuse astrocytoma), PMG (pilomyxoid glioma), 
PMA (pilomyxoid astrocytoma). 99 
 
Sample 
 
Site Age 
 
Sex 
 
Chromosome 
gains 
Chromosome 
losses 
Discrete 
changes 
Position 
(Mb) 
Clones at start and end of 
region 
Size of 
change 
Clones flanking region 
PA1  Cerebellum  20  F  Gain 5, 6  None            
PA3 Cerebellum 7 M  None  None             
PA11  Cerebellum  14  M  Gain 5, 6   None           
PA13 
 
Cerebellum 
10 
 
M 
 
None  
 
None 
 
7q22.1 loss  99Mb  RP11-506M12*, RP5-
1059M17* 
 
1.5Mb RP4-604G5,  RP11-333G13 
PA14 Cerebellum 10 M  None    Loss  17           
PA15 Cerebellum 13 M  None  None           
PA17  Cerebellum  6  M  None   None            
PA18 
 
Cerebellum 3 
 
M 
 
None  
 
None 
 
2p22.1 loss  39Mb  RP11-173C1, RP11-395B14* 
 
500Kb RP11-278G12,  RP11-457F14 
PA20 Cerebellum 4  M  None  Loss  22           
PA23 
 
 
 
Cerebellum 3 
 
 
 
F 
 
 
 
None 
 
 
 
None 
 
 
 
1q42.12 loss 
 
4p15.31 gain 
220Mb 
 
20Mb 
RP11-100E13*, RP11-375H24 
 
RP11-362J17, RP11-10G12* 
 
2.4Mb 
 
1.8Mb 
RP11-105I12, RP11-276J4 
 
PAC963K6, RP11-406E22 
PA32 
 
  
Brainstem 9 
 
 
F 
 
 
Gain 13 
 
 
Loss 22 
 
 
Loss 
terminal end 
1p 
tel - 55Mb  PAC14E10*, RP5-1043G4 
 
 
55Mb  
(62 
clones) 
RP5-1070D5 
 
PMA1 
 
Diencephalo
n 
1 
 
F 
 
None 
 
None 
 
5q33.3 gain 
8q11.23 gain 
157Mb 
53Mb 
RP11-391B7*, CTC-279E3 
RP11-197I11, RP11-182E14* 
1.8Mb 
860Kb 
RP11-102A1, RP11-505G12 
RP11-11C20, RP11-53M11 
Table 3.2 Summary of chromosome gains, losses and point changes, excluding sex chromosomes, found in 20 tumour samples by array CGH. 
 Asterisks denote clones containing known copy number variations or copy number polymorphisms from UCSC Genome Browser (March 
2006 assembly). 100 
Sample 
 
Site Age 
 
Sex 
 
Chromosome 
gains 
Chromosome 
losses 
Discrete 
changes 
Position 
(Mb) 
Clones at start and end of 
region 
Size of 
change 
Clones flanking region 
DA2 
 
Cerebrum 9 
 
M 
 
None 
 
Loss 17 
 
Loss terminal 
end 1p 
tel–55Mb PAC14E10*,  RP5-1043G4 
 
55Mb 
(62 clones) 
RP5-1070D5 
DA3 
 
Cerebrum 17 
 
M 
 
Gain 6, 7, 21 
 
None 
 
5q32 gain  149Mb  CTB-1013H5, CTB-137O22* 
 
500Kb RP5-1070D5 
DA4 
 
 
 
 
 
 
 
 
 
 
Cerebrum 4 
 
 
 
 
 
 
 
 
 
 
M 
 
 
 
 
 
 
 
 
 
 
None 
 
 
 
 
 
 
 
 
 
 
Loss 17, 19, 
20, 22 
 
 
 
 
 
 
 
 
 
Loss terminal 
end 1p 
 
7 cen-7q11.23 
loss 
 
7q22.1 loss 
 
 
7q36.1-tel 
loss 
tel–46Mb 
 
 
cen–74Mb 
 
 
99Mb 
 
 
148Mb-tel 
PAC14E10*, RP11-8J9* 
 
 
RP4-725G10*, RP4-771P4 
 
 
RP4-550A13, RP11-506M12* 
 
 
RP5-1136G13*, PAC3K23 
 
45Mb  
(53 clones) 
 
17Mb  
(17 clones) 
 
800Kb 
 
 
10Mb  
(17 clones) 
RP11-330M19 
 
 
RP11-339F13, RP4-799O8 
 
 
RP11-380G21, RP11-44M6 
 
 
RP4-811H12 
DA7 
 
 
 
 
Cerebrum 5 
 
 
 
 
M 
 
 
 
 
None 
 
 
 
 
None 
 
 
 
 
2q11.2 gain 
 
 
17p12 gain 
102Mb 
 
 
13Mb 
RP11-451C2*, RP11-451G1* 
 
 
RP11-388F14*, RP1-27J12 
 
1.8Mb 
 
 
1.1Mb 
RP11-299H21, RP11-350B7 
 
 
RP11-488L1, RP11-385D13 
DA9 
 
Cerebrum 9 
 
F 
 
None 
 
None 
 
2q11.2 gain  102Mb  RP11-451C2*, RP11-451G1* 
 
1.8Mb RP11-299H21,  RP11-350B7 
PMG1 
 
 
Diencephalon 17 
 
 
M 
 
 
Gain 6, 8, 11, 
12 
 
None 
 
 
  
 
  
PMG2 
 
 
 
Diencephalon 7 
 
 
 
F 
 
 
 
None 
 
 
 
None 
 
 
 
Loss terminal 
end 1p 
tel- 53Mb   PAC14E10*, RP11-117D22* 
 
 
 
52Mb 
(60 clones) 
RP11-243A18 
 
PMG5 
 
Spinal cord  11 
 
F 
 
Gain 9 
 
None 
 
  
 
  
Table 3.2 Continued. 101 
 
 
Figure 3.12 Array CGH whole genome plot for tumour sample PA11, showing 
gains of chromosomes 5 and 6. 
 
Figure 3.13 MA plot using raw array CGH data for sample PA11.  
Equal hybridisation between fluorochromes is shown for the majority of data 
points, along the zero axis. At the lowest signal intensity values the feature values 
become scattered, as they become similar to the background signal intensity. 
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Figure 3.14 Array CGH data plots for selected chromosomes from tumour sample 
PA11.  
A)  Chromosome 2, no net gain or loss of DNA 
 
B)  Chromosome 4, no net gain or loss of DNA 
 
C)  Chromosome 5, whole chromosome copy number gain  
 
D)  Chromosome 6, whole chromosome copy number gain  
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Figure 3.15 Array CGH whole genome plot for tumour sample PMG1, showing 
gain of chromosomes 6, 8, 11 and 12. 
 
Figure 3.16 MA plot using raw array CGH data for sample PMG1. 
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Figure 3.17 Array CGH chromosome plots from tumour sample PMG1. 
 
A)  Chromosome 4, no net gain or loss of DNA 
 
B)  Chromosome 6, whole chromosome copy number gain 
 
C)  Chromosome 8, whole chromosome copy number gain 
  
D)  Chromosome 12, whole chromosome copy number gain 
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Figure 3.18 Array CGH data plots for discrete regions of gain and loss.  
A)  Loss of chromosome 1p in sample DA4. 
 
B)  Gain in chromosome band 2q11.2 (102Mb) in sample DA7. 
 
C)  Loss in chromosome band 7q22.1 (99Mb) in sample PA13. 
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Figure 3.19 Whole genome array CGH plot comparing grouped data from 
cerebellar tumours with non-cerebellar tumours.  
No significant regions of gain or loss were identified within the cerebellar tumour 
group.   107
 
 
Figure 3.20 Array CGH data plots for chromosome 21. 
A)  Array CGH data plot for chromosome 21 using pooled data from all 
cerebellar samples, showing no net gain or loss of DNA.  
 
B)  Array CGH plot for chromosome 21 using pooled data from all non-
cerebellar samples. This indicates a region of gain at ~42Mb which does not 
achieve statistical significance. 
 
C)  Array CGH plot for chromosome 21, subtracting non-cerebellar data from 
cerebellar data to identify differences between the two groups. A significant region 
of copy number loss is identified at ~40Mb, indicating a region of gain in the non-
cerebellar group, when compared to the cerebellar group. 
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3.6  Discussion 
 
In this chapter, gains and losses of whole chromosomes and discrete genomic regions 
were identified by array CGH, in paediatric low-grade astrocytoma samples and in the 
medulloblastoma cell lines Daoy and HTB187.  
 
Array CGH has enabled detailed analysis of copy number changes to be performed in 
cancer. There are, however, limitations to the technique. Gains or losses of genetic 
material are identified relative to the whole genome. Balanced translocations are not 
identified by the technique, as there is no net change of genetic dosage (Gaasenbeek et 
al., 2006, Lichter et al., 2000). Aneuploidy (e.g. monosomy or trisomy) is identified by 
array CGH, this is common in epithelial cancers (Storchova et al., 2004). However the 
data represent an average of genetic imbalances, which is entirely dependent on the 
input DNA. Data plots for array CGH from cell lines contain a pure or almost pure 
population of cells containing the same genetic aberration. DNA extracted from tumour 
samples may contain a heterogeneous population of cells, a proportion of which may 
contain germline karyotypes, while a further proportion have undergone malignant 
transformation. Using a log2 scale, a single DNA copy gain in a tumour sample when 
compared with a control would be expected to be + 0.58 above the x-axis, and a gain of 
2 copies +1. In general, array CGH plots from tumour samples rarely give such clear 
ratios due to contamination by non-malignant cells. This underlies one of the main 
difficulties with array CGH – where to set the thresholds for gain and loss. There has 
not been general consensus of what constitutes gain or loss within the literature. For the 
purposes of this thesis, I designated a single copy gain to be ≥ 0.3 above the x-axis, and 
a single copy loss to be ≤ -0.5 below the Y-axis, to reflect the probable heterogeneity of 
the tumour tissue studied.  
 
Three types of array CGH platform are available. Arrays comprised of BAC/PAC 
genomic DNA clones or cDNA clones may be used for genome-wide analysis, synthetic 
oligonucleotide arrays may be used to study particular regions of interest at higher 
resolution. More recently genome-wide oligonucleotide arrays have become available, 
but these had not been developed at the time this study began (Ylstra et al., 2006).  
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The array platform chosen for a series of experiments should be made after considering 
the merits and the disadvantages of each system. Genomic BAC or PAC clones may 
exhibit significant homology between paralogues or related gene family members at 
different chromosomal locations, which affects binding specificity for individual clones. 
Ideally, all genomic clones selected for use on array slides should undergo mapping by 
fluorescence in situ hybridisation (FISH) to confirm their genomic location (Fiegler et 
al., 2003). Unfortunately this is time-consuming and costly, so is usually not possible 
for each and every clone used to construct an array. Arrays produced using cDNA 
clones provide gene-specific data, and are not subject to the clone mapping errors that 
may occur in genomic arrays. However, many genes exhibit alternative splicing, which 
will produce differences in sequence not covered by individual cDNA clones. Hence, 
genomic BAC DNA arrays may be preferred to probe gene-poor regions that do not 
have representative cDNA clones. 
 
The production of the numerous BAC clones required for an array is hugely expensive 
and time-consuming. Individual BAC clones are produced in large-scale bacterial 
cultures, often giving low yields of DNA per clone (Albertson et al., 2003, Fiegler et 
al., 2003). BAC DNA is generally viscous in solution as large clone inserts have a high 
molecular weight, which makes printing array slides technically difficult (Albertson et 
al., 2003). Early array CGH production methods occasionally used sonication of DNA 
to reduce fragment sizes to overcome this (Cai et al., 2002). Currently, clones can be 
produced by PCR amplification from smaller-scale single-colony DNA clone 
preparations using a variety of PCR amplification methods (Snijders et al., 2001, 
Veltman et al., 2002, Fiegler et al., 2003). Amplification by modified degenerate-
oligonucleotide primed PCR (DOP-PCR), using three different primers selected to 
amplify human DNA sequences in preference to DNA from E.Coli, gave the most 
reproducible and complete results (Fiegler et al., 2003). This was due to reduced 
contamination of clones by E.Coli DNA, and to improved primer efficiency for human 
DNA amplification.  
 
For this study, I selected genomic DNA array slides, as they provided more 
comprehensive information on copy number changes across the whole genome, 
including gene-poor regions.  
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The resolution of array CGH data is determined not only by the quality of the input 
DNA, but also by the size and density of the BAC and PAC clones on the array. The 
methods of printing and drying the slides are very important, to ensure features 
hybridise evenly with the input DNA. Features should be uniformly round to allow 
identification by spot-finding software packages such as Genepix or Spotfinder. 
Deficiencies in printing or drying the slides can compromise array slide quality, and 
hence the sensitivity and specificity of the results obtained. 
 
Sensitivity (i.e. the number of true positive spots identified) was low in the array slides 
used to prepare data for this thesis. I found that there were high numbers of features 
flagged as ‘bad’ when scanning, due to deficiencies with printing. Significant numbers 
of features were rejected by the Genepix software, due to their appearances on scanning. 
Many spots appeared doughnut or rugby-ball shaped, giving uneven hybridisation of 
fluorochrome, and hence not meeting the inclusion criteria for a ‘good’ feature. The 
number of features meeting inclusion criteria for array CGH experiments and replicates 
performed for each sample are shown as percentages in Table 3.3. The range of features 
included in the analyses varied from 23-77% between samples. Twelve out of 20 
samples had 23-49% ‘good’ features available for analysis. However, samples where 
<40% features were used for analysis were still able to assign patient sex correctly by 
gain, loss or no change in the sex chromosomes. For example, DA3 only included 22 
features from the Y chromosome, but showed that there was no net gain or loss of DNA 
when compared to the male control DNA, correctly indicating that the patient was male. 
These data indicate that whole chromosome changes were identified correctly even 
where a low proportion of features were included. However, identification of discrete 
regions of gain or loss would obviously be compromised by the lack of data points 
across the chromosomes caused by the low numbers of ‘good’ features.  
 
High background signal was also a problem when scanning the slides, despite numerous 
changes to the washing protocol during optimisation of the technique. Hence specificity 
(proportion of true negative spots identified) was low. This appeared to be due to non-
specific hybridisation of test and control DNA to the slide surface, which again 
appeared to be related to problems with slide production. The MA plots demonstrated 
equal hybridisation between fluorochromes for the majority of the data. However, at 
lower signal intensities, the feature values became scattered away from the zero axis, as 
they became similar to the background signal intensity. Overall, it appeared that the  111
array slides produced by the ICR did not achieve the quality of arrays previously 
available to the laboratory from another source, which had been used in our laboratory 
to investigate adult glioblastomas (Mulholland et al., 2006). 
 
Array CGH has been used to identify regions of DNA copy number gain and loss in 
adult astrocytomas, particularly in glioblastomas (WHO grade IV). Amplifications of 
the oncogenes EGFR (36%), PDGFR (8%), CDK4 (13%), MDM2 (9%) and MDM4 
(8%) occur frequently in glioblastomas (Roerig et al., 2005, Ruano et al., 2006, Rao et 
al., 2009, Korshunov et al., 2006, Misra et al., 2005). These data indicate that the genes 
involved in gliomagenesis are part of well-known oncogenic pathways, including 
growth factor signalling via receptor tyrosine kinases and inhibition of cell cycle 
progression and apoptosis via the p53 and Rb pathways. Array CGH data have also 
been used to define further sub-classifications within glioblastomas. Primary adult 
glioblastomas (GBMs) arise de novo with a short clinical history, generally less than 3 
months, and comprise over 90% of adult GBMs. Secondary GBMs arise from a pre-
existing low-grade astrocytoma over a longer period, often 5-10 years. Secondary 
GBMs are much less common, constituting 5% of GBMs, and tend to affect younger 
patients (Maher et al., 2006, Ohgaki et al., 2007). Amplification of EGFR is the most 
common abnormality seen in primary GBMs, being found in 36% compared to ~ 8% in 
secondary GBMs. Mutations in PTEN are also seen more commonly in primary GBMs. 
Loss of function mutations affecting p53 are most commonly seen in secondary GBMs. 
These appear to occur early in their malignant progression, as mutations are most 
commonly seen in WHO grade II and III astrocytomas (Raffel et al., 1999, Ohgaki et 
al., 2007). However, both primary and secondary GBMs contain similar levels of some 
aberrations, including homozygous loss of CDKN2A, and amplification of CDK4 and 
MDM2. 
 
Relatively few studies have investigated adult low-grade astrocytomas using metaphase 
or array CGH (Schrock et al., 1996, Hirose et al., 2003). Large copy number gains were 
the most frequent aberrations reported, most commonly involving complete or partial 
gains of chromosomes 5 and 7, and losses of chromosome 1p. The characteristic 
changes present in adult GBMs have not been identified in low-grade adult astrocytoma 
samples. 
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Sample  Slide 1  Slide 1  Slide 2  Slide 2  Slide 3  Slide 3 
   Good features  Plot medians on 45
o line Good features  Plot medians on 45
o line Good features  Plot medians on 45
o line
PA1  48%   No  65%  Yes       
PA3  29%  No  16%  Yes       
PA11  77%  Yes             
PA13 55%  Yes         
PA14  18% Yes 45% Yes 67% Yes 
PA15  18% Yes 30% Yes 72% Yes 
PA17  27% Yes 41% No 10% No 
PA18  34% Yes 37% No 48% Yes 
PA20  32% No 20% No         
PA23  24%  No  77%  Yes       
PA32  19% Yes 37% No 48% Yes 
PMA1  48%  Yes             
DA2  56%  Yes             
DA3  15%  No  23%  Yes       
DA4  30% Yes 31% Yes         
DA7  38%  Yes             
DA9  18% Yes 37% Yes         
PMG1  65%  Yes             
PMG2  25%  No  36%  Yes       
PMG5  23% No 26% Yes 17%   No 
Table 3.3 Percentage of features meeting inclusion criteria for a ‘good’ feature (>75% spot pixels >2SD above background) for array CGH 
experiments performed for each sample from Genepix 6. 113 
Paediatric astrocytomas have also been investigated using metaphase and array CGH. 
Studies investigating paediatric high-grade astrocytomas have identified losses of 
chromosome 10q including the PTEN locus, similar to those seen in adults, but 
amplification of EGFR (7p12) and CDK4 (12q), or chromosome 10p loss have not been 
frequent findings. Warr et al. studied 13 paediatric high-astrocytomas (grades III and 
IV), and found loss of the PTEN locus concurrent with complete loss of chromosome 10 
in 1 case, but did not find amplification of EGFR, or loss of CDKN2A/B or RB in any 
samples (Warr et al., 2001). Similarly, Rickert et al. found a much lower frequency of 
chromosome 7 gains in paediatric high-grade astrocytomas (8%), when compared to 
those seen in adults (32%) (Rickert et al., 2001). No paediatric cases were shown to 
contain loss of 10p, compared with 51% in adult GBMs. In this study: 23% paediatric 
GBMs showed gains of chromosome 1p versus 9% in adult GBMs and 23% paediatric 
GBMs showed 2q gain versus 3% adult GBM. Similar findings were found for 
chromosome 21q gain, 6q loss, 11q loss and 16q loss – which were all more common in 
the paediatric astrocytomas. These results suggest that high-grade paediatric 
astrocytomas appear to contain some similarities, but also contain different genetic 
aberrations to those seen in adult astrocytomas. 
 
Few studies have been performed in paediatric low-grade astrocytomas using CGH. 
Again, the frequent genetic aberrations present in adult GBMs were not found. The 
majority of low-grade astrocytomas from children and adults display balanced 
karyotypes. The most commonly seen aberrations in children are whole chromosome 
gains, involving chromosomes 5, 6, 7, 9, 11 and 19 or losses of 2 or 22, usually 
occurring as a single aberration (Schrock et al., 1996, Sanoudou et al., 2000, Jones et 
al., 2006). The most common aberrations in adult low-grade astrocytomas were partial 
or whole gains of chromosome 7 (Schrock et al., 1996), gains of chromosomes 19 or 22, 
or discrete losses at 1p33-pter, 9q34.1-ter, 17q21.3-ter, 2p22-pter, 9q31-qter and 
12q13.2-q23 (Sanoudou et al., 2000). Chromosome gains have been noted to be more 
common in older patients, aged >10 years with pilocytic astrocytoma (Jones et al., 
2006). Jones et al. showed a median of 4-5 chromosome gains per case in patients aged 
>10 years, whereas younger patients showed one or fewer chromosome gains. These 
results concur with the whole copy number gains identified in 6/20 tumours here, which 
were all identified in patients between the ages of 9 and 20 years (mean 14.6 years, 
standard deviation 4.13 years). Patients with no whole chromosome gains had a mean 
age of 6.5 years, standard deviation 3.4 years.  114
 
Array CGH analysis of the paediatric tumour samples here revealed that 40% of the 
samples had either a balanced karyotype, or a balanced karyotype with a single small 
region of chromosome gain or loss, within the limits of resolution of the technique. 
Whole chromosome gains were identified in 30% of the tumour samples, most 
commonly in chromosomes 6 and 5, and whole chromosome losses were most 
commonly seen for chromosomes 17 and 22, in order of prevalence. The results for 
whole chromosome gains from this study agree with previous findings for chromosome 
gains in low-grade astrocytoma. This study also revealed small numbers of chromosome 
losses and discrete regions of gain and loss, which had not been seen in earlier studies. 
 
Partial losses of chromosome arm 1p were identified in 4 samples (PA32, PMG2, DA2 
and DA4). The regions of loss varied in size from 45 to 55Mb. Two samples showed 
identical regions of terminal 1p loss, ending at the same BAC clone at 55Mb. Currently 
the functions of genes within this region (C1orf175, TTC4, PARS2 and TTC2) are little 
understood; none are known to play any role in cancer.  Two further samples also 
showed partial 1p losses, of different sizes. Both ended within regions of known copy 
number variation. The loss of chromosome 1p has previously been identified in adult 
astrocytomas. Complete loss of 1p, in tandem with 19q loss is a characteristic finding in 
oligodendrogliomas (Idbaih et al., 2005). Oligodendrogliomas have distinct 
morphological appearances from other grade II astrocytomas. Patients with 
oligodendrogliomas, with complete 1p and 19q loss have been shown to have longer 
overall survival and progression-free survival when compared with grade II-III 
astrocytomas and oligoastrocyomas. Partial chromosome 1p losses, without concurrent 
19q losses have also been identified in adult astrocytomas. These are most commonly 
found in GBMs, and appear to correlate with a poorer prognosis.  None of the samples 
with 1p loss in this study had concurrent 19q loss – this was as expected, as no 
oligodendrogliomas were included in this study. However, the size of the region of loss 
made further investigation difficult, as so many genes are contained within the region. 
Further studies on additional samples may help to define the region of loss more 
closely. Additionally, the use of short-term tumour cultures, if available, would allow 
M-FISH and FISH to be performed, to map the boundaries of the region of loss more 
closely. 
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Two samples (DA7, DA9) displayed identical regions of gain covering 1.8Mb, at 
102Mb on chromosome 2q11.1. The clones at both the start and end of this region of 
gain contained regions of known CNV, so the region of gain identified could represent 
normal variation between individuals. Two genes were within the gained region: solute 
carrier family 9 (sodium/hydrogen exchanger), member 2 (SLC9A2),  and 
transmembrane protein 182 (TMEM182). Neither of these genes is known to have a role 
in brain tumours or other malignancies.  
 
Two samples (PA13, DA4) revealed losses of a discrete region on chromosome 7q22.1, 
with a minimal common region of loss covering the clone RP11-506M12. This region 
contains the genes MCM7 and TAF6.  The protein encoded by mini-chromosome 
maintenance complex component 7 (MCM7) is one of a group of highly conserved 
MCM proteins, including MCM2, 4, 6 and 7. These proteins form a complex, which is 
essential for the initiation of DNA replication, and may act as a helicase to unwind the 
DNA (Tachibana et al., 2005). CDK4 is known to associate with this protein complex, 
and may regulate its binding to the tumour suppressor protein Rb.  TAF6 RNA 
polymerase II (TAF6) encodes one of the subunits within transcription factor IID, one of 
the many proteins involved in the initiation of RNA transcription. TAF6 has 4 isoforms, 
and one of these, TAF6 delta has been shown to be part of an apoptosis signalling 
pathway, including activity in tumour cell lines lacking p53 (Wilhelm et al., 2008). 
 
Comparison of cerebellar pilocytic astrocytoma samples with non-cerebellar samples 
did not reveal any significant regions of copy number change in the cerebellar group. A 
small region of gain at chromosome band 21q22.2 was identified in the pooled data 
from the group of varied non-cerebellar tumour samples, represented by 3 BAC clones. 
However, this region was only identified when the data were subtracted from the pooled 
cerebellar samples, and was not identified as a significant region of gain (ratio ≥0.3 in 
raw data, or by CBS) in individual patient samples. The entire length of chromosome 21 
was covered by 26 BAC clones which were sparsely dispersed along the chromosome. 
Further examination of the data plots across chromosome 21 for individual tumours and 
individual arrays revealed a large amount of signal intensity variability. Hence, this 
apparent region of gain might purely represent experimental noise. One of the three 
gained clones was found in each of the 5 diffuse astrocytomas in the non-cerebellar 
group. It was possible that combining the sample data in this way had allowed recurrent 
aberrations present in multiple samples to be revealed, which were not considered  116
significant when considering analyses from single samples. Genes of interest in the 
21q22.2 region include BRWD1, HMGN1 and DSCAM. BRWD1 (bromodomain and 
WD repeat domain containing 1) is a WD repeat protein family member, known to be 
involved in cell cycle progression, signal transduction, apoptosis and gene regulation. 
The encoded protein function is currently unknown. The protein encoded by HMGN1 
(high mobility group nucleosome binding domain 1) may alter the chromatin 
conformation of transcribed genes, by affecting DNA interaction with histone proteins 
(Cherukuri et al., 2008). Finally, DSCAM (Down syndrome cell adhesion molecule) is 
known to play a role in CNS development as an axonal guidance molecule (Liu et al., 
2009). DSCAM expression is involved in the development of the choroid plexus, floor 
and roof of the 4
th ventricle, pons and medulla (Barlow et al., 2002), which makes it an 
attractive candidate to investigate further in non-cerebellar astrocytomas. I felt that 
these changes were most probably due to experimental noise – but was interested to 
follow up gain of this region, particularly in diffuse astrocytomas using a different 
technique, which will be described in chapter 4. 
 
Additional regions of discrete gain and loss were also identified in single tumour 
samples. Discrete changes in single samples were less convincing as regions containing 
possible candidate genes, as these could be attributed to experimental noise.  The array 
CGH slides used for this series of experiments were sufficiently powerful to identify 
gains or losses involving whole chromosomes, or large chromosomal regions. The 
overall resolution and quality of the array slides used was poor. Affymetrix 250k SNP 
arrays became commercially available (and affordable) towards the end of 2006. I 
decided to move to a higher resolution array platform to conduct further analysis of the 
low-grade astrocytoma samples, as I did not feel that the 1Mb array CGH platform had 
sufficient power to identify discrete regions of DNA copy number change. Hence, the 
focus of my DNA copy number investigation moved away from 1Mb array CGH to 
higher resolution SNP array platforms. This decision was subsequently justified by the 
identification of a recurrent discrete region of copy number gain in cerebellar pilocytic 
astrocytomas using Affymetrix 250K and 6.0 SNP arrays, which will be described in 
further detail in chapter 4. 
 
In summary, array CGH analysis correctly identified regions of chromosome gain and 
loss within two medulloblastoma cell lines previously characterised by M-FISH and 
FISH. Examination of 20 cerebellar and non-cerebellar paediatric low-grade  117
astrocytomas showed 100% sensitivity in identification of patient sex, by sex 
chromosome copy number change. Balanced karyotypes, some containing a single 
discrete region of gain or loss were demonstrated in 40% of the tumour samples, and 
small numbers of whole chromosome gains and losses were identified, consistent with 
previously described findings in the literature.  
 
Whole chromosome gains were found in patients aged 9-20 years. No whole 
chromosome gains were found in patients younger than 9 years, supporting data from a 
previous study (Jones et al., 2006). There were no recurrent aberrations identified in the 
array CGH profiles of tumours from the cerebellum. Three recurrent aberrations 
involving discrete copy number changes were found, and these were the primary 
candidate regions of interest for the higher resolution SNP array study.  118 
Chapter 4.  DNA copy number changes by SNP array 
analysis 
 
4.1  Introduction 
 
All human genomes differ, except those from identical twins. Around 99.9% of the 3.2 
billion base pairs forming the genome are common between individuals. However, the 
tiny 0.01% difference involves millions of base pairs, which form the basis of genetic 
variation (Kruglyak et al., 2001). These genetic differences are inherited, and include 
traits for disease and disease susceptibility. Alleles are alternative forms of a particular 
gene. Humans contain two copies of each chromosome, and two alleles (one from each 
chromosome) form an individual’s genotype for a particular gene. Alternate alleles are 
often termed A and B. An individual is homozygous where both alleles for a gene are 
the same (AA, BB), where the alleles are different the individual is heterozygous for a 
particular genetic trait (AB). 
 
A single nucleotide polymorphism (SNPs) is a variation within the DNA sequence 
caused by the change of a single nucleotide. There are estimated to be ~ 10 million 
SNPs in the human genome and around 7 million common SNPs with minor allele 
frequency (MAF) greater than 5% (Kruglyak et al., 2001). The MAF is the frequency of 
a less frequent allele for a SNP within a population. It is estimated that there are a 
further 4 million SNPs with a MAF from 1-5% (Hinds et al., 2005). Previously SNPs 
were defined as polymorphisms occurring at a frequency of >1% within the population 
(Wang et al., 1998), however the definition of a SNP has recently been refined, and a 
minimum frequency is no longer required. Hence, many SNP databases now include 
SNPs with a lowest allele frequency of <1%.  
 
SNPs are the most frequent type of variation found in the human genome, and may vary 
within the same individual (where SNPs differ between alleles) or between individuals 
or species (LaFramboise, 2009). These changes may be used as genetic markers to 
study disease (Bignell et al., 2004, Huang et al., 2004). Large international consortia 
including the International HapMap Consortium and the 1000 Genomes Project are   119
attempting to identify, genotype and catalogue SNPs from large numbers of individuals 
from different ethnic backgrounds (Siva, 2008, HapMap, 2003). These data are freely 
available to researchers, and may be used to link SNP variation with specific disease 
traits. 
 
Array technology was developed for use in SNP identification in 1998 (Wang et al., 
1998). Wang et al. designed 25-oligonucleotide probes centred on an individual SNP 
nucleotide, which was substituted at position 13 by adenine (A), cytosine (C), guanine 
(G) or thymine (T) in four otherwise identical probes. Biotinylated DNA was then 
hybridised to these four probes. DNA homozygous for the SNP sequence (AA) would 
hybridise strongly to the complementary probe, however heterozygotes (AB) and 
different homozygotes (BB) would show different hybridisation patterns at the central 
nucleotide (Figure 4.1). The SNPs within a DNA sample were amplified using 
multiplex PCR, using multiple primer pairs, however the formation of primer dimers 
limited the numbers of primers per reaction.  Sample preparation was very labour 
intensive using this technique. A significant proportion (around 12%) of SNPs 
identified using this method were found to be false positives when compared to 
sequence data (Wang et al., 1998). Non-specific signal hybridisation became more of a 
problem as the resolution of SNP arrays increased. Larger numbers of possible target 
sequences led to increases in cross-hybridisation of genomic DNA across probes, with a 
higher proportion of non-specific signals, as reviewed by Kennedy et.al. in 2003 
(Kennedy et al., 2003). 
 
Kennedy and co-researchers at Affymetrix developed the whole-genome sampling assay 
(WGSA) method currently used for SNP arrays in 2003, which will be described in 
more detail in the Methods section below (Kennedy et al., 2003). The WGSA method 
increased hybridisation specificity by fragmenting the genomic DNA with restriction 
enzymes, followed by ligation to a specific adaptor sequence. PCR amplification, using 
a single primer set for the adaptor sequence, reduced both the complexity and fragment 
sizes of the DNA applied to the array, thus improving specificity. SNPs are 
subsequently genotyped by hybridisation to perfect match or mis-matched 25-mer 
probes for each SNP on the array. Mis-matched probes contain a single base mis-match 
at the centre of each probe (Figure 4.1). Probes are arranged in quartets, which comprise 
perfect match probes for alleles A and B, and mismatch probes for alleles A and B. This 
allows three possible genotypes (AA, AB, BB) to be determined for each SNP, using   120
the intensity measurements for each probe within the quartet. The signal intensity 
depends on the affinity between target and probes, and also on the amount of target 
DNA in the sample. 
 
 
 
 
Figure 4.1 Overview of Affymetrix SNP array genotyping.  
The DNA fragment containing a SNP with alternate alleles adenine/cytosine (A/C) 
is investigated with the 25-mer probes shown below. The DNA will bind to all of 
the probes, but binding is most efficient when all of the 25-mer probe bases are 
complementary (yellow), rather than the single base mismatch at the SNP site 
(blue). The perfectly matched and bound probes produce a strong fluorescent 
signal on scanning, the mismatched probes produce dimmer signals. Figure 
adapted from LaFrambose, Nucleic Acids Research 2009 (LaFramboise, 2009). 
 
 
 
 
25-mer probes 
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SNP arrays were originally designed for genotyping to investigate genetic diversity and 
disease associations and to undertake population studies. They have been used 
extensively for linkage disequlilibrium studies to investigate genetic associations with 
disease, and have more recently been used for genome wide association studies 
(GWAS). GWAS investigates large numbers of individuals with and without a disease, 
and aims to find genetic variants that are more prevalent in those with the disease. The 
genetic variants associated with a disease may directly cause disease or increase 
susceptibility to a condition, or the regions of variation may be linked to nearby alleles. 
Linkage may be autosomal, where alleles are physically located close to each other on 
the same chromosome, or may be via linkage disequilibrium. Here, alleles at different 
loci, sometimes even on different chromosomes occur within the same haplotype more 
frequently than expected by chance (Wall et al., 2003).  Such large studies have huge 
statistical power to find genes implicated in disease; the first GWAS looking at genetic 
risk factors in adult astrocytoma was recently published (Shete et al., 2009). In this 
study, 550 000 single nucleotide polymorphisms (SNPs) from 1,878 glioma cases and 
3,670 controls were genotyped. Five genomic regions with strong disease associations 
were identified, including novel candidate genes. These included the telomerase gene 
TERT at chromosome 5p15.33 (odds ratio: 1.27, p=1.5 x 10
-17), the CCDC26 gene at 
chromosome 8q24.21 (odds ratio: 1.36, p=2.34 x 10
-18) known to modulate cell 
differentiation and cell death as well as to down-regulate telomerase, the cyclin 
dependent kinase inhibitor genes CDKN2A and CDKN2B on chromosome 9p12.3 (odds 
ratio: 1.24, p=7.24 x 10
-15) which play a pivotal role in cell cycle control, the gene 
PHLDB1 on chromosome 11q23.3 (odds ratio: 1.18, p=1.07 x 10
-8) the function of 
which is little understood, as well as the RAD3-like helicase encoding gene RTEL1 at 
chromosome 20q13.33 (odds ratio: 1.28, p=2.52 x 10
-12) involved in telomere 
maintenance. Interestingly, telomere maintenance appears to be a recurring theme 
among the genes identified, and this will need to be investigated further in adult 
astrocytoma (Shete et al., 2009). 
 
In addition to the detection of genes implicated in disease by association studies, SNP 
array technology has become an important tool in the detection and characterisation of 
copy number variation and loss of heterozygosity (LOH) in cancer. The identification of 
LOH, which may occur at chromosomal regions containing tumour suppressor genes, 
was previously performed by genotyping using microsatellite markers (short tandem 
repeat polymorphisms containing 1-4 bp repeats) (Weber et al., 1989). However, this   122
process was extremely time consuming and labour intensive.  The use of SNP arrays to 
identify LOH revolutionised the field (Lindblad-Toh et al., 2000), as the technique is 
simple, quick and allows large numbers of samples to be analysed in a high-throughput 
fashion, which would previously have been unthinkable.  
 
SNP arrays have also been used to investigate DNA copy number in the cancer genome. 
The fluorescent intensity of SNP array probe features vary with DNA copy number 
changes, in exactly the same way as previously described in array CGH (Bignell et al., 
2004, Huang et al., 2004). Hence, SNP arrays are now used to investigate both DNA 
copy number and loss of heterozygosity in tumour samples, providing a greater depth of 
information from a single DNA sample that is not possible from array CGH alone. This 
is extremely important as some regions within tumours that display LOH do not show 
DNA copy number changes, and would not be identified by CGH. SNP arrays therefore 
provide huge advantages over CGH arrays, in terms of the data produced per sample. 
SNP arrays are manufactured under strict quality control conditions, providing accurate 
and highly reproducible genotyping. However they do not provide a comparative 
hybridisation between test and control DNA in a single experiment. Therefore, samples 
from normal individuals must be run using the same platform, to allow comparisons to 
be drawn between tumour samples and normal individuals. Data must be compared 
between ‘normal’ and experimental samples, using statistical methods to determine 
relative gains and losses of DNA across a sample set to improve statistical power. 
Ethnicity must also be considered when selecting control samples, as polymorphisms in 
SNPs are known to vary between ethnic groups. 
 
The first Affymetrix GeneChip Mapping 10k array, developed in 2003, contained 
10,044 SNP markers with a mean inter-marker distance of 105kb. Since then, 
Affymetrix have produced several generations of SNP arrays, each at higher resolution. 
The GeneChip Human Mapping 500K array set enables 500,000 SNPs to be genotyped 
using two separate arrays (each 250K). The Affymetrix Genome-Wide Human SNP 
Array 6.0 contains 1.8 million markers for genetic variation on a single array; >906,600 
SNPs and >946,000 probes to detect regions of copy number variation. This SNP array 
provided the highest genotyping coverage to date, with a median marker spacing of 680 
bases (Affymetrix 6.0 datasheet). However, Affymetrix have recently announced the 
development of a new SNP array platform containing 2.7 million probes, which will be 
available later in 2009. Illumina has developed an alternative platform using 50-bp   123
oligonucleotides attached to indexed beads, randomly arrayed on glass slides. Their 
current highest-resolution array contains 650,000 oligonucleotides, with a median SNP 
spacing of 2kb.  
 
4.2  Aim 
 
The aim of the work described within this chapter was to investigate genome-wide 
DNA copy number changes in paediatric low-grade astrocytomas using Affymetrix 
250K and 6.0 SNP arrays.  
4.3  Affymetrix 250K Nsp SNP array  
4.3.1  Materials 
 
An initial study of 21 tumour samples was run with Tim Forshew, using the Affymetrix 
GeneChip Human Mapping 250K Nsp Array.  
 
The samples comprised 14 pilocytic astrocytomas, 4 diffuse astrocytomas, one infantile 
hypothalamic pilomyxoid astrocytoma, one pilomyxoid glioma and one pleomorphic 
xanthoastrocytoma. Data from the tumour samples were compared to those from two 
healthy male DNA controls (extracted from co-workers at the Cancer Research UK 
London Research Institute), which were run on the same platform. 
 
Briefly, the GeneChip Human Mapping 500K array set comprises two separate arrays 
(each covering 250,000 SNPs or 250K) and two separate assays. The assays each utilise 
one of two restriction enzymes, Nsp I or Sty I to digest the genomic DNA into 
fragments (Figure 4.2). Oligonucleotide adaptor sequences are then ligated onto the 
ends of the DNA fragments. The adaptors bind specifically to 4bp overhangs at the Nsp 
I or Sty I restriction sites. PCR is then performed, with conditions optimised to amplify 
fragments between 200-1100 base pairs long. The amplified DNA is then fragmented, 
denatured and labelled prior to hybridisation onto the array. The process is summarised 
in Figure 4.1. 
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For these experiments, the Nsp 250K array was selected which contains probes for 
262,264 SNPs, each 25 base pairs long. Each SNP is represented by 6 or 10 probe 
quartets. Each quartet contains perfect match and mis-match probes for each of the two 
alleles, A and B. Therefore 24 or 40 different 25-bp oligonucleotides are present on the 
array to probe each SNP. 
 
 
 
 
Figure 4.2 Overview of Affymetrix 250K Nsp GeneChip mapping assay.  
Genomic DNA was digested with the restriction enzyme Nsp I. The resulting 
fragments were ligated with adaptors specific for the restriction sites. A single 
PCR primer was used, which recognised the adaptor sequence used to amplify the 
ligated fragments. PCR conditions were optimised to amplify fragments between 
200 and 1,100 base pairs. Amplified DNA was fragmented, denatured and labelled 
before hybridisation to the 250K Nsp array. The arrays were then washed and 
scanned. Figure adapted from the Affymetrix 500K protocol. 
 
 
4.3.2  Method 
 
The 250K experiments were performed following the protocol provided by the 
manufacturer (Affymetrix Inc., Santa Clara, CA). Two hundred and fifty nanograms of 
genomic DNA at 50ng/μl were used per array. DNA was digested using the Nsp I 
restriction enzyme master mix, and ligated with the Nsp I adaptor. Following PCR, the 
PCR products were purified using the Ultrafree-MC filtration column (Millipore, 
Nsp I Nsp I Nsp I  125
Bilerica, MA); this was the only modification from the manufacturer’s protocol. After 
DNAse-I digestion, the PCR products were labelled with a biotinylated nucelotide 
analogue using terminal deoxynucleotidyl transferase, and hybridised to the array. 
 
Array hybridisation, washing and scanning was performed by Tracy Chaplin at the John 
Vane Science Centre, Charterhouse Square, London. Arrays were scanned using a 
GeneChip 3000 7G scanner (Affymetrix, Santa Clara, CA). Data were exported as cell 
intensity (CEL) and genotyping analysis (CHP) files.  
 
4.3.3  Analysis 
 
Analysis of the Affymetrix 250K Nsp SNP array data was performed with Tim 
Forshew.  
 
Genotype calling was performed using GTYPE (Affymetrix GeneChip Genotyping 
Analysis Software), which converts the 6 or 10 probe quartet intensity measures into a 
genotype inference (AA, AB or BB). GTYPE uses an automated genotype-calling 
algorithm, which calculates the sum of signals from the perfect match probes from the 
array, and subtracts the sum of signals from the mismatched probes for each SNP. A 
confidence score is then assigned for each genotype. This can be used as a quality 
control, where SNPs with low confidence scores and SNPs where no call is assigned are 
not used for further copy number analysis. Samples with a call rate of >95% were used 
for further analysis in this study. 
 
Copy number analysis was performed using Copy Number Analyzer for Affymetrix 
GeneChip Mapping (CNAG) version 2.0 ((Nannya et al., 2005). CNAG is an algorithm 
for SNP array copy number analysis, which uses hidden Markov modelling and local 
mean analysis to reduce the variation in the raw signal ratios, thus improving the signal 
to noise ratio. Accurate genotyping information derived from CNAG enables inference 
of LOH in addition to allele-based copy number analysis. CNAG was developed to 
allow analysis of samples from different experiments, by compensating for variation 
between different experimental conditions. CNAG also allows comparison of tumour 
samples with multiple normal reference samples in the absence of constitutional DNA   126
as a paired control, which was the case for all of the tumour samples in this study. Data 
from the tumour samples were compared to data from two healthy male DNA controls.  
 
Signal intensity, genotype information and gender calls are extracted from the .CEL and 
.CHP files. CNAG normalises the data from the sum of signals over the 6 or 10 perfect 
match probes for the A and B alleles to perform genotyping. Linear regression is then 
performed, to compensate for the length of PCR fragments and GC content of the PCR 
products, which reduces variation between experiments. The log2 ratios of these values 
are then used to compare between different arrays. Signal intensity, genotype 
information and gender calls are used to create .CFH files, which are used for copy 
number calculations. For these, CNAG summarises the data from the sum of signals of 
the 6 or 10 perfect match probes for the A and B alleles to create a single ‘raw’ copy 
number measure for each SNP. These ‘raw’ copy number measures are rough 
measurements of the true underlying copy number state. CNAG performs pair-wide 
analysis between each sample and the available normal reference samples, and 
calculates the best combination of references to minimise the standard deviation for 
diploid autosomal (non-sex chromosome) regions. Gender information is used to infer 
copy number accurately in the X chromosome. Where patient sex is unknown, gender 
can be inferred by a significant number of heterozygous SNP calls from the X 
chromosome. However, LOH on the X chromosome could incorrectly indicate male 
gender in tumour specimens with deletion of one X chromosome. The sex was known 
for all of the cases included in this study.  
 
CNAG uses two methods of analysis to infer DNA copy number from SNPs. The 
overall aim is to infer segments of locally constant copy number change in the tumour 
samples from the noisy raw copy number SNP data. In local mean analysis, the mean 
log2 ratio is calculated between 3 or 10 SNPs depending on the standard deviation of the 
initial log2  values after linear regression. This further eliminates random noise, and 
helps to visualise the array copy number data. An alternate method employed by CNAG 
is hidden Markov modelling, which infers the copy number in a ‘hidden state’ (the true 
integer copy number) by comparison with the ‘observed’ state (the raw copy number, 
produced by the summarisation step). Hidden Markov modelling uses the assumption 
that a copy number change is due to genetic recombination between adjacent SNP loci, 
and calculates the probability of a given copy number change by comparison with 
neighbouring SNPs.   127
4.3.4  Results 
 
The data obtained from the Affymetrix 250K array analysis are available in the GEO 
database under Accession number GSE14960. 
 
Copy number analysis of the 21 tumour samples revealed a novel finding – a discrete 
copy number gain of ~1.9 Mb situated at chromosome band 7q34, in 12/14 cerebellar 
pilocytic astrocytomas and in the single hypothalamic pilomyxoid astrocytoma (Figures 
4.3, 4.4). Furthermore, two samples showed a discrete region of copy number loss at 
9p21, containing the CDKN2A locus. These were both grade II astrocytomas: 1 diffuse 
astrocytoma from the cerebral cortex (DA2) and 1 pleomorphic xanthoastrocytoma 
(PXA1) (Figure 4.4). Additional small regions of gain and loss were identified, however 
the majority of these were situated in known regions of copy number variation. 
 
Whole chromosome gains of chromosomes 5 and 6 were identified in 3 samples, 
respectively. These were all pilocytic astrocytomas from the cerebellum (PA12, PA14, 
PA27), patients were aged 14, 10 and 14 years, respectively (Figure 4.5). Single whole 
chromosome gains for chromosomes 7, 11, 13, 14, 15 and 20 were also identified, again 
in samples PA14 and PA27. The data are summarised in Table 4.1. 
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Figure 4.3 DNA copy number gains and losses in 21 tumours, assessed by 250k Nsp SNP array.  
Red lines above the chromosome indicate gains, blue lines below indicate losses. A discrete copy number gain of ~1.9Mb in chromosome band 
7q34 was identified (indicated by arrow). Whole chromosome gains of chromosomes 5 and 6 were identified in 3 samples, respectively. Data 
obtained from CNAG.  129 
 
 
 
 
Figure 4.4  Copy number views of SNP data showing discrete regions of DNA copy 
number gain and loss in individual tumour samples, obtained using CNAG.  
The X-axis displays genomic position, as shown on the chromosome ideogram 
below. The Y-axis displays DNA copy number. The upper traces in red (A, C) 
show raw SNP data. Here, the majority of SNPs are present in 2 copies, consistent 
with a diploid karyotype. There is considerable variation between individual SNPs 
in the raw trace, and the blue line within this upper trace shows a smoothed copy 
number trace, created using hidden Markov modelling. The lower traces in blue 
(B, D) are smoothed SNP data traces, created using local mean analysis.  
 
(A) DNA copy number gain at chromosome band 7q34 in sample PA4 
 
(B) Smoothed SNP copy number trace showing copy number gain at 7q34. 
 
(C) DNA copy number loss at chromosome band 9p21 in sample PXA1. 
 
(D) Smoothed SNP data trace showing copy number loss at 9p21 
A 
B 
C 
D 
Chromosome 7 – PA4
Chromosome 9 – PXA1130 
 
Figure 4.5 Whole genome DNA copy number view of raw SNP data for sample PA12, showing whole chromosome gains of chromosomes 5 
and 6. 
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Name Site Age 
(years)
Sex 7q34 
gain 
9p21 
loss 
Whole chromosome 
gains 
PXA1 Cerebral  cortex  6  F  -  +   
DA2 Cerebral  cortex  9  M  -  +   
DA7 Cerebral  cortex  5  M  -  -   
DA8 Cerebral  cortex 15  F  -  -   
DA9 Cerebral  cortex  9  F  -  -   
PMA1 Diencephalon  1  F  +  -   
PMG2 Diencephalon  7  F  -  -   
PA3 Cerebellum  7  M  +  -   
PA4 Cerebellum  2  M  +  -   
PA7 Cerebellum 13 M  +  -   
PA10  Cerebellum  19  M  +  -  5, 6, 7, 14 
PA11 Cerebellum  14  M  +  -  5,  6 
PA13 Cerebellum  10  M  +  -   
PA14 Cerebellum  10  M  +  -   
PA16 Cerebellum  10  M  -  -   
PA17 Cerebellum  6  M  -  -   
PA18 Cerebellum  3  M  +  -   
PA20 Cerebellum  4  M  +  -   
PA22 Cerebellum  6  F  +  -   
PA26 Cerebellum  3  F  +  -   
PA29  Cerebellum  14  F  +  -  5, 6, 11, 13, 15, 20 
 
Table 4.1 Summary of DNA copy number gains and losses identified in 21 low-grade astrocytoma samples by 250K SNP array analysis.  
(PXA = pleomorphic xanthoastrocytoma, DA = diffuse astrocytoma, PMA = pilomyxoid astrocytoma, PMG = pilomyxoid glioma, PA = 
pilocytic astrocytoma) 132 
4.4  Affymetrix Genome-Wide Human 6.0 SNP array 
 
The study was extended, to investigate the copy number changes identified above at 
higher resolution, using the Affymetrix 6.0 array. Thirty-seven tumour samples were 
included in this study. These comprised 26 pilocytic astrocytomas, 6 diffuse 
astrocytomas, 3 pilomyxoid astrocytoma, one infantile hypothalamic pilomyxoid glioma 
and one pleomorphic xanthoastrocytoma.  Seventeen of these tumour samples had 
previously been investigated using the Affymetrix 250K array.  
 
Affymetrix Genome-Wide Human 6.0 SNP array experiments were carried out at the 
Hartwell Centre for Bioinformatics and Biotechnology, St Jude Children’s Research 
Hospital, Memphis, USA, in collaboration with Professor David Ellison. The 
experiments were performed following the manufacturer’s instructions. Briefly, 500 
nanograms of genomic DNA were digested with both NspI and StyI restriction 
enzymes, and ligated to adaptors specific for the 4bp overhangs as described above. 
PCR was performed using a single generic primer to amplify the ligated fragments, with 
conditions set to preferentially amplify fragments between 200-1,100 bp. PCR products 
from both restriction enzyme digests were combined and purified using polystyrene 
beads. The amplified DNA was then fragmented, labelled and hybridised to the SNP 
array. 
 
4.4.1  Analysis 
 
Affymetrix Genotyping Console 3.0.2 software was used for most of the analysis for the 
6.0 SNP arrays. Additional analysis tools were used, which gave slightly different 
results, particularly on mapping the boundaries for regions of copy number change. 
 
Control .CEL data from Affymetrix Genome-Wide Human 6.0 SNP arrays were 
obtained from the International HapMap project for 48 unrelated Caucasian controls (27 
males and 21 females). All .CEL data, from tumour samples and the 48 controls were 
uploaded into Affymetrix Genotyping Console 3.0.2. Initial genotyping was performed 
using the Birdseed (version 2) algorithm (Korn et al., 2008). Birdseed estimates the 
signal intensity for each allele of each SNP, and assigns AA, AB and BB genotype calls   133
to each sample containing 2 SNP alleles. SNPs are then assigned to AA, AB or BB 
clusters. These clusters are initially defined by the expected location for each SNP, 
derived from 270 HapMap sample genotypes. SNP positions are then refined according 
to each tumour sample SNP assignment.  
 
A reference copy number file (.REF) was created, within the Affymetrix Genotyping 
Console 3.0.2, using the genotype data from the 48 control samples. This was then used 
as the baseline for copy number comparisons at each SNP for the tumour samples. 
Tumour sample data were normalised using quantile normalisation. This aims to make 
the distribution of probe intensities the same for each array within a wider set of arrays. 
Probes are sorted by intensity across each array, and the mean intensities are then 
calculated by rank across the wider array set. Individual probe intensities at each rank 
are then replaced by the mean intensity from the wider group. However, each tumour 
sample will retain an individual genotype ‘fingerprint’, as the order of probes is specific 
for each when sorted by intensity.  Log2 ratios between each tumour and the reference 
were calculated for each SNP. Smoothed signals were also constructed, using a 
weighted mean of the log2 ratios of surrounding probes. The weights are proportional to 
the genomic distance from the location of each test probe. Allele differences were 
calculated, by subtracting the signals for allele B from allele A, each standardised with 
respect to their median values in the reference copy number file. These data may be 
used to infer regions of LOH.  
 
Copy number states were calculated using hidden Markov modelling, as previously 
described. The overall aim is for the copy number analysis to be able to infer segments 
of constant copy number change in the tumour samples when compared to the control 
samples, from the raw SNP copy number data. Further analysis was performed using 
the segment reporting tool within Affymetrix Genotyping Console 3.0.2. This aims to 
identify regions or segments of copy number change in tumour samples, which are not 
within known regions of copy number variation (CNV). The Affymetrix CNV map 
files, denoting regions of CNV, were obtained from the Toronto database of genomic 
variants (http://projects.tcag.ca/variation/) (Iafrate et al., 2004). The segment reporting 
tool uses the copy number states derived using hidden Markov modelling to define 
regions of copy number change. For this analysis the parameters were defined to 
identify segments larger than 200Kb with <50% overlap with known CNVs. Individual 
segments were also reviewed by eye.   134
 
Regions of copy number gain or loss were also analysed independently by Dr Jing Ma 
at the Hartwell Centre for Bioinformatics and Biotechnology, St Jude Children’s 
Research Hospital, Memphis, USA. Here, the tumour data were compared to 90 
reference samples obtained from children undergoing long-term follow-up, >5 years 
from diagnosis of leukaemia. Affymetrix SNP 6.0 array data were processed from .CEL 
files to extract raw signal intensity values using dChip PM-only model-based 
expression analysis (Zhao et al., 2004). Data were then normalized using a reference 
normalization algorithm (Pounds et al., 2009), which uses only markers from 
chromosomes known or predicted to be disomic to guide array normalization. A log2 
ratio of tumour versus the median signal of 90 reference samples was calculated for 
each marker in each array using the reference-normalized signal intensity values. The 
circular binary segmentation algorithm (Olshen et al., 2004) implemented in the DNA 
copy package from Bioconductor (Gentleman et al., 2004) was applied to the above 
log2 ratio data, to identify change points denoting regions of copy number alteration for 
each tumour sample.  
 
4.4.2  6.0 array results 
 
The results in this section were obtained working with Tim Forshew, Andrew Lawson, 
Jing Ma and David Ellison. 
 
Copy number analysis of the 37 tumour samples revealed a discrete region of copy 
number gain of ~1.9 Mb, situated at chromosome band 7q34 in 24/37 low-grade 
astrocytomas. These included 23 pilocytic astrocytomas and the hypothalamic 
pilomyxoid astrocytoma (Figure 4.6). Further analysis, using the segmentation tool 
from Affymetrix Genotyping Console 3.0.2, revealed that the gained region at 7q34 
shared similar start and end points in the majority of tumours.  Segmentation analysis 
identified 23/24 tumours with 7q34 gains detected by SNP copy number analysis, and 
provided detailed information on the exact genomic locations for the start and end of the 
gained regions. Using this method of analysis there appeared to be some variation 
between the start and end of the gained region between samples. Ten of the 23 samples 
with 7q34 gain by segmental analysis showed the start of the gained segment within   135
KIAA1549 and 14/23 showed termination of the gain within BRAF. The exact positions 
for these segments, in megabases, are shown in Table 4.2.  
 
Start and end points within KIAA1549  and  BRAF were also revealed by separate 
analysis using circular binary segmentation (CBS), performed by Jing Ma at St Jude. 
Some of the 6.0 SNP data were excluded from CBS analysis; these included four of the 
PA samples (PAs 12, 15, 26, 29). For these cases the raw SNP data appeared to be more 
‘noisy’ than for other samples, despite all of the samples passing initial DNA quality 
control checks. The gained region identified by CBS, started within the middle of the 
gene KIAA1549, and ended within the middle of the gene BRAF in the majority of the 
tumours containing 7q34 gain (Figure 4.7). Considerably less variation was apparent 
between the start and end of the gained regions in samples by this method of analysis. 
CBS found 19/19 samples with the start of the gained region within KIAA1549, and 
17/19 with termination of the gained region within BRAF (Table 4.3). 
 
One pilocytic astrocytoma sample (PA30) contained a discrete ~3Mb region of copy 
number gain at chromosome band 3p25. The region of gain began within the middle of 
the gene SRGAP3,  and ended within the middle of the gene RAF1 (Figure 4. 8). 
Segmental analysis identified the region of gain between 9,067,444-12040620Mb, also 
placing the start within SRGAP3. Here, however, the region of gain ended within SYN2, 
~ 500Kb upstream from RAF1. Analysis by CBS was not performed for this sample, as 
the raw SNP data appeared too ‘noisy’. 
 
Two grade II astrocytoma samples, one diffuse astrocytoma and one pleomorphic 
xanthoastrocytoma (DA2 and PXA1), showed discrete copy number loss at 
chromosome band 9p21, containing the gene CDKN2A  (Figure 4.9).  Segmental 
analysis of PXA1 revealed heterozygous copy number loss of ~600kb, between 
21,791,530 - 22,413,279Mb. This region contained CDKN2A and also a known region 
of CNV.  The second sample DA2 showed a larger ~4Mb region of homozygous loss, 
within the context of heterozygous loss for the majority of chromosome 9p. This region 
of loss was between 21,571,712 – 25,614,770, and contained the genes MTAP, 
CDKN2A and ELAVL2. CBS was not carried out for DA2. However, CBS analysis was 
performed for sample PXA1, and agreed exactly with the 21,791,530 - 22,413,279Mb 
region identified by segmental analysis.  
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One diffuse astrocytoma, DA3, contained a discrete region of loss at 10q24.32, between 
104,264,147-104,846,119Mb (Figure 4.10(A)). This region contained the genes SUFU 
(suppressor of fused homolog Drosophila), where loss of function is known to be 
associated with the development of medulloblastomas, through overactivity of the Sonic 
Hedgehog signalling pathway, and TRIM8 (tripartite motif-containing 8), which may 
also be a tumour suppressor gene (Toniato et al., 2002, Taylor et al., 2002). Analysis 
using CBS identified a very similar region of loss, between 104,017,691-
105,023,374Mb, also containing SUFU and TRIM8. 
 
This same sample, DA3, also contained a discrete region of gain at chromosome 11p13, 
of ~300Kb (Figure 4.10(B)). The region of gain was between 33,196,607-
33,514,710MB by the segment reporting tool. A single gene, HIPK3 (homeodomain 
interacting protein kinase 3), is found within this region. HIPK3 is a serine/threonine 
kinase/homeodomain-interacting
  protein kinase, which modulates the Fas signalling 
pathway (Curtin et al., 2004). CBS identified a similar region of gain, between 
33,099,702-33,519,549Mb, which also contained HIPK3. 
 
One pilocytic astrocytoma sample (PA2) contained a discrete ~2Mb region of gain at 
11q23.1, in addition to gain at 7q34 (Figure 4.10(C)). This was between 111,018,800 –
113,008,870Mb by segmental analysis and CBS, and contained, among others, the gene 
NCAM1 (neural cell adhesion molecule 1). 
 
Whole chromosome gains were identified in 9/37 samples. These aberrations are 
summarised in Tables 4.4-4.5.  
 
Loss of heterozygosity (LOH) analysis was performed, using the LOH analysis tool 
within Affymetrix Genotyping Console 3.0.2. LOH analysis did not identify any large 
regions of homozygosity. Particular attention was paid to the LOH analysis for 
chromosome 17 from patient PMA1, who had been diagnosed with Neurofibromatosis 
type I on clinical grounds. No LOH was demonstrated at the NF1 locus on chromosome 
band 17q11.2. 
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Figure 4.6 Chromosome 7 copy number analysis by Affymetrix 6.0 SNP array reveals 7q34 gain in tumour samples PA13, PA5 and PMA1.  
The upper traces (A, C, E) show raw log2 ratios and the lower traces (B, D, F) show smoothed signals. Regions of copy number gain identified 
by the segmentation tool are shown as a blue bar overlaid with an arrow. 
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Figure 4.7 DNA copy number gain at 7q34 in 9/10 representative low-grade 
astrocytomas, identified by circular binary segmentation.  
Red shading represents regions of DNA copy number gain, where increased colour 
intensity indicates the degree of amplification. The boundaries of the gained region 
fall within the genes KIAA1549 and BRAF, as shown below. Sample PA31 did not 
contain gain at 7q34.   139
 
Sample  Start of segment, Mb  End of segment, Mb 
PA1  138,207,608  140,096,654 
PA2  138,207,608 139,656,577 
PA3 138,413,825  139,719,145 
PA4  138,182,168  140,134,713 
PA5 138,414,600  139,754,451 
PA6  138,172,165  140,144,933 
PA9  138,182,168  140,134,713 
PA10 137,807,619  141,409,151 
PA11 138,814,009  139,754,451 
PA12 139,520,846  140,090,492 
PA13  138,182,168  140,142,094 
PA14  138,182,168  140,142,094 
PA15 138,154,050  140,090,492 
PA17  138,216,399 139,754,451 
PA18 138,547,517  139,754,451 
PA19  138,182,168  140,096,654 
PA22 138,467,471  140,082,280 
PA23 138,401,224  140,134,713 
PA25 138,814,009  139,689,768 
PA26 138,839,105  139,590,942 
PA27  - - 
PA29 138,592,363  140,090,492 
PA32  138,188,628  140,141,917 
PMA1 138,467,471  140,134,713 
 
Table 4.2 Segment reporting identified the start and end of the 7q34 region of gain 
within 23/24 samples containing 7q34 gain by 6.0 SNP analysis.  
Start segments highlighted in grey are contained within the gene KIAA1549, end 
segments highlighted in grey are within BRAF. The genomic regions for KIAA1549 
are  138,166,667 - 138,255,110Mb and BRAF 140,080,282 - 140,271,033Mb 
(University of California Santa Cruz [UCSC] genome browser, March 2006 
assembly).  Sample PA27 did not appear to contain segmental gain ≥200Kb, 
however on visual inspection of the raw data PA27 did contain copy number gain 
at 7q34. The height of the gain was <2.5 copies; this sample may have contained a 
proportion of normal tissue, thus reducing the size of the copy number gain.  
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Sample  Start of segment, Mb  End of segment, Mb 
PA1  138207878  140141903 
PA2  138216385  140134561 
PA3  138191752  140134713 
PA4  138188628  140134713 
PA5  138253456  140129896 
PA6  138188768  140141917 
PA9  138189780  140134713 
PA10  138189780  140141917 
PA11  138207608  140121296 
PA12  Not analysed  Not analysed 
PA13  138189780  140142320 
PA14  138184937  140240542 
PA15  Not analysed  Not analysed 
PA17  138192396 139696552 
PA18  138188768 139486243 
PA19  138184937  140129287 
PA22  138202445  140144933 
PA23  138202445  140141903 
PA25  138192396  140134462 
PA26  Not analysed  Not analysed 
PA27  - - 
PA29  Not analysed  Not analysed 
PA32  138189780  140141903 
PMA1  138191752  140134713 
 
Table 4.3 Start and end of gained segments at 7q34, identified by circular binary 
segmentation analysis.  
Start segments highlighted in grey are contained within the gene KIAA1549, end 
segments highlighted in grey are within BRAF. The genomic regions for KIAA1549 
are 138,166,667 - 138,255,110Mb and BRAF 140,080,282 - 140,271,033Mb (UCSC, 
genome browser, March 2006 assembly). Sample PA27 did not appear to contain 
segmental gain ≥200Kb, however on visual inspection of the raw data copy number 
gain was seen at 7q34. The height of the gain was <2.5 copies; this sample may 
have contained a proportion of normal tissue, thus reducing the size of the copy 
number gain.  
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Figure 4.8 DNA copy number gain at 3p25 in PA30.  
The upper trace shows raw log2 ratios, the lower trace shows smoothed copy 
number data. The gained region identified by the segmentation tool, is denoted by 
a blue bar and arrow. 
 
 
 
 
Figure 4.9 DNA copy number loss at 9p21 in samples PXA1 and DA2. 
The upper traces show raw log2 ratios, the lower traces smoothed copy number 
data and regions of copy number loss identified by segmentation (red bars and 
arrows). 
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Figure 4.10   DNA copy number changes by SNP 6.0 analysis.  
Raw log2 ratios and smoothed copy number data are shown. Regions of copy 
number gain identified by segmentation are shown as blue bars and arrows and 
regions of loss as red bars and arrows.  
 
(A) DNA copy number loss at 10q24.32 in sample DA3.  
 
(B) DNA copy number gain at 11p13 in sample DA3.  
 
(C) DNA copy number gain at 11q23.1 in sample PA2. 
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Name  Site  Age (yrs)  Sex  3p25 gain  7q34 gain  9p21 loss  11q32 gain  Whole chromosome gains 
PA1 Cerebellum  20  F  -  +  -  -  5,6 
PA2 Cerebellum  4  M  -  +  -  +  - 
PA3 Cerebellum  7  M  -  +  -  -  - 
PA4 Cerebellum  2  M  -  +  -  -  - 
PA5 Cerebellum  6  F  -  +  -  -  - 
PA6 Cerebellum  5  M  -  +  -  -  - 
PA9  Cerebellum  14  F  -  +  -  -  5, 6 , 7, 8, 9, 10, 11, 12, 14, 15, 17, 18, 20 
PA10  Cerebellum  19  M  -  +  -  -  5, 6, 7, 14 
PA11 Cerebellum  14  M  -  +  -  -  5,  6 
PA12 Cerebellum  14  M  -  +  -  -  - 
PA13 Cerebellum  10  M  -  +  -  -  - 
PA14 Cerebellum  10  M  -  +  -  -  - 
PA15 Cerebellum  13  M  -  +  -  -  - 
PA16 Cerebellum  10  M  -  -  -  -  - 
PA17 Cerebellum  6  M  -  +  -  -  - 
PA18 Cerebellum  3  M  -  +  -  -  - 
PA19 Cerebellum  3  M  -  +  -  -  - 
PA22 Cerebellum  6  F  -  +  -  -  - 
PA23 Cerebellum  3  F  -  +  -  -  - 
PA25 Cerebellum  4  F  -  +  -  -  - 
PA26 Cerebellum  3  F  -  +  -  -  - 
PA27 Cerebellum  14  F  -  +  -  -  - 
PA29  Cerebellum  19  M  -  +  -  -  5, 6, 11, 13, 15, 20 
PA30 Cerebellum  13  F  +  -  -  -  - 
PA31 Cerebellum  1  F  -  -  -  -  - 
PA32 Brain  stem  9  F  -  +  -  -  - 
Table 4.4 DNA copy number changes in 26 pilocytic astrocytomas by 6.0 SNP array. (- = no abnormality found).   144
 
Name Pathology  Site  Age 
(years)
Sex 3p25 
gain 
7q34 
gain 
9p21 
loss 
10q24.32 
loss 
11p13 
gain 
Whole chromosome gains 
PXA1 Pleomorphic 
xanthoastrocytoma 
Cerebral 
cortex 
6 F -  -  +  -  -  7 
DA2 Diffuse  astrocytoma  Cerebral 
cortex 
9 M -  -  +  -  -  - 
DA3 Diffuse  astrocytoma  Cerebral 
cortex 
17  M  -  -  -  +  +  5, 6, 7, 15, 20, 21 
DA4 Diffuse  astrocytoma  Cerebral 
cortex 
4 M -  -  -  -  -  - 
DA5 Diffuse  astrocytoma  Cerebral 
cortex 
7 F -  -  -  -  -  - 
DA6 Diffuse  astrocytoma  Cerebral 
cortex 
5 F -  -  -  -  -  - 
DA7 Diffuse  astrocytoma  Cerebral 
cortex 
5 M -  -  -  -  -  - 
PMA1 Pilomyxoid 
astrocytoma 
Diencephalon 1  F  -  +  -  -  -  - 
PMG1 Pilomyxoid   
glioma 
Diencephalon  17  M  -  -  -  -  -  6, 8, 11, 12 
PMG2 Pilomyxoid   
glioma 
Diencephalon 7  F  -  -  -  -  -  - 
PMG5 Pilomyxoid   
glioma 
Spinal cord  11  F  -  -  -  -  -  6, 7, 8, 9, 11, 12 
 
Table 4.5  DNA copy number changes in 11 grade II astrocytomas by 6.0 SNP array. (- = no abnormality found). 145 
4.4.3  Comparison of results from SNP arrays and array CGH 
 
The results obtained by Affymetrix 250k or 6.0 SNP arrays were compared to data 
obtained by array CGH (Table 4.6).  There was some concordance between array CGH 
and SNP array data for 3 samples where no whole chromosome gains or losses were 
identified, and between 4 tumour samples with whole chromosome gains. Whole copy 
number gains and losses were identified by array CGH in a further 6 cases, but these 
were not subsequently found by SNP array analysis. In general, the SNP array data did 
not identify any whole chromosome losses.  
 
The region of gain at 7q34 was not identified in cerebellar pilocytic astrocytoma 
samples by array CGH analysis (Figure 4.11). I investigated the density of clones on the 
array slides covering the 7q34 region of interest, to see where probes in this region were 
situated. 
 
Three clones were present on the array CGH slides in the region of interest at 7q34, 
spanning a region of  ~ 2.6Mb. The first clone in the region was RP11-269N18 (101980 
bps), situated at position 138341354-138443333, around 70Kb downstream towards the 
centromere from the 3’ end of the gene KIAA1549 (Figure 4.12 (A)). The second clone 
present in the region was RP5-886O8 (143569 bps), situated at 139539734-139683302, 
within the gene TBXAS1 (Figure 4.12 (B)). The final probe in the region of interest was 
RP5-1173P7 (129223 bps). This was situated ~100Kb upstream from the start of BRAF, 
the next gene of interest, at position 140,080,751-140,271,033 (Figure 4.12(C)). The 
two clones RP11-269N18 and RP5-1173P7 were both outside the region of gain, 
however RP5-886O8 was situated within the centre of the gained region (Figure 4.13). 
This probe would have been expected to identify the copy number gain present in the 
cerebellar samples. None of the cerebellar pilocytic astrocytomas showed any 
significant region of gain at clone RP5-886O8 (at position 138947011 on chromosome 
7 in raw and smoothed wig data files).  
 
These data are available on the Cancer Research UK London Research Institute’s 
bioinformatics and biostatistics website at the following link: 
https://bioinformatics.cancerresearchuk.org/~kelly02/index.php?id=Ruth146 
Sample  Site  Age  Sex  aCGH copy number gains / losses  SNP array copy number gains/ losses 
PA1  Cerebellum  20  F  Gain 5, 6  Gain 5, 6, 7q34 gain 
PA3 Cerebellum  7  M  -  7q34  gain 
PA11  Cerebellum  14  M  Gain 5, 6  Gain 5, 6, 7q34 gain 
PA13  Cerebellum  10  M  7q22.1 loss  7q34 gain 
PA14  Cerebellum  10  M  Loss 17  7q34 gain 
PA15 Cerebellum  13  M  -  7q34  gain 
PA17 Cerebellum 6  M  -  7q34  gain 
PA18  Cerebellum  3  M  2p22.1 loss  7q34 gain 
PA20  Cerebellum  4  M  Loss 22  7q34 gain 
PA23 
 
Cerebellum 
 
3 
 
F 
 
1q42.12 loss 
Gain 4p15.31 
7q34 gain 
 
PA32  Brain stem  9  F  Gain 13, loss terminal end 1p  7q34 gain 
PMA1  Diencephalon  1  F  Gain 5q33.3, 8q11.23  7q34 gain 
DA2 
 
Cerebrum 
 
9 
 
M 
 
Loss 17 
Loss terminal end 1p 
- 
 
DA3 
 
Cerebrum 
 
17 
 
M 
 
Gain 6, 7, 21 
Gain 5q32 
Gain 5, 6, 7, 15, 20, 21 
 
DA4 
 
 
Cerebrum 
 
 
4 
 
 
M 
 
 
Loss 17, 19, 20, 22 
Loss terminal end 1p, 7 cen-7q11.23, 
7q22.1 and 7q36.1-tel 
- 
 
 
DA7  Cerebrum  5  M  Gain 2q11.2, 17p12  - 
DA9 Cerebrum  9  F  Gain  2q11.2  - 
PMG1  Diencephalon  17  M  Gain 6, 8, 11, 12  Gain 6, 8, 11, 12 
PMG2  Diencephalon  7  F  Loss terminal end 1p  - 
PMG5  Spinal cord  11  F  Gain chromosome 9  Gain 6, 7, 8, 9, 11, 12 
Table 4.6 Comparison of whole chromosmome gains from 20 tumour samples (11 cerebellar PA, 9 non-cerebellar PA) by array CGH and 
250k or 6.0 SNP array analysis. 147 
 
 
Figure 4.11 Array CGH plot for chromosome 7 comparing pooled data from 
cerebellar samples to non-cerebellar samples.  
No copy number differences were identified between the two groups on 
chromosome 7. Clone RP5-886O8 (within the region of gain at 7q34) was situated 
at ~ 139.5Mb, and was not gained in any of the pilocytic astrocytoma samples. 
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Figure 4.12 Array CGH clones at the 7q34 region of gain. Figures adapted from 
Ensembl, release 55. 
 
(A)   Clone RP11-269N18 (highlighted with an asterisk) is situated ~ 70Kb 
downstream from KIAA1549 towards the centromere. 
 
(B)  Clone RP5-88608, situated in the centre of the gained region, within 
TBXAS1. 
 
(C)  Clone RP5-1173P7, situated ~ 100Kb upstream from BRAF. 
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Figure 4.13 Overview of the region of interest within 7q34.  
The gained region, identified by SNP array analysis is overlaid by a red bar. Array 
CGH clones within the region are marked by asterisks. The clones marked in red 
lie outside the region of gain (RP11-269N18, RP5-1173P7), the clone marked in 
black (RP5-88608) is the single clone present within the gained region. Figure 
adapted from Ensembl, release 55. 
 
 
4.5  Discussion 
4.5.1  SNP array investigation of astrocytomas  
 
SNP array studies have begun to yield a wealth of detailed information on the biology 
of cancer. Two comprehensive studies have recently been published which yield new 
insights into the genetic aberrations involved in the development of adult glioblastoma 
(GBM) (CGARN et al., 2008, Parsons et al., 2008). These studies utilised SNP data to 
investigate frequent copy number changes seen in GBM, in combination with mutation 
and methylation analysis. Both of these studies revealed that deregulation of the RB, 
TP53 and RAS/PI(3)K pathways are obligatory events in the majority of adult GBM, 
affecting much larger proportions of both patients and genes within each pathway than 
had previously been suspected.  New genes and signalling pathways not previously 
known to be implicated in the development of GBMs were also identified, for example 
mutations in the isocitrate dehydrogenase genes IDH1 and IDH2 were found to occur 
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early in the development of adult grade II-III astrocytomas which progress to become 
secondary GBMs (Parsons et al., 2008). 
 
Few studies to date have used SNP arrays to investigate paediatric astrocytomas. Wong 
et al. published the first study in 2006, using Affymetrix 10K SNP arrays (Wong et al., 
2006). Fourteen low-grade astrocytomas (6 pilocytic astrocytomas, 5 gangliogliomas, 2 
subependymal giant cell astrocytomas (SEGA) and one unspecified low-grade 
astrocytoma) and 14 high-grade astrocytomas (13 GBMs, 1 anaplastic astrocytoma) 
were studied. No regions of LOH were detected in the pilocytic astrocytomas, and the 
majority of low-grade astrocytomas showed either no detectable LOH, or LOH 
affecting a single chromosome arm. Two gangliogliomas showed LOH of a single 
chromosome arm (3q and 9p), the unspecified astrocytoma had LOH at 6q and the two 
SEGAs showed LOH of 16p and 21q, respectively. In contrast the high-grade 
astrocytomas studied showed highly complex patterns of LOH involving multiple 
different chromosomes. Amplification of EGFR and PDGRF were found to be 
relatively uncommon in paediatric high-grade astrocytoma; each was seen in 2/13 
GBMs, and amplification was confirmed by real-time PCR. This study was, however, 
performed using one of the earliest SNP array platforms, which was still at a fairly low 
resolution.  
 
A later study by Deshmukh et al. compared array CGH and SNP array analysis for 10 
paediatric patients with pilocytic astrocytomas (PAs), using matched blood and tumour 
samples (Deshmukh et al., 2008). Here the high-resolution 385K NimbleGen 
oligonucleotide array and the Affymetrix Mapping 500K SNP array sets were used. One 
of the 10 tumour samples showed whole chromosome gains of 6 and 21, identified by 
both array platforms, the remaining 9 PAs showed no whole chromosome gains or 
losses. Multiple focal copy number changes were seen in individual samples, but no 
recurrent regions of gain or loss were identified by visual inspection of the data.   
However, segmental analysis revealed a single recurrent region of copy number gain on 
chromosome 7q34, between 138,151,200-139,456,000 (NCBI build 35). This was seen 
in 8/10 PAs by SNP array and in 6/10 PAs by array CGH. The common minimal region 
of gain between the two data sets was localised in the upstream region of 
homeodomain-interacting protein kinase 2 (HIPK2). Gain of HIPK2 was validated by 
quantitative PCR using matched tumour and peripheral blood DNA in 6/10 PAs. In a 
separate cohort of 61 PAs 42% (26/61) showed amplification of HIPK2. The gained   151
region identified here also included partial gain of BRAF in three PAs, and partial gain 
of KIAA1549 in two PAs. 
 
The 7q34 region of gain in pilocytic astrocytomas was also identified by array CGH in 
two studies published last year (Jones et al., 2008, Pfister et al., 2008). Pfister et al. 
found a 0.97Mb region of gain at 7q34 involving 2 BAC clones (RP5-886O8 and RP4-
726N20) in 30/66 low-grade paediatric astrocytomas (53 PAs, 13 diffuse astrocytomas). 
Similarly, Jones et al. found a recurrent 2Mb region of gain by array CGH at 7q34 and 
followed this up using a chromosome 7 tiling path array, where 7q34 gains between 
clones RP11-355D18 (within KIAA1549) and RP11-543P6 (within BRAF) were seen in 
29/44 pilocytic astrocytomas. These, and further studies which identified 7q34 gain in 
pilocytic astrocytomas will be discussed in more detail in chapter 5. 
 
These data confirm the most striking change found by SNP array analysis in this study: 
a discrete ~1.9Mb region of gain situated at chromosome band 7q34 in 24/37 samples. 
Twenty-three of 26 cerebellar pilocytic astrocytomas and the single hypothalamic 
pilomyxoid astrocytoma contained 7q34 gains. HIPK2 was contained within this region 
of gain, as found by Deshmukh et al. (Deshmukh et al., 2008). However, further 
analysis by segmentation revealed that this gained region had highly recurrent start and 
end points, partially contained within the genes BRAF  and  KIAA1549. BRAF is a 
partner in two different fusion genes, with AKAP9 in radiation induced thyroid cancer 
and with FCHSD1  in large melanocytic naevi (Dessars et al., 2007, Ciampi et al., 
2005). In both cases only the 3’ portion of BRAF, which encodes the active kinase 
domain, were included in the gene fusion. These findings led to speculation that BRAF 
might be involved in a gene fusion with KIAA1549 in pilocytic astrocytomas. I will 
discuss this further in chapter 5. 
 
Array CGH, as described in chapter 3, did not identify this region of gain at 7q34 in the 
pilocytic astrocytoma samples. This was, perhaps, understandable as there was only a 
single BAC clone situated in the region of gain on the array slides used. Furthermore, 
none of the potential regions of interest identified by array CGH (1p loss, 2q11.1 gain, 
7q22.1 loss and 21q22.2 gain) were subsequently identified by either 250K or 6.0 array 
analyses. Overall the quality and resolution of the array CGH data appeared noisy, and 
few significant regions of copy number change were identified.    152
Whole chromosome gains and losses were, however, identified by array CGH, and 
some of these were subsequently confirmed by SNP array analysis. The array CGH and 
SNP array results concurred in 8 cases (Table 4). Three samples (PA3, PA15, PA17) 
contained no whole chromosome gains or losses (although all contained 7q34 gains by 
SNP analysis). Five cases contained whole chromosome gains; the majority of the 
results for whole chromosome gains were the same between the two platforms. The 
250K and 6.0 SNP arrays showed whole chromosome gains in 9/37 patients.  
 
The most commonly affected chromosomes were: 6 (8 cases), 5 (6 cases), 7 (5 cases), 
11 (4 cases); 8, 12, 15 and 20 (3 cases each); 9 and 14 (2 cases each). The mean age of 
patients with whole chromosome gains was 15.2 years, compared to a mean age of 7 
years for patients with no chromosome gains. A single young patient aged 6 years, 
showed trisomy 7. The cases aged >10 years had an average of 5 chromosomes gained 
per patient. These data confirm findings from the previous chapter, and from the 
literature that whole chromosome gains are more prevalent in older patients with 
pilocytic astrocytoma, aged > 10 years (Jones et al., 2006).  
 
In general, the low-grade astrocytomas appeared to display stable genomes, with few 
discrete regions of copy number gain and loss. This observation is in line with previous 
analyses by conventional cytogenetics and array CGH, and also fits with the natural 
history of low-grade astrocytomas. Pilocytic astrocytomas are slow-growing tumours, 
with extremely good 5- and 10-year survival data following surgical resection 
(Burkhard et al., 2003, Ohgaki et al., 2005a). Paediatric glioblastomas, on the other 
hand, are highly aggressive tumours, and display hugely rearranged karyotypes, in 
keeping with the general observation that high-grade malignancies appear to accumulate 
large numbers of genomic aberrations (reviewed by Stratton, 2009) (Stratton et al., 
2009). 153 
4.5.2   Further discrete changes identified by SNP array analysis 
 
SNP array analysis enabled the detection of regions of copy number change at much 
higher resolution than array CGH, with considerably less experimental noise. Four 
further regions of copy number change were identified in low-grade astrocytomas, in 
addition to the gains at 7q34, although these were found at significantly lower 
frequencies.  
 
4.5.2.1  Gain of 3p25 in sample PA30 
 
The pilocytic astrocytoma PA30, from a 13 year old female, was found to contain a 
discrete ~3Mb region of copy number gain at chromosome band 3p25, within parts of 
the genes SRGAP3 and RAF1 (Figure 4. 8). No other copy number changes were found, 
and there was no gain at 7q34. Further segmental analysis identified the start of the 
gained region within SRGAP3, however, the region of gain appeared to end within 
SYN2,  ~ 500Kb upstream from RAF1. Analysis by CBS was not possible for this 
sample. 
 
RAF1 was an attractive candidate gene, particularly in light of the similar partial gains 
within BRAF seen in the majority of pilocytic astrocytomas. Both BRAF and RAF1 are 
serine-threonine-specific protein kinases within the mitogen activated protein kinase 
pathway (MAPK pathway), activated downstream from RAS. Deregulation of the 
MAPK pathway has recently been identified as highly significant in low-grade 
astrocytomas, and this will be discussed in detail in chapter 5 (Sharma et al., 2005, 
Pfister et al., 2008, Jones et al., 2008, Forshew et al., 2009, Jones et al., 2009, Sievert et 
al., 2009). 
 
4.5.2.2  Loss of 9p21 in DA2 and PXA1 
 
Two grade II astrocytoma samples DA2 and PXA1, showed discrete copy number loss 
at chromosome band 9p21, containing the gene CDKN2A  (cyclin-dependent kinase 
inhibitor 2A) (Figure 4.9). DA2 showed homozygous loss of CDKN2A, with general  154
heterozygous loss of the whole short arm of chromosome 9. PXA1 revealed 
heterozygous copy number loss of CDKN2A at 9p21 and single copy gain 
encompassing the whole of chromosome 7. For PXA1, analysis using the segmentation 
tool within Affymetrix Genotyping Console 3.0.2 and further analysis by segmentation 
and CBS showed exact agreement on the boundaries of the region of loss.  
 
CDKN2A is a known tumour suppressor gene, and encodes several transcript variants, 
which have different first exons. CDKN2A is deleted or mutated in a wide range of 
cancers, including leukaemias and solid tumours (Kohno et al., 2006). Homozygous 
loss of CDKN2A  is a common finding in adult glioblastomas: two recent studies 
reported  CDKN2A  loss in ~ 50% adult GBMs, with overall alterations in the RB 
pathway in 77% (CGARN et al., 2008, Parsons et al., 2008). Only one of the samples 
identified by SNP array analysis here had homozygous loss of CDKN2A.  Hence, 
sequencing was undertaken in 50 low-grade astrocytomas to search for additional 
inactivating mutations in CDKN2A. These results will be described in further detail in 
chapter 6.  
 
4.5.2.3  Loss of 10q24.32 in sample DA3 
 
One diffuse astrocytoma in a 17 year-old male, DA3, contained a discrete region of loss 
at 10q24.32 containing, among others, the genes SUFU (suppressor of fused homolog 
Drosophila) and TRIM8  (tripartite motif-containing 8)(Figure 4.10(A)). SUFU is a 
negative regulator of the Sonic Hedgehog (SHH) signalling pathway: deletions or 
inactivating mutations in SUFU are known to be associated with the development of 
desmoplastic medulloblastomas, through overactivity of the SHH signalling pathway 
(Rubin et al., 2002, Taylor et al., 2002, Pasca di Magliano et al., 2003, Gilbertson et al., 
2008). TRIM8 is a putative tumour suppressor gene; the protein it encodes has a similar 
structure to other tumour suppressor proteins, and the 10q24.32 genomic region is 
known to be a common site for deletions and rearrangements in glioblastoma, 
suggesting that the region may be involved in tumorigenesis (Toniato et al., 2002, 
Carinci et al., 2007). SNP copy number analysis indicated heterozygous loss at 
10q24.32. Hence, further follow-up of the genes in this region will be required, to 
search for a possible inactivating mutation in the remaining allele of SUFU or TRIM8.  155
The tumour from this patient contained a further discrete copy number change discussed 
below, and numerous additional whole chromosome gains of 5, 6, 7, 15, 20 and 21. 
4.5.2.4  Gain of 11p13 in sample DA3 
 
Sample DA3 also contained a ~300Kb region of gain at chromosome 11p13, which 
contains the gene HIPK3 (homeodomain interacting protein kinase 3) (Figure 4.10(B)). 
This region of gain was identified by segmental analysis and CBS. HIPK3  is a 
serine/threonine kinase/homeodomain-interacting
 protein kinase, which modulates the 
Fas signalling pathway. Increased activation of the mitogen-activated protein kinase 
JNK, leading to increased levels of HIPK3 expression has been shown to promote 
resistance to apoptosis in prostate cancer cell lines (Curtin et al., 2004). Sensitivity to 
apoptosis in the prostate cancer cells was restored in this study using RNA interference 
directed against HIPK3 and a specific JNK inhibitor (Curtin et al., 2004). HIPK3 does 
not currently have any known association with brain tumours, but is widely expressed in 
mammalian tissues including the brain and spinal cord (Rochat-Steiner et al., 2000). As 
increased levels of HIPK3 expression were found to promote resistance to apoptosis, 
and sample DA3 shows genomic gain at this region it is possible that this might play a 
role in promoting tumour growth. As previously mentioned, this sample contained 
numerous whole chromosome gains in addition to the two discrete copy number 
changes described. 
 
4.5.2.5  Gain of 11q23.1 in sample PA2 
 
Finally, one pilocytic astrocytoma sample in a 4-year old male, PA2, contained a 
discrete ~2Mb region of gain at 11q23.1, in addition to gain at 7q34 (Figure 4.10(C)). 
This contained, among others, the gene NCAM1 (neural cell adhesion molecule 1). 
NCAM1 is expressed on the surface of the majority of neural cells, and has been shown 
to play a major role in the development of the nervous system (reviewed by Ditlevsen, 
2008) (Ditlevsen et al., 2008). In the adult brain NCAM1 is associated with neuronal 
plasticity, which is part of the process for learning and consolidation of memory. 
NCAM1 binds neuronal cells together, but also has a significant function in 
coordinating intracellular signalling, resulting from stimuli on or in the vicinity of the 
cell surface. Stimulation of NCAM1 has also been shown to lead to activation of the  156
MAPK pathway via ERK1/2 phosphorylation, which may ultimately lead to neurite 
outgrowth, although the method of MAPK pathway activation is currently unclear. It 
may be that stimulation of NCAM1 leads to activation of RAS via the cytoplasmic 
protein tyrosine kinases Fyn and FAK, but this remains to be determined. Initiation of 
neurite outgrowth is known to be coordinated via a highly complex web of signalling 
pathways, so activation of a single pathway may not necessarily induce neurite growth. 
NCAM1 and a related neural cell adhesion molecule L1  have also been shown to 
promote neuronal survival, so it is possible that a survival advantage may be conferred 
by increased expression of NCAM1 (Ditlevsen et al., 2008). Further investigations using 
quantitative PCR for NCAM1 in sample PA2 will be required to confirm whether 
increased levels of expression are found. 
 
4.5.2.6  Astrocytomas with no copy number changes identified by SNP 
array analysis 
 
One pilocytic astrocytoma (PA31) and seven grade II astrocytomas (DA4, DA5, DA6, 
DA7, DA8, DA9 and PMG2) had no apparent copy number changes found by analysis 
of the SNP data. Other mechanisms may underlie tumorigenesis in this group, and 
further investigations will be required to investigate whether activating mutations, 
epigenetic changes or possible aberrations in microRNA expression are present in these 
samples   157
4.6   Summary 
 
SNP array analysis identified a striking copy number change in pilocytic astrocytomas, 
at a frequency that was both unprecedented and completely unexpected, in tumours that 
were previously thought to contain few or no genetic rearrangements. A discrete 
~1.9Mb region of gain was seen at 7q34 in 23/26 cerebellar pilocytic astrocytomas and 
in the single hypothalamic pilomyxoid astrocytoma. Additional discrete copy number 
changes were also identified in further samples, although these were present at much 
lower frequencies.  
 
Two separate statistical analyses were performed concurrently with the Affymetrix 6.0 
SNP data: each was entirely independent of the other. Analysis using the Affymetrix 
Genotyping console segmentation tool, and further segmental analysis were performed 
at our laboratory in London: CBS was performed by Dr Jing Ma at St Jude Children’s 
Research Hospital in Memphis. Both analysis methods identified the region of gain at 
7q34 and the additional discrete regions of gain and loss described. The 3p25 gain in 
PA30 was the only discrete change found using a single method, as CBS was not 
possible for this sample. All of the methods for analysing SNP data gave essentially 
similar results. Although there were subtle differences in the exact boundaries for 
segments of loss or gain, the majority of genes contained within these regions were the 
same.  
 
However, these data highlight the importance of verifying copy number changes by 
different techniques. Additional methods of ascertaining DNA copy number changes 
include fluorescence in situ hybridisation (FISH), quantitative real-time PCR and 
multiplex ligation-dependent probe amplification (MLPA). FISH was used to 
investigate the region of 7q34 gain in paraffin tissue sections from pilocytic 
astrocytomas, and these results will be discussed further in chapter 5. The additional 
regions of copy number change identified by SNP array analysis require further 
validation, and I will continue with this work following the completion of my PhD. 
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Chapter 5. Identification and characterisation of 
fusion genes 
5.1  Introduction 
 
A discrete region of DNA copy number gain was identified by Affymetrix 250K and 
6.0 SNP arrays, at chromosome band 7q34, in 23/26 pilocytic astrocytomas and the 
single pilomyxoid astrocytoma. The gained region showed recurrent start and end 
points, partially contained within the genes BRAF and KIAA1549. This suggested that a 
duplication event had occurred across this genomic region, including parts of BRAF and 
KIAA1549. BRAF has been shown to be involved in chromosomal rearrangements 
leading to the creation of two different fusion genes in thyroid carcinoma and large 
melanocytic naevi (Ciampi et al., 2005, Dessars et al., 2007). In both of these cases 
only part of BRAF is included in the fusion. Both result in constitutive activation of 
BRAF, through loss of the N-terminal auto-inhibitory domain of BRAF, however this is 
achieved via different genomic rearrangements. 
 
The  AKAP9-BRAF fusion was identified in radiation-induced papillary thyroid 
carcinoma (Ciampi et al., 2005). FISH demonstrated duplication of the BRAF locus, in 
the presence of two copies of chromosome 7, and subsequent analysis revealed a gene 
fusion between exons 1-8 of A-kinase anchor protein 9 (AKAP9) and exons 9-18 of 
BRAF. Both genes are situated on chromosome 7: AKAP9 at 7q21-q22 and BRAF at 
7q34. The gene fusion results from paracentric inversion of the q arm of chromosome 7, 
creating an in-frame AKAP9-BRAF fusion. The 5’ region encoding the auto-inhibitory 
N-terminal Ras-binding domain of BRAF is lost. The C-terminal protein kinase domain 
of BRAF is retained in the AKAP9-BRAF fusion, which was shown to display elevated 
kinase activity and induced transformation of NIH3T3 cells (Ciampi et al., 2005).  
 
A further fusion between BRAF and FCHSD1 has been identified in large melanocytic 
naevi (Dessars et al., 2007). This arises by a different mechanism, from a translocation 
between FCHSD1 at chromosome 5q31 and BRAF at 7q34. Here the fusion junction lies 
between exon 13 of FCHSD1 and exon 9 of BRAF.  Again, the auto-inhibitory N-  159
terminal Ras-binding domain of BRAF was lost from the FCHSD1-BRAF fusion 
transcript, and the protein kinase domain was retained.  
 
The SNP copy number analyses of low-grade astrocytomas described in chapter 4 of 
this thesis suggested that the region of 7q34 copy number gain did not include the 5’ 
end of BRAF or the 3’ end of KIAA1549. This led to the hypothesis that KIAA1549 and 
BRAF were involved in a gene fusion in the pilocytic astrocytomas. 
 
5.2  Aim 
 
The aim of the work described within this chapter was to investigate whether fusion 
genes were present in paediatric low-grade astrocytomas, using the following 
techniques: 
1)  PCR from tumour cDNA and DNA 
2)  DNA sequencing 
 
5.3  Interphase fluorescence in-situ hybridisation (i FISH) 
 
Dual-colour interphase FISH was performed by James Dalton, at St Jude Children’s 
Research Hospital, Memphis, to confirm whether the 7q34 region of gain included a 
duplicated region. The iFISH method is described in detail in section 2.11. Tumours 
containing 7q34 gain were selected for interphase FISH analysis, using 5-8µm paraffin 
tissue sections. Probes were derived from BAC clones (Invitrogen, Carlsbad, CA) and 
labelled with either FITC or rhodamine fluorochromes. BAC clone RP11-837G3 was 
selected to target exons 11-18 of BRAF, and labelled with rhodamine. BAC clones 
RP11-251I15 + RP11-746C13 were selected as control probes for chromosome arm 7p, 
and labelled with fluorescein isothiocyanate (FITC).  
 
Interphase FISH indicated the presence of a tandem duplication at 7q34, in the presence 
of two homologues of chromosome 7 (Figure 5.1). This duplicated region included 
exons 11-18 of the BRAF locus, encoding the C-terminal protein kinase domain. These 
results confirmed the 7q34 copy number gain identified by SNP analysis, and led to 
further experiments designed to identify a possible fusion gene between KIAA1549 and 
BRAF.   160
 
 
Figure 5.1 Tandem duplication within 7q34 including BRAF, identified by iFISH 
from paraffin sections.  
BAC clone RP11-837G3 was used to target exons 11-18 of BRAF (red) in 
combination with control probes to 7p (BAC clones RP11-251I15 + RP11-746C13, 
green). Images were selected from nuclei in tumour PA1 and showed signals from 
both homologues of chromosome 7 (green) and 3 signals from BRAF (red), 
indicating duplication of the BRAF region on one homologue. Many nuclei showed 
an incomplete set of FISH signals as these images were from FFPE sections. All 
iFISH was performed at St Jude Children’s Research Hospital, Memphis. 
 
5.3.1   PCR identifies KIAA1549-BRAF fusion 
 
Oligonucleotide primers were designed to identify any possible gene fusion between 
BRAF  and  KIAA1549. Twelve forward primers were designed stepping along 
KIAA1549 at approximately 500bp intervals (Appendix C, Table 8.2). A single reverse 
primer was designed within the kinase domain of BRAF in exon 12, based on the 
presumption that the kinase domain would be retained within any possible fusion gene 
(Figure 5.2).  
 
PCRs were performed to identify possible fusion gene products in cDNA from two 
tumours with 7q34 copy number gain (PA7, PA29) and cDNA prepared from control 
whole brain total RNA. PCR products were visualised using 1.5% agarose gels. Both 
tumours revealed PCR products, indicating the presence of a KIAA1549-BRAF gene 
fusion. PCR products were seen in sample PA7 between BRAF exon 12 and KIAA1549 
primers 9 (exon 12), 10 (exons 14/15) and 11 (exon 16). These three bands stepped 
down in size, consistent with the primer positions moving along KIAA1549 in 500bp 
increments (Figure 5.3). Sample PA29 showed PCR products between BRAF exon 12 
and KIAA1549 primers 10 (exons 14/15) and 11 (exon 16). No PCR products were 
identified in normal brain cDNA. 
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Figure 5.2. Schematic diagram showing the design of primer placement for the 
identification of a possible fusion gene.  
Forward primers are situated at ~ 500 bp intervals along KIAA1549. The single 
reverse primer was in exon 12 of BRAF within the kinase domain. Both genes are 
transcribed in the same direction. The exact locations and sequences of the 
primers are shown in Appendix C Table 8.2. 
 
 
 
    
Figure 5.3.  1.5% agarose gel showing results of PCR between KIAA1549 and 
BRAF in sample PA7.  
The PCR products indicate the presence of a KIAA1549- BRAF gene fusion. From 
left to right the wells contain: DNA ladder (Hyperladder I; 200 base pairs (bp) -
10kb, Bioline), KIAA1549 forward primers 7-12 and negative control (water). All 
PCRs used the same reverse primer within BRAF exon 12.  A non-specific product 
was seen for KIAA1549 forward primer 7. Product sizes are 1300, 800 and 300 base 
pairs, in descending order. 
7 8 9 10 11 12 Neg 
PCR 
products 
BRAF kinase domain
KIAA1549 
BRAF 
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5.3.2    Sequencing confirms the presence of a KIAA1549-BRAF gene 
fusion 
Direct sequencing was performed for the PCR products identified from samples PA7 
and PA29. These confirmed the presence of a fusion gene product between KIAA1549 
exon 16 and BRAF exon 9 in sample PA7 (Figure 5.4.A). A different fusion product 
was identified in sample PA29, between KIAA1549 exon 19 and BRAF exon 9 (Figure 
5.4.B). These data were reproducible, and were repeated on cDNA from separate 
reverse transcription reactions. 
 
 
 
 
 
 
 
Figure 5.4. Sequence analysis of two KIAA1549-BRAF fusions in tumour cDNA.  
(A) Fusion junction between KIAA1549 exon 16 and BRAF exon 9 in PA7.  
 
(B) Fusion junction between KIAA1549 exon 19 and BRAF exon 9 in PA29. 
 
5.3.3   Nested PCR identifies three further KIAA1549-BRAF fusions 
 
Primers were designed for a nested PCR, to increase the specificity of the reaction to 
detect fusions. Previously a few tumour samples had produced weak PCR products with 
KIAA1549 and BRAF primer combinations. These products did not reveal gene fusions 
on direct sequencing, suggesting that some non-specific binding of PCR primers was 
present. Nested PCR uses two sets of PCR primers, in two successive runs. The second 
primer set is specifically designed to amplify a product contained within the first PCR 
A
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product (Garson et al., 1990). This increases the overall sensitivity of the PCR reaction, 
as it is very unlikely that any non-specific PCR products will contain binding sites for 
the second primer set.  
 
The primers for the first stage of the nested PCR were KIAA1549 primer 9 (forward) 
and BRAF exon 13 (reverse) (Appendix C, Table 8.2).  The primers for the second stage 
of the nested PCR were KIAA1549 primer 10 (forward) and BRAF exon 12 (reverse). 
Primer products were visualised using 1.5% agarose gels. 
 
Three further KIAA1549-BRAF fusion variants were identified using the nested PCR 
primer combination: between KIAA1549 exon 15 and BRAF exon 9, KIAA1549 exon 16 
and BRAF exon 11 (Figure 5.5) and KIAA1549 exon 18 and BRAF exon 10. Validation 
of the additional fusion variants was performed by direct sequencing (Figure 5.6). 
During these experiments, both the KIAA154-BRAF exon 16-exon 9 and the KIAA154-
BRAF exon 19-exon 9 fusion variants were used as positive controls. Both were 
identified successfully using the nested PCR primers. Hence, the nested PCR primer 
combination was used to detect all five KIAA1549-BRAF  fusion variants described 
within this thesis. Again, these data were reproducible, and were repeated on cDNA 
from separate reverse transcription reactions. 
 
 
 
Figure 5.5  1.5% agarose gel showing results of the second stage of the nested PCR.  
PCR was performed for 9 tumour samples and a negative control (water). The 
PCR products indicate the presence of 3 fusion variants. Products indicated by (a) 
contain a KIAA154-BRAF exon 15-exon 9 variant of 505bp, (b) a KIAA154-BRAF 
exon 16-exon 11 variant of 649bp and (c) a KIAA154-BRAF exon 16-exon 9 variant 
of 823bp. The DNA ladder is Hyperladder I (200 bp-10kb, Bioline). 
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Figure 5.6 Sequence analysis of three further KIAA1549-BRAF fusion variants in 
tumour cDNA.  
(A) Fusion junction between KIAA1549 exon 15 and BRAF exon 9 in PMG4.  
 
(B) Fusion junction between KIAA1549 exon 16 and BRAF exon 11 in PA26.  
 
(C) Fusion junction between KIAA1549 exon 18 and BRAF exon 10 in PA28. 
 
 
Due to the success of the nested PCR in the identification of KIAA1549-BRAF fusion 
variants, the study was extended to include 9 additional low-grade astrocytoma samples, 
which had not been analysed by 250k or 6.0 SNP array. In total, 50 low-grade 
astrocytoma samples were investigated using the nested PCR. KIAA1549-BRAF fusion 
variants were identified in 33/50 low-grade astrocytomas, including 30/32 pilocytic 
astrocytomas (Table 5.1). The majority were the KIAA1549-BRAF exon 16-exon 9 
variant, which was found in 22/32 pilocytic astrocytomas. The frequencies of the 
different fusion variants are summarised in Table 5.2. Fusions were found in all 26 
samples that contained 7q34 copy number gain, and in 6/9 samples with no copy 
number data. A KIAA1549-BRAF exon 16-exon 9 fusion was found in one sample, 
PA16, which did not contain 7q34 gain by 250k or 6.0 SNP array analyses. 
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Name Site  Age    Sex  KIAA1549-BRAF 
fusion 
7q34 gain by 250K/ 
6.0 SNP analysis 
PA1  Cerebellum  20  F  Exon 16 -Exon 9  + 
PA2  Cerebellum  4  M  Exon 16 - Exon 9  + 
PA3  Cerebellum  7  M  Exon 16 - Exon 9  + 
PA4  Cerebellum  2  M  Exon 16 - Exon 9  + 
PA5  Cerebellum  6  F  Exon 16 - Exon 9  + 
PA6  Cerebellum  5  M  Exon 16 - Exon 9  + 
PA7  Cerebellum  13  M  Exon 16 - Exon 9  + 
PA8  Cerebellum  2  M  Exon 16 - Exon 9  Not tested 
PA9  Cerebellum  14  F  Exon 16 - Exon 9  + 
PA10  Cerebellum  19  M  Exon 16 - Exon 9  + 
PA11  Cerebellum  14  M  Exon 16 - Exon 9  + 
PA12  Cerebellum  14  M  Exon 16 - Exon 9  + 
PA13  Cerebellum  10  M  Exon 16 - Exon 9  + 
PA14  Cerebellum  10  M  Exon 16 - Exon 9  + 
PA15  Cerebellum  13  M  Exon 16 - Exon 9  + 
PA16  Cerebellum  10  M  Exon 16 - Exon 9  - 
PA17  Cerebellum  6  M  Exon 16 - Exon 9  + 
PA18  Cerebellum  3  M  Exon 16 - Exon 9  + 
PA19  Cerebellum  3  M  Exon 16 - Exon 9  + 
PA20  Cerebellum  4  M  Exon 16 - Exon 9  + 
PA21  Cerebellum  12  F  Exon 16 - Exon 9  Not tested 
PA22  Cerebellum  6  F  Exon 15 - Exon 9  + 
PA23  Cerebellum  3  F  Exon 15 - Exon 9  + 
PA24  Cerebellum  4  F  Exon 15 - Exon 9  Not tested 
PA25  Cerebellum  4  F  Exon 16 - Exon 11  + 
PA26  Cerebellum  3  F  Exon 16 - Exon 11  + 
PA27  Cerebellum  14  F  Exon 16 - Exon 11  + 
PA28  Cerebellum  7  M  Exon 18 - Exon 10  Not tested 
PA29  Cerebellum  19  M  Exon 19 - Exon 9  + 
PA30 Cerebellum 13  F  -  - 
PA31 Cerebellum  1  F  -  - 
PA32  Brain stem  9  F  Exon 16 - Exon 9  + 
DA1  Cerebral cortex  5  F  Exon 15 - Exon 9  Not tested 
DA2 Cerebral  cortex 9 M  -  - 
DA3 Cerebral  cortex  17 M  -  - 
DA4 Cerebral  cortex 4 M  -  - 
DA5 Cerebral  cortex 7  F  -  - 
DA6 Cerebral  cortex 5  F  -  - 
DA7 Cerebral  cortex 5 M  -  - 
DA8 Cerebral  cortex  15 F  -  - 
DA9 Cerebral  cortex 9  F  -  - 
DA10  Cerebral cortex  5  F  -  Not tested 
DA11  Cerebral cortex  2  M  -  Not tested 
PMA1  Diencephalon 1 F Exon  15  -  Exon  9  + 
PMG1 Diencephalon 17 M  -  - 
PMG2 Diencephalon  7  F  -  - 
PMG3 Diencephalon  8  M  -  Not  tested 
PMG4  Spinal cord  12  M  Exon 15 - Exon 9  Not tested 
PMG5 Spinal  cord 11  F  -  - 
PXA1 Cerebral  cortex  6  F  -  - 
Table 5.1 KIAA1549-BRAF fusion variants identified in 50 low-grade 
astrocytomas.  
PA (pilocytic astrocytoma), DA (diffuse astrocytoma), PMA (pilomyxoid 
astrocytoma), PMG (pilomyxoid glioma), PXA (pleomorphic xanthoastrocytoma), 
- (no abnormality found).   166
 Frequency 
Fusion variant  Pilocytic astrocytoma Non-pilocytic  astrocytoma 
KIAA1549-BRAF exon 15-exon 9  3/32  - 
KIAA1549-BRAF exon 16-exon 9  22/32  3/18 (1 DA, 1 PMA, 1 PMG) 
KIAA1549-BRAF exon 16-exon 11  3/32 - 
KIAA1549-BRAF exon 18-exon 10  1/32 - 
KIAA1549-BRAF exon 19-exon 9  1/32 - 
 
Table 5.2 Summary of KIAA1549-BRAF fusion variants found in 50 low-grade 
paediatric astrocytomas. 
 
All of the fusion variants would theoretically produce in-frame gene fusions. Each 
variant was found to occur between exons in the same start and end phases for 
transcription, ensuring the production of an in-frame protein (Figure 5.7). The most 
frequent fusion combination was between KIAA1549-BRAF exon 16-exon 9. Several 
other fusion combinations producing in-frame proteins are theoretically possible, but 
have not, as yet, been identified. Based on the fusion pairings discovered to date, the 
two most likely to occur are KIAA1549-BRAF exon 19-exon 11 and KIAA1549-BRAF 
exon 17-exon 8. The fusion transcript and predicted fusion protein sizes are shown in 
Table 5.3.  
 
 
 
 
Figure 5.7  Five KIAA1549-BRAF fusion variants, the thickness of the black lines 
indicates the frequency of each variant.  
The start phase of the exons in BRAF and the end phases of the exons in KIAA1549 
are denoted by the following colours: blue = 0, yellow = 1, green = 2, white = 
untranslated. Only a fusion between exons in the same colour (i.e. start and end 
phase) will produce an in-frame protein. 
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KIAA1549-BRAF fusion  Transcript length  Predicted protein size 
Exon 15-Exon 9 (short transcript)  2626bp  90.77kDa 
Exon 15-Exon 9 (long transcript)  6257bp  221.4kDa 
Exon 16-Exon 9 (short transcript)  2944bp  101.8kDa 
Exon 16-Exon 9 (long transcript)  6575bp  232.5kDa 
Exon 16-Exon 11 (short transcript)  2770bp  95.7kDa 
Exon 16-Exon 11 (long transcript)  6401bp  226.4kDa 
Exon 18-Exon 10 (short transcript)  3112bp  107.7kDa 
Exon 18-Exon 10 (long transcript)  6743bp  238.3kDa 
Exon 19-Exon 9 (short transcript)  3195bp  114.1kDa 
Exon 19-Exon 9 (long transcript)  6926bp  244.8kDa 
Table 5.3 Transcript lengths and predicted protein sizes for the five KIAA1549-
BRAF fusion variants. 
Transcript lengths and predicted protein sizes are shown for the short form where 
transcription may have been initiated from the promotor within intron 8, as in the 
short form of the KIAA1549-BRAF fusion described by Jones et al. (Jones et al., 
2008). The long transcript is shown where protein transcription may have 
commenced from the promotor within exon 1 of KIAA1549.  
 
5.4  Mapping genomic DNA KIAA1549-BRAF fusion 
breakpoints 
 
The KIAA1549-BRAF fusion breakpoints were confirmed by sequencing whole-genome 
amplified (WGA) genomic DNA from 9 tumours (PAs 1, 2, 3, 4, 5, 6, 7, 8 and 32). All 
contained the most prevalent KIAA1549-BRAF exon 16-exon 9 fusion variant. Forward 
primers were designed, spaced approximately 600bp apart throughout KIAA1549 intron 
16, reverse primers were designed similarly across BRAF intron 8. A 96-well format 
was used, where each column corresponded to one of 12 KIAA1549 DNA primers, and 
each row corresponded to one of 8 BRAF DNA primers (Appendix C, Table 8.3). PCRs 
were performed using pooled WGA genomic DNA from the 9 tumour samples, and 
pooled male control DNA. PCR products were visualised using 1.5% agarose gels 
(Figure 5.8). All primer combinations producing a tumour-specific product were then 
tested in individual tumour DNA samples, and validated by direct sequencing (Figure 
5.9).    168
 
The genomic DNA fusion breakpoints were identified within intron 16 of KIAA1549 
and intron 8 of BRAF for all 9 tumours tested. These are summarised in Figure 5.10. 
Two tumours (PA4 and PA7) showed a sequence change from KIAA1549 to BRAF 
across a single base within the intronic sequence. Six tumours (PAs 1, 2, 3, 5, 6 and 8) 
showed small regions of microhomology, ranging from 2-4 bases, between the two 
intronic sequences across the fusion junction. One of these samples (PA1) also 
contained three additional bases (TAA) inserted at the fusion junction, a single base 
after the region of microhomology. Finally, one sample (PA32) contained a single 
cytosine base insertion at the fusion junction. 
 
All of the tumours showed breakpoints at different sites within these introns, suggesting 
that the fusion breakpoints were not associated with a specific sequence motif. No 
known fragile sites were identified within this region, or within the wider genomic 
region involving KIAA1549  and BRAF. The positions of Alu elements, which are 
implicated in tandem duplications in acute myeloid leukaemia, were mapped across the 
region of DNA fusion breakpoints. The fusion breakpoints were not related to the 
situation of Alu elements (Figure 5.11). Further scrutiny of the region was performed to 
identify regions of segmental duplication or low-copy repeats. These duplicated 
segments of DNA contain nearly identical sequence, which may act as foci for non-
allelic homologous recombination, leading to translocations or other genomic 
rearrangements (Cheung et al., 2003, Bailey et al., 2006). Human segmental 
duplications are defined as continuous portions of DNA >1kb in size containing >90% 
sequence identity, which map to more than one genomic location (Bailey et al., 2006). 
No segmental duplications were identified in the genomic sequences of KIAA1549 or 
BRAF, after searching within the Human Genome Segmental Duplication Database 
(http://projects.tcag.ca/humandup/) or the Human Segmental Duplication Database 
(http://humanparalogy.gs.washington.edu/). 
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Figure 5.9 1.5% agarose gel for the identification of KIAA1549-BRAF  fusion 
breakpoints in pooled genomic DNA from 9 tumours.   
Each well contains the PCR from one primer combination in the 96-well plate 
format, and each PCR product indicates a gene fusion identified by a specific 
primer combination. Thirty-six separate reaction results are shown here. Positive 
PCR products were then validated by PCR in separate tumour DNA samples 
followed by direct sequencing. 
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Figure 5.10 Sequence traces for the fusion junctions between KIAA1549 intron 16 
and BRAF intron 8 in genomic DNA from three tumour samples.  
(A) Fusion junction in PA4, showing the sequence change at a distinct site between 
KIAA1549 and BRAF. 
 
(B) The fusion junction in PA3 demonstrates microhomology across 4 bases 
(highlighted in blue) between KIAA1549 and BRAF.  
 
(C) The fusion junction in PA32 demonstrates the insertion of a single cytosine 
base (highlighted in blue) between KIAA1549 and BRAF. 
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KIAA1549 TTGCATTTGATAAGAATTA---AAACTCGGGTGATGGGTC 
PA1   TTGCATTTGATAAGAATTATAATATATTTTTAAATTATAC 
BRAF   ACCAGTGTACTTTTAATTT---TATATTTTTAAATTATAC 
 
KIAA1549 TGCTATGGATTGAACTGTGTCCTCCCCAAAATCACATGTT 
PA2   TGCTATGGATTGAACTGTGTCATTTGTTAAGGAAATGAAA 
BRAF   CATAAGGGGGTTAGGAAAGTCATTTGTTAAGGAAATGAAA 
 
KIAA1549 TGCAATGCAGTGGATAAATTCAAGAGGAAGAATCAGCGAG 
PA3   TGCAATGCAGTGGATAAATTCAGACAAGAAATGATATTTA 
BRAF   ATGTGGTTTTTACAGTATTTCAGACAAGAAATGATATTTA 
 
KIAA1549 AATGTATTCTTGTTGATGTCTCCAGAAAAGTTTCAGTTTA 
PA4   AATGTATTCTTGTTGATGTCAAGATTGTCAAGGAGCTTTA 
BRAF   GTAACCTAGAATGAGTAGAAAAGATTGTCAAGGAGCTTTA 
 
KIAA1549 AGAAGGAAAGATCTAGAAATGAGTTGTGTGTTTTCTAAAG 
PA5   AGAAGGAAAGATCTAGAAATGCACCAGTATAATTTTTTTT 
BRAF   ATTTTTATCTCTCTTAATGTGCACCAGTATAATTTTTTTT 
 
KIAA1549 GTATGCATATGTGTTTGTATGGAGAGAGTGAGGGGGAGAG 
PA6   GTATGCATATGTGTTTGTATGGCCTTTGCCCTCAAGGAAG 
BRAF   TTATTTATGAATTAGCACATGGCCTTTGCCCTCAAGGAAG 
 
KIAA1549 GCAGGAGGACTTTTGCTTTGTGGAGGAACGGAGGGGGATT 
PA7   GCAGGAGGACTTTTGCTTTGAAGATGCCTGTGGGACTTTC 
BRAF   TGGGGGCATATATTGACTTTAAGATGCCTGTGGGACTTTC 
 
KIAA1549 TGAGCATTCTGGGGATGGGCTTAGGAGCCACATCGTGCTG 
PA8   TGAGCATTCTGGGGATGTGCTTGCTTGGAATAAATATACA 
BRAF   GCTACTCTCTGATTATATGCTTGCTTGGAATAAATATACA 
 
KIAA1549 TAGTTACTGTTCTTCTGAAA-TATCTAATTCCAAAAGGAA 
PA32   TAGTTACTGTTCTTCTGAAACAAGGAAAACAAGGTTTGCA 
BRAF   GCACAGTTTGTTAAATACCA-AAGGAAAACAAGGTTTGCA 
 
 
Figure 5.11 Sequence traces for the DNA fusion junctions in 9 pilocytic 
astrocytomas, all containing the KIAA1549-BRAF exon 16-exon 9 fusion.  
The tumour sequence traces are compared with KIAA1549 (identical sequence is 
highlighted in green) and BRAF (identical sequence is highlighted in yellow). 
Regions of microhomology between all three sequences are highlighted in red.   
Two tumour samples (PA1, PA32) contain base insertions (highlighted in blue), 
both occurring at the fusion junction. Two samples (PA4, PA7) do not show any 
region of microhomology, as the sequence changes abruptly in-frame from 
KIAA1549 to BRAF. 
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Figure 5.12 Schematic representation of the mapping results for DNA fusion 
breakpoints within intron 16 of KIAA1549 and intron 8 of BRAF in 9 tumours with 
the KIAA1549-BRAF exon 16-exon 9 fusion.  
Both genes are transcribed in the same direction. The fusion breakpoints are 
different in all of the 9 tumours, and are not related to the positions of Alu 
elements. The red arrow indicates the position of the AKAP9-BRAF  fusion in 
thyroid carcinoma. 
 
 
5.5  Identification of SRGAP3-RAF1 fusion in the single 
pilocytic astrocytoma with 3p25 DNA copy number gain 
 
Two of the 32 pilocytic astrocytomas studied did not contain a KIAA1549-BRAF fusion. 
One of these tumours, PA30, contained a discrete region of DNA copy number gain at 
chromosome 3p25, starting within SRGAP3 and ending within RAF1. RAF1 is also a 
Raf kinase, from the same family as BRAF. Following the successful identification of 
the KIAA1549-BRAF gene fusion, a similar approach was used to search for a fusion 
gene between SRGAP3 and RAF1. 
 
Nine primers were designed throughout SRGAP3, and 3 primers were designed within 
the kinase domain of RAF1 (Appendix C, Table 8.4). PCR indicated the presence of a 
gene fusion, from a number of different primer combinations. The PCR product from 
SRGAP3  forward primer 5 (exon 10) and RAF1 reverse primer 2 (exon 11) was 
sequenced (as other products were too large). This identified a fusion gene between 
SRGAP3 exon 11 and RAF1 exon 8 (figure 5.12). Sequence analysis also identified an 
in-frame duplication of SRGAP3 exon 11, before the fusion junction with RAF1. 
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Figure 5.13 Sequence analysis of the SRGAP3-RAF1 exon11-exon8 fusion junction 
in tumour PA30. Exon 11 of SRGAP3 has been duplicated, remaining in-frame. 
 
5.5.1  Western blotting confirms activation of the MAPK pathway  
BRAF and RAF1 are serine-threonine-specific protein kinases, activated downstream of 
RAS. They activate the extracellular signal-regulated kinases MEK 1/2 by 
phosphorylation, which in turn activate the kinases ERK1/2 by phosphorylation (Figure 
5.13). Once activated, ERK1 and ERK2 translocate into the nucleus where numerous 
physiological responses are elicited, including cell proliferation, differentiation and 
apoptosis (Roberts et al., 2007). 
 
 
Figure 5.14 Schematic representation of the MAPK pathway.  
Both MEK and ERK are activated by phosphorylation. Once activated, phospho-
ERKs translocate to the nucleus, where a variety of responses are elicited. These 
include the promotion of cell proliferation, differentiation and apoptosis. 
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Figure 5.15 Western blots showing ERK and phospho-ERK in a representative 
number of tumour samples and controls.  
Protein sizes are indicated in kilodaltons. C1 (fetal cerebellum control), C2 (fetal 
frontal lobe control). 
 
Western blotting was performed by Dr William Ogunkolade, at the Blizard Institute of 
Cell and Molecular Science, London, to confirm whether the MAPK pathway was 
activated in samples with fusion genes. Eleven tumours were examined: 7 contained 
KIAA1549-BRAF  fusions (PAs 2, 11, 13, 14, 15, 25 and 29), one contained the 
SRGAP3-RAF1 fusion (PA30) and three did not contain gene fusions (DAs 3, 4 and 7). 
Total protein was obtained from two fetal brain controls, one from cerebellum and one 
from the cerebrum (frontal lobe), (BioChain, Hayward, CA).  
 
Twenty micrograms of protein lysates and control brain protein were separated on 
Nupage®Novex® 4-12% Bis-Tris Gel 4 (Invitogen) and transferred to polyvinylidene 
difluoride membranes (GE Healthcare, Buckinghamshire, UK). Membranes were then 
probed with antibodies specific to MEK1/2, phospho-MEK1/2, ERK1/2 and phospho-
ERK1/2 (p44/42) (all from Cell Signaling Technology, Hertfordshire, UK). After 
probing the PVDF membranes with appropriate peroxidase-labelled secondary 
antibodies (GE Healthcare, Buckinghamshire, UK), signals were developed using ECL 
Plus Western blotting detection reagents (GE Healthcare, Buckinghamshire, UK) 
according to the manufacturer’s recommendations, and visualized on a Kodak film   
(BioMax MR; Kodak, Rochester, NY).  
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Western blot analysis showed no differences in the levels of MEK and ERK between 
tumours and controls. However, high levels of phospho-MEK (data not shown) and 
phospho-ERK were found in all of the tumour samples when compared to controls 
(figure 5.14). These results confirmed that activation of the MAPK pathway was present 
in tumours containing RAF gene fusions, implying that activation of the pathway may 
have occurred due to the presence of gene fusions. However, these data do not show a 
causal role for activation of the MAPK pathway by gene fusions, as MAPK pathway 
activation was also seen in three tumours without gene fusions. These data suggest that 
activation of the MAPK pathway is, however, a critical event leading to the 
development of paediatric low-grade astrocytomas. 
 
 
5.6   Discussion: RAF fusion genes in paediatric low-grade 
astrocytoma 
 
Fusions involving two RAF genes, RAF1 and BRAF were identified in 34/50 low-grade 
astrocytomas, including 31/32 pilocytic astrocytomas and 3/18 Grade II astrocytomas. 
Both were identified by the presence of discrete regions of DNA copy number gain at 
3p25 and 7q34, respectively. Each RAF gene appeared to show duplication only at the 
3’ end, which contains the coding sequence for the kinase domain. Duplication at 7q34 
was confirmed using iFISH in paraffin sections from tumours known to contain 7q34 
gain by SNP analysis. BRAF has been shown to fuse with AKAP9 and FCHSD in other 
malignancies, retaining the kinase domain in each case. These data suggested a possible 
mechanism for the RAF gene fusions to arise, via tandem duplications (Figure 5.15).  
 
The SRGAP3-RAF1 fusion was found in a single pilocytic astrocytoma. One of the five 
KIAA1549-BRAF fusion variants was found in 30/32 pilocytic astrocytomas. In both 
RAF fusion genes the autoinhibitory domains within BRAF and RAF1 are replaced in-
frame with the N-terminal segments of KIAA1549 and SRGAP3, respectively (Figure 
5.16). Hence, the fusion proteins retain the kinase domains of BRAF and RAF1. 
 
 
 
   176
 
 
 
Figure 5.16 Proposed mechanism for the KIAA1549-BRAF fusion to arise by 
tandem duplication and reinsertion.  
The fusion would also arise if the duplicated segment inserted into BRAF rather 
than  KIAA1549. The SRGAP3-RAF1 fusion is proposed to arise by the same 
mechanism.  
 
 
 
 
Figure 5.17 Schematic representations of protein domains within KIAA1549, 
BRAF, SRGAP3, RAF1 and the resulting fusion proteins.  
The dotted lines indicate the positions of the fusion breakpoints. The auto-
inhibitory domains within BRAF and RAF1 are found within the Ras-binding and 
cysteine-rich domains. 
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BRAF and RAF1 are well-characterised protein kinases within the MAPK pathway, and 
both retain their kinase domains in the gene fusions described here. However, their 
fusion partner genes, KIAA1549 and SRGAP3, may also have an important part to play 
in the process of tumorigenesis. 
 
KIAA1549 is expressed in many tissues, including the brain, however, nothing is known 
about the normal cellular role of the protein it encodes (Nagase et al., 2000).  An 
additional exon was recently identified at the start of KIAA1549 (Jones et al., 2008), 
which was confirmed by sequencing here. Hence, all exon numbering here for 
KIAA1549 contains the additional first exon, giving a total of 20 exons. KIAA1549 is 
thought to contain two transmembrane domains: it is possible that these may be used to 
attach the fusion gene product to the cell membrane. KIAA1549 has also recently been 
shown to have two alternative transcripts, one long and one short (Jones et al., 2008). 
The shorter transcript originates from a promoter within intron 8, and may contain only 
a single transmembrane domain. The relative abundance of the two transcripts, and 
whether one or both contribute to the fusion with BRAF is currently unknown.  
 
The second fusion partner SRGAP3 (Slit-Robo GTPase activating protein) has been 
characterised much more fully, and has been shown to play roles in neuronal migration, 
axonal branching and in the regulation of neuronal development in a complex with the 
scaffolding protein WAVE1 (Wiskott-Aldrich syndrome protein family member 1) 
(Wong et al., 2001, Soderling et al., 2007). SRGAP3 expression has also been shown at 
sites of neural proliferation in the developing murine brain, suggesting that SRGAP3 has 
a role in the control of neurogenesis (Bacon et al., 2009). SRGAP3 is involved in a 
balanced constitutive translocation t(X;3)(p11.2;p25) in a patient with severe mental 
retardation, however the breakpoint is within intron 3, unlike the  intron 11 breakpoint 
described here (Endris et al., 2002). SRGAP3 contains three functional motifs: the N-
terminal FCH (Fes/CIP4 homology) domain is retained in the fusion, but the RhoGAP 
and C-terminal SH3 domains are lost. FCH domains are present in other proteins, where 
they have a putative function in regulating the microtubule cytoskeleton (Yang et al., 
2006). The FCH domain is retained in the FCHSD1-BRAF fusion in large congenital 
melanocytic naevi, which suggests that a selective advantage may be conferred to cells 
containing these fusion proteins. 
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The identification of KIAA1549-BRAF and SRGAP3-RAF1 fusion genes, particularly at 
such a high frequency in pilocytic astrocytoma, has been a huge breakthrough in the 
understanding the importance of MAPK pathway activation in the origins of paediatric 
low-grade astrocytoma. These findings were published in the Journal of Pathology in 
March 2009, entitled ‘Activation of the ERK/MAPK pathway: a signature genetic 
defect in pilocytic astrocytomas’, where I am joint first author (Forshew et al., 2009). 
 
The MAPK pathway was first implicated in the development of astrocytomas from 
studies of patients with the tumour-predisposition syndrome Neurofibromatosis type 1 
(NF-1). NF-1 is a common autosomal dominant disorder, which affects around 1 in 
3,000 individuals, and is caused by a germ-line inactivating mutation in the NF-1 
tumour suppressor gene located at chromosome band 17q11.2 (von Deimling et al., 
1995, Rubin et al., 2005, Brems et al., 2009). Neurofibromin, the protein encoded by 
NF-1 acts as a negative regulator of the RAS signal transduction pathway, as shown in 
figure 5.13. Neurofibromin interacts with RAS via a GTPase activating domain, 
converting active RAS-GTP to its inactive form. Loss of a single allele of NF-1 is 
insufficient for tumorigenesis – the second allele must also be lost, as outlined in 
Knudson’s two-hit hypothesis (Knudson, 1985).  Loss of heterozygosity (LOH), by 
partial chromosome deletion, whole chromosome loss or mitotic recombination causes 
the second hit in NF-1 associated tumours. Penetrance of NF-1 is 100% by 5 years of 
age (Huson et al., 1989). Nearly all individuals with NF-1 will develop a benign or 
malignant nervous system tumour during their lifetime – these include optic pathway 
gliomas (pilocytic astrocytomas of the optic nerve and chiasm), neurofibromas and 
hamartomas of the iris (Lisch nodules) (Rubin et al., 2005, Brems et al., 2009). 
Pilocytic astrocytomas of the optic pathway are seen in 15-20% children with NF-1 
(Listernick et al., 2007). These may remain indolent for years, however, between 30-
50% will cause symptoms including sudden and unpredictable loss of vision. Their 
histological appearance is usually indistinguishable from that of sporadic pilocytic 
astrocytoma (PA). However, very few sporadic PAs exhibit NF-1 inactivation, either by 
LOH or chromosomal deletions at 17q11.2, or DNA methylation, and expression of 
neurofibromin has also been demonstrated in these tumours (Kluwe et al., 2001, 
Wimmer et al., 2002, Ebinger et al., 2005). These indications that sporadic PAs arise by 
different mechanisms to those for NF-1 associated PAs led to a number of studies 
investigating alternative methods of MAPK pathway activation in low-grade 
astrocytomas.   179
The ERK/MAPK pathway is upregulated in about a third of all cancers, and in many 
cases this is due to activating point mutations in the RAF and RAS genes (Downward, 
2003, Dhillon et al., 2007). Activating mutations in RAS are most commonly found at 
codons 12, 13 and 61: all prevent the hydrolysis of GTP. Thus, RAS remains in an 
active GTP-bound form, activating its effectors including RAF. The most common RAF 
mutation is BRAF  V600E, seen in over 90% cases, which causes a conformational 
change in the kinase activation loop, inducing constitutive catalytic activation. In 
contrast, ARAF and RAF1 (CRAF) mutations are extremely rare (Lee et al., 2005a, 
Dhillon et al., 2007). The reason for this may be the fact that serine 445 is constitutively 
activated in BRAF, while ARAF and RAF1 (CRAF) require further phosphorylation to 
become activated (Wellbrock et al., 2004). Hence, BRAF  appears to be poised for 
activation, which may explain the propensity for mutations in cancer to occur in BRAF. 
RAS and RAF mutations appear to be mutually exclusive (Petti et al., 2006, Dhillon et 
al., 2007). Melanomas containing both NRAS and BRAF mutations have been described, 
but these do not appear to occur within the same cell: co-expression of NRAS Q61R and 
BRAF V600E was found to induce senescence within cultured melanoma cells (Petti et 
al., 2006). 
 
Activation of the MAPK pathway was found in 21/21 sporadic pilocytic astrocytomas 
using immunohistochemistry for phospho-AKT, a downstream effector from RAS 
(Sharma et al., 2005). However, this high level of pathway activation was not explained 
by the presence of RAS and RAF activating mutations. KRAS activating mutations 
affecting codons 12, 13 and 61 have been identified in pilocytic astrocytomas, however 
this is a rare event affecting between 4-7% of tumours (Maltzman et al., 1997, Sharma 
et al., 2005, Janzarik et al., 2007). Similarly low incidence rates (~ 6%) have also been 
found for BRAF V600E mutation, which has been identified in 5 pilocytic astrocytomas 
and 2 diffuse astrocytomas to date (Jones et al., 2008, Pfister et al., 2008, Sievert et al., 
2009).  
 
Gene transcription and expression may be inactivated epigenetically, by methylation of 
CpG islands in gene promoters. RASSF1 is a tumour suppressor gene located on 3p21.3, 
which acts downstream in the RAS signal transduction pathway. RASSF1A  is 
inactivated by promoter hypermethylation in many cancers, including lung, breast, 
ovarian and thyroid cancer (Agathanggelou et al., 2001). RASSF1A  promoter 
hypermethylation has been identified in astrocytomas of all grades, including pilocytic   180
astrocytomas (Yu et al., 2004, Lorente et al., 2009). Thus, a range of mechanisms for 
deregulating the ERK/MAPK pathway have been identified in low-grade astrocytomas, 
including NF1 deletion and mutations, RASSF1A methylation, BRAF V600E and KRAS 
activating mutations. Taken together, these data indicated that other factors were 
implicated in the pathogenesis of low-grade astrocytomas, as none appeared to account 
for the high numbers of samples with MAPK pathway activation identified by Sharma 
et al (Sharma et al., 2005). 
 
DNA copy number analysis by array CGH of 66 paediatric low-grade astrocytomas, by 
Pfister et al identified a discrete 0.97Mb region of gain at chromosome 7q34 in 13 
pilocytic astrocytomas, encompassing the majority of BRAF (Pfister et al., 2008). Dual 
colour FISH, using a chromosome 7 centromeric probe and RP4-726N20 to probe the 3’ 
end of BRAF was conducted for 28 adult low-grade astrocytomas (3 pilocytic 
astrocytomas and 25 diffuse astrocytomas) in a tissue microarray. Results confirmed 
duplication of the BRAF locus in the presence of two homologues of chromosome 7 in 6 
diffuse astrocytomas. Furthermore, ten tumours (3 PAs and 7 DAs) displayed gains of 
both BRAF and the chromosome 7 centromeric probes, indicating large genomic gains 
of chromosome 7. Western blot analysis of tumour samples containing the BRAF 
duplication showed high levels of expression of phosphorylated ERK when compared 
to non-neoplastic brain, suggesting constitutive activation of the MAPK pathway in 
pilocytic astrocytomas.  
 
A further study by Deshmukh et al., published the same month, identified a 1Mb region 
of copy number gain at 7q34 in 10 paediatric patients with cerebellar pilocytic 
astrocytomas by array CGH (Deshmukh et al., 2008). Here the gained region 
encompassed the 3’ terminal portion of BRAF in three samples, however the majority 
contained a common region of copy number gain spanning the genes HIPK2 
(homeodomain-interacting kinase 2) and TBXAS1  (thromboxane A synthase 1). 
Similarly, Bar et al. identified the 7q34 region of gain in 17/20 pilocytic astrocytomas, 
commenting that the gained region only encompassed exons coding for the BRAF 
kinase domain (Bar et al., 2008). Quantitative RT-PCR confirmed the presence of 3 or 
more copies of the 7q34 locus, using sequences within HIPK2, RAB19B and BRAF. 
Western blotting also revealed high levels of phospho-ERK in 3/6 pilocytic 
astrocytomas with 7q34 gain, when compared to one tumour without 7q34 gain and two 
normal brain specimens.    181
 
Two studies published within a week of each other in late 2008 revealed gene fusions 
between KIAA1549 and BRAF at regions of 7q34 duplication in low-grade astrocytomas 
(Jones et al., 2008, Sievert et al., 2009). The first study by Sievert et al. used Illumina 
HumanHap550K SNP arrays, and found 7q34 gain in 17/22 paediatric PAs and 3/6 
fibrillary astrocytomas. A novel KIAA1549-BRAF fusion product was identified by 
reverse transcription PCR, and sequence analysis revealed an in-frame fusion between 
KIAA1549  exon 15 and BRAF  exon 9. The predicted fusion product contained the 
protein kinase domain of BRAF  and lacked the N-terminal regulatory domains, 
conferring constitutive kinase activity. However, an additional first exon was 
subsequently found in KIAA1549,  approximately 60kb upstream of the previously 
documented first exon using 5’ RACE analysis (Jones et al., 2008). Hence Sievert et al 
identified the KIAA1549-BRAF exon 16-exon 9 variant, once the exon numbering was 
altered due to the additional first exon in KIAA1549. 
 
Jones et al. found the 7q34 region of gain in 44 pilocytic astrocytomas using 1Mb array 
CGH, and a chromosome 7 tiling path array to investigate the region at higher 
resolution (Jones et al., 2008). Three fusion variants were identified: between 
KIAA1549-BRAF  exon 16-exon 9 (20 cases), KIAA1549-BRAF  exon 16-exon 11 (2 
cases) and KIAA1549-BRAF exon 15-exon 9 (7 cases). An additional first exon was 
identified in KIAA1549 by 5’ RACE analysis. Two possible KIAA1549 transcripts, one 
long and one short (beginning at a promoter within intron 8) were confirmed by PCR, 
and an alternative splice site was found in intron 19, giving rise to two possible variants 
of KIAA1549 exon 20, one 48bp longer than the other. The long and short isoforms of 
the KIAA1549-BRAF exon 16-exon 9 were cloned, and used alongside BRAF V600E 
and wild-type BRAF to transfect Cos-7 cells. Kinase activity was tested for all using a 
chemiluminescence assay. Both fusion isoforms showed constitutive kinase activity, the 
highest levels were seen for the long isoform, the short form displayed similar levels to 
those seen for BRAF V600E when compared to wild-type BRAF. NIH3T3 cells were 
stably transduced with an empty vector, HRAS  V12,  BRAF V600E and the short 
KIAA1549-BRAF exon 16-exon 9 isoform. Anchorage independent growth was seen in 
cells containing the short KIAA1549-BRAF isoform, BRAF V600E and HRAS V12, but 
not in cells containing wild-type BRAF or the empty vector. This study concluded that 
the 7q34 gains seen in 26/29 PAs were highly specific for pilocytic astrocytomas. Six 
grade II astrocytomas were also found to have 7q34 gains, however, these were felt to   182
represent false positives or misdiagnosed pilocytic astrocytomas as patient survival was 
>12 years for all 6 cases. The 7q34 gain was not seen in 60 anaplastic astrocytomas or 
184 glioblastomas, suggesting that the gain was highly specific for pilocytic 
astrocytomas. These latter cases were not described in detail, however, and it is likely 
that the majority of these tumours were from adults.  
 
Five KIAA1549-BRAF fusion variants were identified in 30/32 PAs and 3/18 Grade II 
astrocytomas, from the work described in this chapter. The most common variant was 
between KIAA1549-BRAF exon 16-exon 9, which was found in 22/32 PAs. Further 
fusion variants were present at much lower frequencies, as summarised in Table 5.2. 
Some fusion gene variants were only revealed by sequencing, as not all of the 50 
tumour samples had undergone DNA copy number analysis.  Where present, copy 
number data confirmed 7q34 gain in all of the samples with fusions except for one, 
PA16. This tumour was found to contain a KIAA1549-BRAF exon 16-exon 9 fusion, but 
did not show DNA copy number gain at 7q34 by either 250k or 6.0 SNP array analyses. 
It is possible that this sample contained a higher amount of contaminating normal tissue, 
which obscured the presence of DNA copy number gain. Interphase FISH has not been 
possible on this sample to date, but would be an important piece of evidence to show 
whether DNA duplication at 7q34 is present in this tumour. If not, it is possible that the 
KIAA1549-BRAF  fusion has occurred by another mechanism, not involving tandem 
duplication. Sievert et al described a similar case, where a single pilocytic astrocytoma 
was found to contain the KIAA1549-BRAF exon 16-exon 9 fusion by sequencing, but 
did not show 7q34 gain by SNP analysis (Sievert et al., 2009). However, this sample 
was shown to contain three copies of LUC7L2 by FISH, which lies between KIAA1549 
and BRAF within the region of 7q34 gain. 
 
All of the studies have found KIAA1549-BRAF fusions in a large proportion of pilocytic 
astrocytomas, but their role in grade II astrocytomas is less clear. Three KIAA1549-
BRAF exon 15-exon9 fusions were found in Grade II astrocytomas (DA1, PMA1, 
PMG4) in this study. PMA1 had previously been shown to contain 7q34 gain; the two 
further samples had not undergone copy number analysis. Copy number gains at 7q34, 
indicative of the KIAA1549-BRAF fusion, have been identified by CGH or SNP copy 
number analysis in 7/52 Grade II astrocytomas and 5/96 mixed 
astrocytic/oligodendroglial tumours studied to date (Jones et al., 2008, Pfister et al., 
2008, Forshew et al., 2009, Sievert et al., 2009). Pfister et al also identified duplication   183
of the BRAF locus without concurrent gain of chromosome 7 or 7q by FISH in 6 adult 
diffuse astrocytomas (Pfister et al., 2008). Further studies are necessary to elucidate 
whether these grade II astrocytomas with RAF  fusions are PAs with unusual 
histopathological features, a benign sub-group of non-pilocytic astrocytomas, which 
arose de novo or tumours which have progressed from PAs by accumulating additional, 
as yet unidentified, changes. 
 
An SRGAP3-RAF1 fusion variant was described by Jones et al. from further analysis of 
a discrete region of gain at chromosome 3p25 in a single pilocytic astrocytoma (Jones et 
al., 2009). RT-PCR identified an in-frame fusion gene between SRGAP3 exon 12 and 
RAF1 exon 10. This SRGAP3-RAF1  fusion variant was cloned, and conferred an 
anchorage independent growth phenotype and increased ability to phosphorylate 
endogenous MEK in NIH3T3 cells when compared to cells transduced with wild-type 
RAF1. The breakpoints described by Jones et al. are different to those found for the 
SRGAP3-RAF1 fusion in this thesis. Here, the breakpoints are between SRGAP3 exon 
11 and RAF1 exon 8. Intriguingly, an additional duplication of SRGAP3 exon 11 is seen 
within this variant, creating an in-frame gene fusion with partial tandem duplication of 
SRGAP3 exon 11. Both fusions retain the RAF1 kinase domain. These are currently the 
only two SRGAP3-RAF1 fusion variants to have been described in the literature. 
 
In summary, this thesis has described the identification of an SRGAP3-RAF1 and five 
KIAA1549-BRAF fusion variants: with the former and two of the latter previously 
undescribed in the literature. Combining these results with those from other studies, in-
frame  KIAA1549-BRAF fusion variants have been found in 76/95 (80%) sporadic 
pilocytic astrocytomas. The majority (59/76) are the KIAA1549-BRAF exon 16-exon 9 
fusion variant. These results are summarised in Table 5.4. 
 
 
 
   184
 
Fusion gene variant  Relative frequency in PAs 
KIAA1549-BRAF exon 16-exon 9  59/76 
KIAA1549-BRAF exon 15-exon 9  10/76 
KIAA1549-BRAF exon 16-exon 11  5/76 
KIAA1549-BRAF exon 18-exon 10  1/76 
KIAA1549-BRAF exon 19-exon 9  1/76 
SRGAP3-RAF1 exon11-exon 8  1/2 
SRGAP3-RAF1 exon 12-exon 10  1/2 
Table 5.4 Summary of RAF fusion gene variants. 
Fusion variants were identified in 78/95 pilocytic astrocytomas by three separate 
studies (Jones et al. 2008, Forshew et al. 2009 and Sievert et al. 2009). The study by 
Sievert did not include the additional exon for KIAA1549. Hence, the KIAA1549-
BRAF exon 15-exon 9 fusions described have been recorded as KIAA1549-BRAF 
exon 16-exon 9 fusions. 
 
5.6.1  Possible mechanisms for the development of fusions  
 
The KIAA1549-BRAF and SRGAP3-RAF1 fusions appear to have arisen from tandem 
duplication events. Two well-characterised mechanisms are used to repair DNA double 
strand breaks (DSB) in eukaryotes: homologous recombination (HR) and non-
homologous end joining (NHEJ). Both processes have been described in the genesis of 
tandem duplications in cancer and other genetic disorders, although in this context HR 
becomes non-allelic homologous recombination (Batzer et al., 2002, Gu et al., 2008, 
Lieber et al., 2008).  
 
Non-allelic homologous recombination (NAHR) occurs between non-allelic repetitive 
sequences that may occur frequently throughout the genome, such as Alu elements 
(short repetitive sequences <500bp long), or low-copy repeats, which may only occur a 
few times and may range from one to hundreds of kilobases in size (Batzer et al., 2002, 
Gu et al., 2008, Hastings et al., 2009). Homologous recombination is primarily used to 
repair DSBs during G2 or late S phase during the cell cycle, as the sister chromatid is 
used as a template. Sequences which lie between the regions that recombine may be 
duplicated or deleted, changing the DNA copy number. NAHR may give rise to 
deletions, duplications or inversions, depending on the orientation of the repetitive   185
sequences, and whether the rearrangement is intrachromatid, interchromatid or 
interchromosomal (Gu et al., 2008). NAHR has been implicated in the partial tandem 
duplication of MLL in acute myeloid leukaemia (Strout et al., 1998, Basecke et al., 
2006).  
 
Genomic DNA sequencing was carried out for 9 PAs with the same KIAA1549-BRAF 
exon 16-exon9 fusion variant, with the expectation of finding a common site for the 
DNA breakpoints. However, sequencing revealed that the DNA breakpoints were 
distributed widely throughout intron 16 of KIAA1549 and intron 8 of BRAF, with no 
apparent relationship to Alu elements or to any other repetitive sequences (Figure 5.11). 
Repetitive sequences are essential to create the origins for NAHR. Hence, these data 
suggest that the KIAA1549-BRAF fusion did not occur by Alu-Alu mediated 
recombination or NAHR.  
 
Non-homologous end joining (NHEJ) has also been implicated in the creation of 
tandem duplications. NHEJ is used to repair DSBs, which may be physiological, for 
example in VDJ recombination to generate the T-cell receptor or pathological, for 
example in response to ionizing radiation (reviewed by Lieber) (Lieber, 2008). Unlike 
NAHR, NHEJ may repair DSBs during any stage of the cell cycle, as the process does 
not use a homologous chromosome as a template. When the DSB is detected in NHEJ, 
the protein heterodimer Ku binds to the broken DNA ends. Ku interacts with the 
nuclease Artemis-DNA-dependent protein kinase catalytic subunit (Artemis-DNA-
Pkcs), polymerases μ and λ and a DNA ligase (XLF-XRCC4-DNA ligase IV), which 
appear to be capable of binding in any order. Binding of these elements can take place 
without Ku, but efficiency is improved by its presence. In essence, Ku functions as a 
‘work bench’, where repair of the DSB can take place. Artemis-DNA-Pkcs resects any 
overhangs at the broken DSB ends, making them compatible in order to allow the DNA 
to re-anneal (Figure 5.17). This editing process may require deletion and/or addition of 
bases by the polymerases μ and λ, which creates an ‘information scar’, the hallmark of 
NHEJ (Gu et al., 2008, Lieber, 2008).  
 
Genomic rearrangements may arise through NHEJ by ligating DNA ends together from 
different DSBs: repetitive sequences are not required for the process to occur. The 
NHEJ mechanism is an attractive candidate for the tandem duplications identified in the 
KIAA1549-BRAF fusion. Two of the nine PA samples sequenced show insertions of 1   186
and 3 base pairs, which would be consistent with the ‘information scar’ created by the 
process. However, none of the samples show sequence deletions, and it is difficult to 
explain how the in-frame duplication of exon 11 in the SRGAP3-RAF1 fusion could 
have occurred by this method. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.18 Non-homologous end-joining (NHEJ) repair of a double strand DNA 
break.  
Ku binds to the broken DNA ends, and allows the Artemis complex to resect the 
overhanging ends.  The polymerases μ and λ add nucleotides (shown in red) to 
complete the sequence and the DNA ligase complex then repairs the double 
stranded DNA. Figure adapted from Lieber, 2008 (Lieber, 2008). 
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A number of alternative mechanisms for the creation of genetic rearrangements, relating 
to errors in DNA replication have recently been proposed, however these are all 
currently hypothetical models.  These include fork stalling and template switching 
(FoSTeS) and microhomology-mediated break-induced replication (MMBIR). FoSTeS 
suggests that stalling of the DNA replication fork may allow the ‘lagging’ DNA strand 
to detach from the original template (Figure 5.18) (Lee et al., 2007). This ‘lagging’ 
DNA strand may then attach to another replication fork nearby through regions of 
microhomology, allowing DNA replication to continue. Switching to a replication fork 
downstream of the original would result in deletion, and switching to a replication fork 
upstream would create a region of duplication. The FoSTeS model proposes that the 
lagging strand may switch DNA templates multiple times before resuming DNA 
replication on the original template strand, however the reasons for this to occur are not 
entirely clear. A single FoSTeS event could explain the tandem duplication leading to 
the KIAA1549-BRAF fusion, and two FoSTeS events occurring during one round of 
replication could explain the duplicated exon 11 in the SRGAP3-RAF1 fusion.  
 
Figure 5.19 Proposed mechanism for FoSTes (fork stalling template switching) to 
induce genomic rearrangements.  
Figure adapted from Lee, 2007 (Lee et al., 2007). 
 
FoSTeS was originally described in an attempt to explain the complex genetic 
rearrangements in Pelisaeus-Merzbacher disease, a recessive X-linked genetic disorder 
affecting the central nervous system.  This condition arises through complex 
nonrecurring chromosome changes involving the PLP1 gene. Microarray copy number 
analysis revealed sections of duplicated or tripled regions of DNA, interspersed with 
regions of deletion or normal copy number (Lee et al., 2007). Regions of 
microhomology between 2 to 5 nucleotides long were found by sequencing the 
duplication junctions. Detailed analysis of the regions of microhomology within the   188
sequence data suggested DNA duplication had occurred in different orientations within 
the same DNA strand, leading to the development of the FoSTes model. This model is 
attractive to explain the genesis of the RAF  fusion genes, however the situation in 
Pelisaeus-Merzbacher disease is not directly comparable. The genomic region 
surrounding  PLP1 contains numerous LCRs, which may act as foci for FoSTeS to 
occur, which is not the case in the region surrounding KIAA1549 and BRAF.   
Furthermore two of the samples, PA4 and PA7, do not show any region of 
microhomology at the fusion junction. In addition, the region of duplication involving 
the 7q34 region is generally the only copy number change present in an otherwise 
balanced genome, and there are no further regions of duplication or deletion nearby, 
which might be expected to be present if FoSTeS had occurred.  
 
In budding yeast, Payen et al found that segmental duplications arise from accidents in 
the replication process, via two alternative replication-based mechanisms (Payen et al., 
2008). The first involves break-induced DNA replication, by strand invasion of the 
sister chromatid, however only half of the segmental duplications seen in yeast 
contained homologous repeats at their junctions, suggesting another mechanism could 
also lead to segmental duplications. This was termed microhomology/microsatellite-
induced replication (MMIR). In MMIR replication forks collapse and break down rather 
than stalling, before rejoining via regions of microhomology or at microsatellites 
(simple repeating sequences between 1-4 bases long (Weber et al., 1989)). The MMIR 
mechanism has yet to be identified in humans.  
 
A similar mechanism, micro-homology mediated break-induced replication (MMBIR), 
has also been suggested for the development of regions of copy number variation 
(Hastings et al., 2009). Again this model was proposed to explain genetic 
rearrangements in Pelisaeus-Merzbacher disease, by the same group who proposed the 
FoSTeS model. Here, collapse of a replication fork occurs rather than stalling, possibly 
due to hypoxic stress, creating a single strand DNA break. The free DNA end 
dissociates, and may attach and form a further replication fork on a nearby DNA strand 
through regions of microhomology, allowing DNA replication to continue. The 
proposed MMBIR mechanism is theoretical, and suggests that microhomology is 
required for the process to occur. There is, as yet, no experimental evidence for this 
mechanism in humans. At the moment it does not appear that MMBIR can be used to   189
explain the genesis of the KIAA1549-BRAF fusion in the two PAs with no regions of 
microhomology at the fusion junctions. 
 
Both FoSTes and MMBIR are highly speculative. Currently it appears that none of 
these proposed mechanisms are able to explain how all of the fusion junctions identified 
by sequencing could have arisen. Hence, further investigations will be required to 
elucidate how the RAF gene fusions in PAs are formed. 
 
5.6.2    MAPK pathway activation in low-grade astrocytomas is 
confirmed by Western blotting 
 
Western blot analysis revealed high levels of phopsho-MEK and phospho-ERK in 
eleven tumour samples when compared to two fetal brain controls, consistent with 
results from previous studies. No differences in the levels of MEK and ERK were found 
between the two groups. These results confirmed that activation of the MAPK pathway 
was present in tumours. Seven of the tumours contained KIAA1549-BRAF fusions and 
the tumour containing the SRGAP3-RAF1 fusion were studied. However, three of the 
tumours examined did not, to our knowledge, contain any RAF gene fusions. Hence, the 
MAPK pathway was also activated in three tumours without gene fusions. These data 
led me to search for different mechanisms for MAPK activation in these samples, by 
sequencing for activating point mutations in BRAF and the three RAS genes. These data 
are discussed in chapter 6. 
 
So far no groups, including ours, have demonstrated either the KIAA1549-BRAF or 
SRGAP3-RAF1 fusion proteins by Western blot analysis. The predicted size for the 
most common KIAA1549-BRAF fusion would be 232 kDa if protein transcription 
commenced from the promoter within exon 1 of KIAA154. If transcription commenced 
from the promoter within intron 8, as in the short form described by Jones et al. the 
shorter predicted transcript would be 101 kDa (Jones et al., 2008). The SRGAP3-RAF1 
fusion protein is predicted to be 99 kDa. These experiments are ongoing, but initial 
attempts have not, as yet, identified a protein band of the expected size. Efforts are 
currently hampered by the lack of a suitable antibody with which to probe for 
KIAA1549.  
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Chapter 6. Candidate gene sequencing in paediatric 
low-grade astrocytoma 
 
6.1  Introduction 
 
Gene fusions between KIAA1549  and BRAF were identified in 30/32 pilocytic 
astrocytomas and 3/18 non-pilocytic astrocytomas (one cerebral diffuse astrocytoma, 
one hypothalamic pilomyxoid astrocytoma and one spinal pilomyxoid glioma). An 
additional gene fusion between SRGAP3 and RAF1 was identified in a single pilocytic 
astrocytoma. These gene fusions were shown to be associated with activation of the 
ERK/MAPK pathway, using Western blotting for MEK1/2, phospho-MEK1/2, ERK1/2 
and phospho-ERK1/2. However, MAPK pathway activation was also identified in three 
diffuse astrocytomas that did not contain gene fusions, suggesting that the pathway 
could be activated by another mechanism in these cases. The single pilocytic 
astrocytoma, which did not contain the KIAA1549-BRAF or SRGAP3-RAF1 fusions, 
was of particular interest in this respect, as were the 15/18 non-pilocytic astrocytomas 
without KIAA1549-BRAF fusions. The possibility of MAPK pathway activation through 
specific gene mutations was thus considered. 
 
BRAF and RAF1 are critical serine-threonine-specific protein kinases, activated 
downstream of RAS within the MAPK pathway. Malignant transformation is known to 
occur in many cancers, due to activating point mutations in BRAF and the RAS gene 
family (Downward, 2003). Hence, screening for possible activating mutations at known 
mutation hotspots in KRAS, NRAS, HRAS (exons 2 and 3) and BRAF (exons 11 and 15) 
was undertaken in 50 paediatric low-grade astrocytomas. Mutation screening was also 
performed for CDKN2A, PTEN, IDH1 and IDH2, as aberrations in these genes have 
been implicated in the development of adult astrocytomas (Ichimura et al., 1996, 
Rasheed et al., 1997, Wang et al., 1997, Raffel et al., 1999, Furnari et al., 2007, Parsons 
et al., 2008, De Carli et al., 2009, Watanabe et al., 2009). CDKN2A was also selected 
for mutation screening as deletions were identified within the CDKN2A locus by SNP 
copy number analysis in two grade II astrocytomas. Neither of these tumours contained 
the KIAA1549-BRAF or SRGAP3-RAF1 fusions.  
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The prevalence of mutations in members of the receptor tyrosine kinase (RTK) /PI3K 
pathway were recently elucidated by two large studies in adult glioblastoma, one from 
the Cancer Genome Atlas Research Network, and one from Williams Parsons et al 
(CGARN et al., 2008, Parsons et al., 2008). The Cancer Genome Atlas study 
investigated 91 glioblastomas (72 treated and 19 untreated), with matched normal tissue 
or peripheral blood for mutations in 601 selected genes. This study found that 86% of 
adult glioblastomas contained at least one genetic aberration in the RTK/PI3K pathway. 
The most common abnormalities within this pathway were mutations and amplifications 
in EGFR (45%), followed by mutations and homozygous deletions of PTEN (36%) and 
NF1 (18%). Mutations in RAS family members were found in 2%. Aberrations in the 
p53 pathway were found in 87% of glioblastomas, and mutations or homozygous 
deletions of CDKN2A and TP53 were found in 49% and 35% of these cases, 
respectively. Finally, aberrations in RB were seen in 78% cases, and mutations or 
homozygous deletions of CDKN2A and CDKN2B were found in 52% and 47% of these 
cases, respectively. Deregulation of all three signalling pathways was found in 74% 
glioblastomas studied here, suggesting that aberrations in all three pathways are 
required for glioblastoma development.  
 
The study by Williams Parsons et al looked at 22 glioblastoma tumour samples, and 
sequenced 20,661 protein-coding genes (Parsons et al., 2008). This study found the 
most commonly mutated genes in glioblastomas to be TP53 (35%), PTEN (26%), NF1 
(15%) and EGFR  (14%).  CDKN2A  showed homozygous deletions in 50% of 
glioblastomas studied. This study also identified recurrent mutations within the active 
site of the novel gene isocytrate dehydrogenase I (IDH1), as discussed above.  
 
Both of these large studies were conducted in adult glioblastomas, which are highly 
rearranged, and appear to contain different molecular signatures when compared to 
those seen in paediatric low-grade astrocytomas. EGFR and MDM2  amplification, 
mutations in PTEN and LOH of 10p are typical findings in primary glioblastomas, 
which tend to develop rapidly after a short clinical history with no evidence of a 
precursor lesion. Mutations in TP53, and LOH at 19q and 22q are more typical of 
secondary glioblastomas, which have arisen more slowly from a less malignant low-
grade astrocytoma (Watanabe et al., 2009). 
   192
6.2  Aim 
The aim of the work described within this chapter was to investigate the presence of 
gene mutations in paediatric low-grade astrocytomas using DNA sequencing. 
6.3  Materials and methods 
 
Mutational analysis of KRAS, NRAS, HRAS (exons 2 and 3) and BRAF (exons 11 and 
15) was undertaken by direct sequencing in 50 paediatric low-grade astrocytomas and 
one healthy male control, as described in sections 2.13.2-2.15 in chapter 2. Water was 
included as a negative control. The primers used are shown in Appendix C Table 8.5. 
 
Mutational analysis of CDKN2A, PTEN, IDH1 and IDH2 was undertaken by direct 
sequencing in 41 paediatric low-grade astrocytomas, one healthy male and human 
glioma cell line U251. Water was included as a negative control. The primers used are 
shown in Appendix C, Table 8.6. 
 
Target exons were amplified by PCR from whole-genome amplified (WGA) tumour 
DNA, followed by direct sequencing in both directions using the di-deoxy chain 
termination method on an ABI 3730 DNA sequencer. Results were screened by eye 
using the Applied Biosystems software packages Sequence Scanner version 1.0 and 
Variant Reporter version 1.0.  Further mutational analysis was performed by eye. 
 
6.4  Results 
6.4.1  ERK/MAPK pathway member sequencing 
 
50 paediatric low-grade astrocytomas were screened for activating mutations at known 
hotspots in KRAS, NRAS, HRAS and BRAF. The single cerebellar pilocytic astrocytoma 
(PA31), which did not contain any fusions in KIAA1549-BRAF or SRGAP-RAF1, was 
found to contain the G12A activating mutation in KRAS (Figure 6.1.A). This causes 
substitution of glycine to alanine in codon 12. Two grade II astrocytomas (1 diffuse 
astrocytoma, DA2, and the pleomorphic xanthoastrocytoma, PXA1) were found to 
contain the V600E activating mutation in BRAF  (Figure 6.1.B). This leads to the 
substitution of valine by glutamic acid at position 600.    193
 
 
      
 
Figure 6.1 Activating mutations in KRAS and BRAF. 
(A) KRAS G12A activating mutation (G to C) in tumour PA31. 
  (B)  BRAF V600E activating mutation (T to A) in tumour PXA1. 
 
 
The sequencing results for all the MAPK pathway members are summarised below for 
32 pilocytic astrocytomas (Table 6.1) and 18 non-pilocytic astrocytomas (Table 6.2). 
6.4.2  CDKN2Aα sequencing 
 
CDKN2Aα exons 1, 2 and 3 were sequenced in 43 tumour samples, normal male DNA 
as a positive control and the human glioma cell line U251, as a negative control. U251 
is known to contain homozygous deletion of CDKN2A (Fuxe et al., 2000). Water was 
also included as a negative control. Sequencing was successful in the normal male DNA 
and failed, as expected, in U251, due to homozygous loss of CDKN2A.  
 
Exon 1 sequencing was successful in all of the 41 tumour samples. Exon 2 sequencing 
was successful in 32 tumour samples, and failed in the following 9 samples: PA4, 
PA32, PA18, DA4, PA8, PMA1, PMG3, PA7 and PMG4. Exon 3 sequencing was 
successful in 36 tumour samples, and failed in the following 5 samples: PMG5, PA17, 
PA15, DA8 and PA13. No CDKN2Aα mutations or variants were identified in any of 
the tumour samples or in the male DNA. 
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Name 
 
Site 
 
Age 
 
Sex 
 
KIAA1549-
BRAF fusion 
SRGAP3-RAF1 
fusion 
MAPK pathway 
sequencing 
Discrete copy  
Number changes 
PA1 Cerebellum  20  F  Ex16-Ex9  -  -  7q34  gain 
PA2 Cerebellum  4  M  Ex16-Ex9  -  -  7q34  gain 
PA3 Cerebellum  7  M  Ex16-Ex9  -  -  7q34  gain 
PA4 Cerebellum  2  M  Ex16-Ex9  -  -  7q34  gain 
PA5 Cerebellum  6 F  Ex16-Ex9  -  -  7q34  gain 
PA6 Cerebellum  5  M  Ex16-Ex9  -  -  7q34  gain 
PA7 Cerebellum  13  M  Ex16-Ex9  -  -  Not  run 
PA8 Cerebellum  2  M  Ex16-Ex9  -  -  Not  run 
PA9 Cerebellum  14  F  Ex16-Ex9  -  -  7q34  gain 
PA10 Cerebellum  19  M  Ex16-Ex9  -  -  7q34  gain 
PA11 Cerebellum  14  M  Ex16-Ex9  -  -  7q34  gain 
PA12 Cerebellum  14  M  Ex16-Ex9  -  -  7q34  gain 
PA13 Cerebellum  10  M  Ex16-Ex9  -  -  7q34  gain 
PA14 Cerebellum  10  M  Ex16-Ex9  -  -  7q34  gain 
PA15 Cerebellum  13  M  Ex16-Ex9  -  -  7q34  gain 
PA16 Cerebellum  10  M  Ex16-Ex9  -  -  - 
PA17 Cerebellum  6 M  Ex16-Ex9  -  -  7q34  gain 
PA18 Cerebellum  3 M  Ex16-Ex9  -  -  7q34  gain 
PA19 Cerebellum  3 M  Ex16-Ex9  -  -  7q34  gain 
PA20 Cerebellum  4 M  Ex16-Ex9  -  -  Not  run 
PA21 Cerebellum  12 F  Ex16-Ex9  -  -  Not  run 
PA22 Cerebellum  6 F  Ex15-Ex9  -  -  7q34  gain 
PA23 Cerebellum  3 F  Ex15-Ex9  -  -  7q34  gain 
PA24 Cerebellum  4 F  Ex15-Ex9  -  -  Not  run 
PA25 Cerebellum  4 F  Ex16-Ex11  -  -  7q34  gain 
PA26 Cerebellum  3 F  Ex16-Ex11  -  -  7q34  gain 
PA27 Cerebellum  14 F  Ex16-Ex11  -  -  7q34  gain 
PA28 Cerebellum  7 M  Ex18-Ex10  -  -  Not  run 
PA29 Cerebellum  19  M  Ex19-Ex9  -  -  7q34  gain 
PA30 Cerebellum  13 F  -  Ex11-Ex8  -  3p25  gain 
PA31 Cerebellum  1 F  -  -  KRAS p.G12A  - 
PA32 Brain  stem  9 F  Ex16-Ex9  -  -  7q34  gain 
Table.6.1 Summary of results for MAPK pathway member sequencing and fusion screening in 32 pilocytic astrocytomas.    195
Name 
 
Pathology 
 
Site 
 
Age 
 
Sex 
 
KIAA1549-BRAF 
fusion 
SRGAP3-RAF1 
fusion 
MAPK pathway 
sequencing 
Discrete copy 
number changes 
DA1  Diffuse astrocytoma  cerebral cortex  5  F  Ex15-Ex9  -  -  Not run 
DA2  Diffuse astrocytoma  cerebral cortex  9  M  -  -  BRAF p.V600E 9p21  loss 
DA3  Diffuse astrocytoma  cerebral cortex  17  M  -  -  -  - 
DA4  Diffuse astrocytoma  cerebral cortex  4  M  -  -  -  - 
DA5  Diffuse astrocytoma  cerebral cortex  7  F  -  -  -  - 
DA6  Diffuse astrocytoma  cerebral cortex  5  F  -  -  -  - 
DA7  Diffuse astrocytoma  cerebral cortex  5  M  -  -  -  - 
DA8  Diffuse astrocytoma  cerebral cortex  15  F  -  -  -  Not run 
DA9  Diffuse astrocytoma  cerebral cortex  9  F  -  -  -  Not run 
DA10  Diffuse astrocytoma  cerebral cortex  5  F  -  -  -  Not run 
DA11  Diffuse astrocytoma  cerebral cortex  2  M  -  -  -  Not run 
PMA1  Pilomyxoid astrocytoma  diencephalon  1  F  Ex15-Ex9  -  -  7q34 gain 
PMG1 Pilomyxoid  glioma  diencephalon 17  M  -  -  -  - 
PMG2 Pilomyxoid  glioma  diencephalon  7  F  -  -  -  - 
PMG3 Pilomyxoid  glioma  diencephalon  8  M  -  -  -  Not  run 
PMG4  Pilomyxoid glioma  spinal cord  12  M  Ex15-Ex9  -  -  Not run 
PMG5 Pilomyxoid  glioma  spinal  cord  11  F  -  -  -  - 
PXA1 
 
Pleomorphic 
xanthoastocytoma 
cerebral cortex 
 
6 
 
F 
 
- 
 
- 
 
BRAF p.V600E 
 
9p21 loss 
 
 
Table.6.2 Summary of results for MAPK pathway member sequencing in 18 Grade II astrocytoma samples. 
Results for KRAS, NRAS, HRAS and BRAF are shown, with the presence of fusion genes and specific DNA copy number changes. 196 
6.4.3  PTEN sequencing 
 
Exons 1 to 9 of PTEN were sequenced in 41 tumour samples, normal male DNA as a 
positive control and the human glioma cell line U251. U251 is known to contain a 
homozygous insertion of TT within exon 7 of PTEN. This causes a frameshift within the 
translated protein sequence at glutamic acid 242, which is thought to cause an 
oncogenic mutation (Ikediobi et al., 2006). Water was also included as a negative 
control. 
 
The homozygous c.723_724insTT insertion mutation was identified successfully in 
U251 (Figure 6.2). 
 
 
Figure 6.2 Homozygous insertion of TT within exon 7 of PTEN in cell line U251. 
The sequence traces for forward and reverse strands are shown. 
 
Sequencing was successfully completed for all 41 samples in exons 2, 5, 7, 8 and 9 of 
PTEN. Sequencing failed in both directions for 1 sample in exon 1, 9 samples in exon 3, 
3 samples in exon 4 and 1 sample in exon 6. A single polymorphism, where a single 
cytosine was substituted by thiamine, was identified within exon 1 in sample PA6. 
However, this change was within the intron of exon 1, eleven base pairs from the exon 
1/intron boundary, and would not have altered the transcribed protein sequence. No 
other abnormal variants were identified. Results are shown in Table 6.3. 
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 Exon 
1 
Exon 
2 
Exon 
3 
Exon 
4 
Exon 
5 
Exon 
6 
Exon 
7 
Exon 
8 
Exon 
9 
PA1  - - X - - - - - - 
PA2  - - X - - - - - - 
PA3  - - - - - - - - - 
PA4  - - X - - - - - - 
PA5  - - - - - - - - - 
PA6  C  >  T  - - - - - - - - 
PA7  - - - - - - - - - 
PA8  - - X - - - - - - 
PA9  - - X  X - - - - - 
PA10  - - - - - X - - - 
PA11  - - - - - - - - - 
PA13  - - - - - - - - - 
PA14  - - - - - - - - - 
PA15  - - X - - - - - - 
PA16  - - - - - - - - - 
PA17  - - - - - - - - - 
PA18  - - - - - - - - - 
PA19  - - - - - - - - - 
PA20  - - - - - - - - - 
PA22  - - - - - - - - - 
PA23  - - - - - - - - - 
PA25  - - - - - - - - - 
PA26  - - - - - - - - - 
PA27  X  - - - - - - - - 
PA29  - - - - - - - - - 
PA31  - - - - - - - - - 
PA32  - - - - - - - - - 
PMA1  - - - - - - - - - 
DA1  - - - - - - - - - 
DA2  - - - - - - - - - 
DA3  - - - - - - - - - 
DA4  - - - - - - - - - 
DA7  - - X  X - - - - - 
DA8  - - X - - - - - - 
DA9  - - - - - - - - - 
PMG1  - - - - - - - - - 
PMG2  - - - - - - - - - 
PMG3  - - - - - - - - - 
PMG4  - - X - - - - - - 
PMG5  - - - - - - - - - 
PXA1  - - - X - - - - - 
U251  - - - - - -  TT  ins  - - 
Control  - - - - - - - - - 
H2O  X X X X X X X X X 
Table.6.3 Sequencing results for PTEN 
Exons 1-9 were sequenced in 41 tumour samples, U251, male control and water.  
X = sequencing failed in both directions, - = no abnormality detected.  
The c.723_724insTT mutation was detected in U251. The C>T substitution within 
PA6 is within the intronic sequence of exon 1, so would not have altered the 
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6.4.4  IDH1 and IDH2 sequencing 
 
IDH1 exon 4 and IDH2 exons 4 and 5 were sequenced in 41 tumour samples, normal 
male DNA as a positive control and the human glioma cell line U251. IDH1 exon 4 was 
sequenced successfully in all samples except PXA1. A variant sequence within the 
coding region of exon 4 was found in 3 samples (DA4, DA8 and PA17). This 
corresponds to a known SNP, rs11554137, which does not alter the amino acid 
sequence. No other abnormal variants were detected. IDH2  exons 4 and 5  were 
successfully sequenced in all of the 41 tumour samples, and no abnormal variants were 
identified. 
 
 
6.5  Discussion 
6.5.1  MAPK pathway sequencing  
 
Direct sequencing identified activating mutations within KRAS  and  BRAF in three 
tumour samples. Hence, alternate mechanisms were identified for activation of the 
MAPK pathway, as none of these three tumours contained the KIAA1549-BRAF  or 
SRGAP3-RAF1 gene fusions. This was particularly important in the case of the single 
pilocytic astrocytoma, PA31, which was found to contain the KRAS G12A activating 
mutation. This result confirmed that MAPK pathway activation was present in 100% of 
the 32 pilocytic astrocytomas examined for this thesis. The discovery of genetic changes 
leading to activation of a molecular pathway in an entire cohort of pilocytic 
astrocytomas was unprecedented.  
 
Tumours containing BRAF- and KRAS-activating mutations were separate from those 
containing BRAF or RAF1 gene fusions. Earlier work presented in this thesis has shown 
that gene fusions are associated with MAPK pathway activation in pilocytic 
astrocytomas. Activating mutations in KRAS and BRAF are uncommon in low-grade 
astrocytomas. However, their presence highlights the fact that activation of the MAPK 
pathway, however this may be achieved, is of critical importance in the development of 
low-grade astrocytomas.  
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RAS proteins have an essential role in regulating normal rates of cellular proliferation, 
and were some of the first proteins to be identified as constitutively activated in tumours 
due to point mutations in their coding sequences (Bos, 1989). It is estimated that ∼20% 
of all tumours contain an activating mutation in one of the three RAS genes. The 
majority of these mutations (85%) are within KRAS, a further 15% are within NRAS, 
and ~1% in HRAS (Downward, 2003). RAS mutations are most commonly found in 
pancreatic, lung, thyroid and colorectal cancers. Activating mutations in KRAS at codon 
12 (G to C transversion, resulting in amino acid change from glycine to alanine), codon 
13 (G to C transversion, resulting in amino acid change from glycine to arginine) and 
codon 61 (A to T transversion, resulting in amino acid change from glutamic acid to 
glutamine) have previously been identified in paediatric pilocytic astrocytomas. 
However, these are rare events, seen in around 4-7% tumours (Maltzman et al., 1997, 
Sharma et al., 2005, Janzarik et al., 2007). This incidence is slightly higher than the 3% 
incidence found in the 32 pilocytic astrocytomas examined here, where a single KRAS 
G12A mutation was found. 
 
Mutations in BRAF have also been associated with many cancers, most commonly 
malignant melanoma, colorectal cancer, and lung cancer. The majority of mutations 
within BRAF involve the substitution of valine for glutamate at residue 600 (V600E) 
within the kinase domain. The resulting mutant BRAF protein has kinase activity 
elevated tenfold from wild-type BRAF, conferring a huge advantage in the 
transformation of NIH3T3 cells (Davies et al., 2002). A low incidence rate, between 4-
6%, for BRAF V600E activating mutations has also been found in paediatric grade I-II 
astrocytomas (Jones et al., 2008, Pfister et al., 2008, Sievert et al., 2009). These 
mutations were shown to be somatic in 5 patients (3 PA, 2 DA), where germline blood 
did not show the V600E mutations (Pfister et al., 2008, Sievert et al., 2009). A novel 
BRAF  activating mutation was recently identified in a single pilocytic astrocytoma, 
where insertion of 3 nucleotides in the DNA sequence leads to the addition of a 
threonine residue close to the mutational hotspot at position 600 (Jones et al., 2009). 
This mutation conferred constitutive kinase activity and transformed NIH3T3 
fibroblasts, however it was not identified in the set of patient samples examined for this 
thesis. 
 
From the three samples with activating mutations identified by this study, it appears that 
low-grade astrocytomas do not contain concurrent BRAF  and  KRAS activating  200
mutations. Concurrent mutations in BRAF and NRAS have been found in studies on 
malignant melanoma and naevi, although these are rare (Pollock et al., 2003, Goel et 
al., 2006). The majority of benign melanocytic naevi show mutations in BRAF, but most 
do not progress to malignant melanoma. The prognostic significance of mutations in 
BRAF  within benign naevi is unclear, as most studies do no appear to show any 
significant link with malignant transformation or patient outcome. In melanoma, it 
appears that further changes, in addition to mutations in BRAF,  are required for 
malignant transformation (Goel et al., 2006). It remains to be seen if this is also the case 
in paediatric low-grade astrocytoma.  
 
6.5.2   CDKN2A sequencing 
 
Two proteins are produced from the CDKN2A locus, using alternate first exons. Exons 2 
and 3 are common to both transcripts. p16
INK4A is encoded from CDKN2Aα, and p14
ARF 
by transcript CDKN2Aβ (Stott et al., 1998). Both transcripts of CDKN2A are negative 
regulators of the cell cycle, affecting different pathways. p16
INK4A inhibits the 
retinoblastoma (Rb) pathway by inhibition of CDK4, p14
ARF inhibits the p53 pathway 
via MDM2. Deletion of CDKN2A was identified by SNP array analysis in two grade II 
tumour samples, as described in chapter 4 of this thesis. Hence, CDKN2A was selected 
as a candidate for sequencing.  
 
Sequencing was performed successfully for CDKN2Aα exons 1-3. Primers were also 
designed for sequencing the alternate first exon in CDKN2Aβ. Unfortunately attempts to 
sequence this exon were unsuccessful, despite multiple experiments, and will be 
repeated in the future. Previous studies have shown, however, that mutations within 
CDKN2A are most commonly situated within exon 2, which is shared by both 
CDKN2Aα and β (Ichimura et al., 2000). CDKN2A exon 2 was sequenced successfully 
in 32/41 tumour samples.  
 
Homozygous deletion of CDKN2Aα (p16
INK4A) has been identified in many studies of 
high-grade astrocytomas in adults and children (Ichimura et al., 1996, Raffel et al., 
1999, Furnari et al., 2007, CGARN et al., 2008, Parsons et al., 2008). However, many 
studies of adult astrocytomas have shown that inactivation of the RB pathway through 
loss of CDKN2Aα  alone is not sufficient to initiate malignant transformation in  201
astrocytomas (Furnari et al., 2007). A recent microarray study, comparing tumour tissue 
samples from 16 adult patients with low-grade gliomas who subsequently developed 
high-grade gliomas found that loss of the CDKN2Aα locus at 9p21 was the most 
frequent change seen following malignant transformation (Idbaih et al., 2008). These 
data suggest that CDKN2Aα loss is a major factor involved in secondary glioblastoma 
formation in adult low-grade glioma patients, but it does not appear to be an initiating 
factor in low-grade astrocytoma formation.  
 
No mutations or variants were identified in CDKN2Aα  by direct sequencing in the 
tumour samples studied for this thesis. From these results, and those from previous 
studies, it appears that CDKN2Aα does not play a significant role in the development of 
low-grade paediatric astrocytomas. 
 
Both CDKN2A deletion and BRAF V600E activating mutations were identified in two 
grade II astrocytomas (DA2 and PXA1). Both patients were relatively young, aged 9 
and 6 years, respectively. It is possible that these grade II tumours display more genetic 
rearrangements, and that these two samples had acquired a second aberration. One 
sample, DA2, contained homozygous loss of CDKN2A, the second, PXA1 had lost a 
single copy of CDKN2A as identified by SNP copy number analysis. Both samples were 
sequenced successfully, and no CDKN2Aα mutations were identified in either sample. 
The fact that sequencing was successful for CDKN2Aα in both samples with copy 
number loss, particularly in the sample with homozygous loss of CDKN2A by SNP 
analysis suggests that some normal stromal tissue was present in the tumour samples 
prior to DNA extraction. Hence, these sequencing results may in fact represent germline 
DNA from normal tissue within the sample rather than purely tumour DNA. 
Alternatively the lack of an identified CDKN2Aα mutation in the remaining copy within 
sample PXA1, which contains single copy loss by SNP analysis could also suggest that 
this gene is silenced by other mechanisms, for example by DNA hypermethylation, 
which is known to occur in lung and breast cancer (Baylin et al., 2006). The effects of 
haploinsufficiency may also be important here, where reduction in gene dosage caused 
by loss of one allele may cause a phenotypic change leading to tumorigenesis 
(Santarosa et al., 2004). CDKN2A is a cyclin dependent kinase, which acts as a cell 
cycle checkpoint. Hence, haploinsufficiency here may facilitate cell cycle progression. 
Initial studies of homozygous deletions involving CDKN2A in urothelial cell  202
carcinomas indicate that haploinsufficiency may affect tumour invasion and disease 
recurrence (Chapman et al., 2005).  
Further research is necessary to determine what additional genetic changes are present 
in histological subtypes of low-grade astrocytoma in larger patient sets. The two 
patients identified here with both BRAF V600E activating mutations and deletion of 
CDKN2A had tumours with very different histopathological features. As yet 
unidentified genetic changes may help to uncover the molecular biology underlying 
different histological subtypes of grade II astrocytoma.  
 
6.5.3   PTEN sequencing 
 
The tumour-suppressor gene phosphatase with tensin homology (PTEN) is mutated or 
deleted in many tumours, including glioblastomas, breast cancer and melanoma. 
Mutations in PTEN are common in high-grade astrocytomas, but have not previously 
been identified in low-grade astrocytomas in adults or children (Rasheed et al., 1997, 
Wang et al., 1997, Yan et al., 2009). PTEN encodes a protein containing a phosphatase 
domain, with both lipid and protein phosphatase activity. The phosphatase domain is 
encoded by exon 5, where ~30% germline and somatic mutations are found (Bonneau et 
al., 2000). PTEN is a negative regulator of the phosphatidylinositol 3-kinase (PI3K) 
cell-signalling pathway. The protein inactivates phosphatidylinositol (3,4,5)-
trisphosphate (PIP3) by removing the phosphate at position D3, regenerating 
phosphatidylinositol (3,4)-biphosphate (PIP2), which functions as an “on-off” switch for 
the pathway (Sansal et al., 2004). PIP3 recruits kinases from the protein kinase B (Akt) 
family. Many downstream targets are activated by Akt, including Forkhead, the Bcl-2-
associated death promoter (BAD) and mTOR, which are involved in critical functions 
including cell proliferation, apoptosis, and DNA damage repair (Wu et al., 2003, Sansal 
et al., 2004). When PTEN is inactivated by mutation, deletion or promoter 
hypermethylation, PI3K pathway activation occurs. PTEN may also downregulate 
MAPK pathway signalling. Dephosphorylation of the adaptor proteins FAK and Shc by 
PTEN leads to decreased MEK and MAPK activity.  Studies in malignant melanoma 
have indicated that PTEN loss and oncogeneic RAS activation may occur in a reciprocal 
manner (Wu et al., 2003). Hence, the possibility of loss of function mutations in PTEN 
leading to tumorigenesis was a further mechanism to explore within the paediatric 
astrocytoma tumour samples, particularly in the grade II tumours without gene fusions.  203
 
No loss-of-fuction mutations were detected in any of the tumour samples studied. 
Hence, it appears that loss of fuction of PTEN is not implicated in the development of 
grade II astrocytomas in children, in agreement with the findings from previous studies.  
 
 
6.5.4   IDH1 and IDH2 sequencing 
 
Recurrent mutations within the active site of the gene isocitrate dehydrogenase I 
(IDH1), on chromosome 2q33 were recently discovered in 12% of glioblastoma patients 
(Parsons et al., 2008). The IDH1 mutations were more prevalent in young patients, with 
a mean age of 33 years compared to patients with wild-type IDH1, whose mean age was 
53 years. This finding was highly novel and was particularly exciting, as the mutations 
appeared to be more prevalent in young patients. Isocitrate dehydrogenase catalyses the 
production of ∝-ketoglutarate from isocitrate, producing nicotinamide adenine 
dinucleotide phosphate (NADPH). Mutations occurred at codon 132 within exon 4 of 
IDH1,  resulting in an amino acid sequence change from arginine to histidine. An 
equivalent residue is also present in IDH2, at codon 172.  
 
Hence, mutation analysis by direct sequencing of the relevant exons in IDH1 and IDH2 
was performed in the set of paediatric low-grade astrocytomas investigated in this 
thesis. No mutations were found, suggesting that mutations in IDH1 and IDH2 are not 
implicated in the development of paediatric low-grade astrocytomas. This result was 
subsequently confirmed by more recent studies, which have found IDH1 mutations 
within >70% WHO grade II and III astrocytomas, oligodendrogliomas and secondary 
glioblastomas which had evolved from lower-grade tumours in adults (Watanabe et al., 
2009, Yan et al., 2009). Yan et al. studied 445 central nervous system tumours. The 
majority were from adults, but 52 paediatric astrocytoma samples were included. These 
comprised 21 pilocytic astrocytomas, 2 sub-ependymal giant cell astrocytomas (SEGA 
– WHO grade I), 14 WHO grade II astrocytomas and 15 paediatric glioblastomas (grade 
IV) (Yan et al., 2009). IDH1/2 mutations were identified in a small number of 
paediatric astrocytomas: IDH1 mutations were found in 4/14 WHO grade II 
astrocytomas and 1/14 grade II astrocytomas contained an IDH2 mutation. No IDH1/2 
mutations were found in 21 pilocytic astrocytomas, or in 15 paediatric glioblastomas.  204
The paediatric cases with mutations in IDH1/2 were older than those without mutations; 
median ages were 17 years and 5 years, respectively (p=0.002). These findings were 
complemented by a further study by De Carli et al., who found IDH1 mutations in 4/73 
(5%) children with non-pilocytic astrocytomas (De Carli et al., 2009). This group did 
not identify any IDH2 mutations in children. Paediatric patients with IDH1 mutations 
were again found to be older than children without mutations in IDH1. In this study 
median ages were 16 years for patients with mutations, and 7 years for patients without 
mutations, respectively (p=0.002). These data suggest that low-grade astrocytomas from 
adolescents contain similar biological markers to those seen in adult astrocytomas. 
Paediatric low-grade astrocytomas remain a distinct biological group from those seen in 
adults and adolescents. 
 
6.6   Conclusion 
 
In conclusion, this chapter has identified activating mutations within the MAPK 
pathway members BRAF and KRAS in a small but highly significant number of patients 
with low-grade astrocytoma. The discovery of an activating mutation in KRAS in the 
only pilocytic astrocytoma without gene fusions confirmed that MAPK pathway 
associated defects were present in 100% of the 32 pilocytic astrocytomas examined in 
this thesis. 
 
The high frequency of MAPK pathway activation by genetic aberrations in all of the 
pilocytic astrocytomas studied suggests that this pathway is of critical importance in the 
development of these tumours. The extent of MAPK pathway activation in low-grade 
astrocytomas was previously unknown. This exciting finding provides the opportunity 
to exploit an entirely novel therapeutic target in this patient group. Fortuitously, 
activation of the MAPK pathway is a common abnormality in many adult cancers, 
including lung cancer and malignant melanoma. Hence, drug development aimed at 
producing new agents to target the MAPK pathway is already in progress. Specific 
inhibitors of the MAPK pathway are currently being tested in clinical trials for use in 
adult lung cancer and melanoma. This will be discussed in further detail in the final 
chapter of this thesis. 
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Additional sequencing of CDKN2A, PTEN and IDH1/2 did not identify any mutations 
within the tumour samples. Preliminary studies to investigate TP53 by sequencing were 
also undertaken for this thesis. A large number of exons were completed. However, 
sequencing was unsuccessful for exons 4 and 7, which contain the two main mutation 
hotspots. These experiments will be repeated in the future, and may provide further 
information on genetic aberrations present in grade II astrocytomas.  206
Chapter 7.  Final discussion 
 
7.1   Review of thesis aims and findings 
 
The initial aim for this thesis was to study DNA copy number changes in paediatric 
low-grade astrocytomas using array CGH, the best available technique at the time the 
study began. I tested the hypothesis that differences in DNA copy number were present 
between pilocytic astrocytomas arising in the cerebellum and grade II astrocytomas 
from the cerebrum. There were a variety of pathologies within the group of grade II 
astrocytomas, so conclusions could only be drawn regarding the presence or absence of 
changes in pilocytic astrocytomas from the cerebellum when compared to the other 
group. No data were found to support the hypothesis of a difference in DNA copy 
number between the two groups by array CGH. Forty percent of the samples tested 
showed an apparently balanced karyotype. A few recurrent regions of discrete copy 
number change were, however, identified in a small number of samples. 
 
When SNP array technology became available and began to supersede array CGH, the 
study was extended at higher resolution using Affymetrix 250K and 6.0 SNP arrays. 
None of the regions of interest suggested by array CGH analysis were confirmed by the 
SNP arrays. However, for the very first time a discrete region of copy number gain was 
identified at chromosome 7q34, primarily although not exclusively in pilocytic 
astrocytomas of the cerebellum. This region was initially identified using the 250K SNP 
arrays. The 7q34 gain and further regions of discrete copy number change were 
identified in additional samples by 6.0 SNP analysis.  
 
Duplication of BRAF was confirmed within the gained region at 7q34 by interphase 
FISH in paraffin tissue samples. Further analysis of this region, by PCR and 
sequencing, demonstrated the presence of gene fusions between KIAA1549 and BRAF. 
Five  KIAA1549-BRAF fusion variants were subsequently identified. A further gene 
fusion between SRGAP3 and RAF1 was also found in a single tumour with DNA copy 
number gain at chromosome band 3p25. Both fusion genes lacked the auto-inhibitory 
domains of BRAF and RAF1, which were replaced in-frame by N-terminal segments of 
KIAA1549 and SRGAP3, respectively, conferring constitutive kinase activity.   207
Sequencing of the DNA breakpoints for 9 tumours with the same KIAA1549-BRAF 
fusion variant, suggested that the RAF  fusions may arise through the formation of 
tandem duplications and non-homologous end-joining (NHEJ) within the same 
chromosome. Further investigations are necessary to consider the important questions of 
how, where and when these fusions arise within the developing brain. Currently these 
questions are beyond the scope of this thesis, but the data presented here may begin to 
provide some insights into how to address these issues. 
 
Sequencing also confirmed the presence of activating mutations in KRAS and BRAF in 
some tumours where gene fusions had not been found. Both the gene fusions and the 
activating mutations were shown to be associated with activation of the ERK/MAP 
kinase pathway by Western blotting.  
 
Surprisingly, gene fusions or activating mutations were identified in 100% pilocytic 
astrocytomas studied. This was an unprecedented finding considering that pilocytic 
astrocytomas had previously been thought to contain very few genetic changes, with the 
majority of samples analysed previously showing apparently normal karyotypes. In 
addition, gene fusions and activating mutations were found in 28% of grade II 
astrocytomas, highlighting the importance of the ERK/MAPK pathway in the 
development of other paediatric low-grade gliomas. These findings have been 
complemented by other studies in the literature, although few studies have looked at 
significant numbers of grade II astrocytomas so far (Jones et al., 2008, Pfister et al., 
2008, Forshew et al., 2009, Sievert et al., 2009). It is currently unclear whether the 
grade II astrocytomas with RAF fusions are in fact pilocytic astrocytomas with unusual 
histopathological features, a benign sub-group of de novo grade II astrocytomas or a 
group of tumours that have progressed from pilocytic astrocytomas. 
 
Very few published studies have investigated all known methods of activation for the 
MAPK pathway in low-grade astrocytomas. Furthermore, additional novel mechanisms 
for MAPK pathway activation, such as ARAF fusions may be as yet unidentified in 
these tumours. This raises a further question, whether different mechanisms of MAPK 
activation can be used as diagnostic or prognostic markers for children with low-grade 
astrocytomas. Pilocytic astrocytomas associated with NF-1 have been shown to be more 
indolent than sporadic PAs (Rubin et al., 2005), and are often treated with a “watch and 
wait” strategy, as up to 50% may not progress further (Hargrave, 2009). Mutations  208
within the RAS genes may affect branches of the MAPK pathway that are unaffected by 
alterations in BRAF.  Are there differences in clinical outcomes for these patients, 
depending on whether the MAPK pathway is activated by a gene fusion or an activating 
mutation? Do the different variants of the KIAA1549-BRAF fusion result in differences 
in kinase activity? Collaborative studies investigating large cohorts of well-
characterised tumour samples with corresponding clinical information are needed to 
address these questions, which may lead to the development of molecular diagnostic 
and prognostic criteria for low-grade astrocytomas. 
 
Sequencing was performed for the genes CDKN2A, PTEN and IDH1/2 to assess the 
frequency of abnormalities in paediatric low-grade astrocytoma. These genes have all 
previously been found to contain aberrations within adult high-grade astrocytomas. To 
date, no significant aberrations have been identified in the paediatric astrocytoma 
samples examined. This confirms previous findings in adult and paediatric 
astrocytomas, where distinct molecular changes appear to vary depending on patient 
age.  
 
The additional regions of copy number change identified by SNP array analysis are 
awaiting further validation and investigation. The sample numbers in the study cohort 
will be increased to include more grade II astrocytomas, and I look forward to 
continuing with this work following the completion of my PhD.  
 
There were 13 grade II astrocytomas that did not contain RAF fusions or activating 
mutations. Other mechanisms may underlie tumorigenesis in this group, and further 
studies are required to investigate the role of epigenetic changes or aberrations in 
microRNA profiles in this sample group.  
 
The relative specificity of the KIAA1549-BRAF fusion for pilocytic astrocytomas has 
led to speculation on the possibility of FISH being used as a diagnostic test to identify 
the fusion. A recent paper by Korshunov et al. described a combined diagnostic 
approach, using FISH for BRAF and KIAA1549 to detect KIAA1549-BRAF fusions and 
sequencing for IDH1  to distinguish between pilocytic astrocytomas and diffuse 
astrocytomas (Korshunov et al., 2009). This study used FITC-labelled RP11-355D18 
probe (green), situated between introns 8-9 and 16-17 on KIAA1549, and digoxigenin-
labelled RP4-726N20 probe (red), just downstream from the 3’ end of BRAF,  for  209
interphase FISH analysis. A tissue microarray was prepared, using 5μm paraffin 
sections from 70 pilocytic astrocytomas and 50 diffuse astrocytomas. Signals were 
scored by two investigators in >100 non-overlapping nuclei. Samples with 7q34 gain 
were defined as having >10% nuclei containing 3 or more signals for KIAA1549 and 
BRAF. Samples with the fusion were defined as those showing co-localisation of a red 
and green probe resulting in a yellow signal, however it was unclear from the method if 
this was the presence of a single yellow signal within a sample or co-localisation in 
>10% nuclei, as for 7q34 gain. The Korshunov study found 7q34 gain in 52/70 pilocytic 
astrocytomas and 31/50 diffuse astrocytomas. Co-localisation of signals, indicating the 
presence of KIAA1549-BRAF fusions were seen in 49/70 pilocytic astrocytomas and in 
no diffuse astrocytomas. IDH1 mutations were only identified in diffuse astrocytomas 
(41/50), leading the authors to suggest that a combination of FISH and mutation 
analysis for IDH1 could be used to distinguish between pilocytic and diffuse 
astrocytomas. The inclusion criteria for both 7q34 gain or the presence of a co-localised 
fusion signal appear to be very low in this study, considering that the technique 
visualises interphase nuclei in 2D where partial nuclei may be present above or below a 
selected nucleus within the section. In similar circumstances I would have used a 
proportion of >50% nuclei with 3 signals to imply 7q34 gain or the presence of a fusion, 
or to have considered the use of 3D FISH to be sure that there were no possible artifacts 
from partially overlapping nuclei.  
 
An attempt was made to develop a technique to identify the KIAA1549-BRAF fusion by 
interphase FISH, in collaboration between our laboratory and David Ellison and his 
team at St Jude in Memphis. BAC probes were selected within the 5’ proximal and 3’ 
distal portions of BRAF (RP11-837G3 and RP11-948019), and within the 5’ proximal 
portion of KIAA1549 (RPL11-148L5). It was hoped that these probes would enable us 
to identify separation between the proximal and distal portions of BRAF,  and 
subsequently to identify co-localisation of probes between KIAA1549 and BRAF  to 
indicate the presence of a fusion gene. KIAA1549 and BRAF are separated by ~ 1.72Mb, 
and the probes used were separated by 1.65Mb. Normally a 1.65MB distance between 
probes would be expected to give good signal separation in interphase FISH. 
Unfortunately this was not the case in our experience, and neither technique proved to 
be sufficiently sensitive to enable it be used as a diagnostic test for the KIAA1549-BRAF 
fusion in paraffin tissue sections (data not shown). Many overlapping nuclei were seen, 
which gave confusing and highly variable signal patterns. Very occasionally co- 210
localised signals were seen, indicating the presence of the fusion, but these were rare 
events and did not occur with sufficient frequency in samples known to contain a fusion 
to be used with confidence as a diagnostic test. Korshunov et al. suggest that FISH 
would be particularly suitable to detect the presence of the fusions in small samples, 
obtained by stereotactic biopsy.  In our experience this would not be possible using 
interphase FISH alone.   
 
It is possible that there might be a specific chromatin configuration, such as a loop 
within the region, which may complicate the probe separation for these genes when 
studied by FISH. It is also possible that if such a configuration were present this might 
be implicated in the genesis of the fusion. The two genes may be brought together 
spatially during a particular phase of growth or development, perhaps during specific 
periods of rapid brain growth in the developing embryo. If DNA double strand breaks 
should occur during this time of spatial proximity, repair by NHEJ could conceivably 
bring about the creation of the fusion. This process could be associated with increased 
levels of gene expression or DNA replication, for example both genes may be brought 
together within the same transcription machinery or replication factory (Ottaviani et al., 
2008). There is currently no information on chromatin folding within this genomic 
region, however, and this will be an interesting avenue for further study in an attempt to 
understand how the fusions might arise.  
 
Currently I feel that nested PCR for the KIAA1549-BRAF fusion using cDNA from 
fresh or frozen tumour samples provides the most reliable diagnostic test for 
identification of the fusions. This technique is also potentially possible for cDNA 
generated from paraffin samples, which would allow retrospective studies including 
larger sample numbers to be conducted. Successful studies have been conducted on 
RNA extracted from formalin-fixed paraffin embedded archival tissue (Specht et al., 
2001, Macabeo-Ong et al., 2002). It would also be interesting to consider whether 
evidence of the fusion could be detected from the peripheral blood of patients with 
fusion positive tumours.  
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7.1.1    Targeted therapy against the MAPK pathway in low-grade 
astrocytomas 
 
One of the most exciting outcomes to emerge from the findings in this thesis, and from 
other similar studies has been the identification of the MAPK pathway as a possible 
therapeutic target in low-grade astrocytomas. Surgery is currently the best available 
treatment for low-grade astrocytomas in childhood, but for some patients this may not 
be possible, for example where tumours are sited in the brainstem, optic pathways or 
hypothalamus. Overall survival rates for children with low-grade gliomas are excellent, 
but around 50% of patients will show evidence of tumour progression at some stage 
during their treatment (Hargrave, 2009). Adjuvant chemotherapy and/or radiotherapy 
are used for patients with unresectable, recurrent or metastatic disease. These strategies 
are not always curative, and leave a significant number of patients with severe long-
term side effects from treatment including neuroendocrine abnormalities, growth 
failure, learning disabilities, vasculopathy and secondary neoplasms (Packer et al., 
1987, Packer et al., 2003, Mulhern et al., 2004).  
 
MAPK pathway inhibitors are already in development for use in adult cancers, and 
these agents may also be suitable for use in clinical trials for paediatric patients with 
low-grade astrocytomas. Sorafenib is a small molecule inhibitor of tyrosine protein 
kinases including RAF and RET, and has additional activity against vascular endothelial 
growth factor receptors (VEGFR) and platelet-derived growth factor receptor β 
(PDGFRβ), among others (Escudier et al., 2007). Sorafenib has shown efficacy in the 
treatment of hepatocellular carcinoma and renal cell carcinoma in adults (Escudier et 
al., 2007, Llovet et al., 2008). AZD6244 is a MEK inhibitor, currently undergoing early 
clinical trials in adult patients with a variety of solid tumours (Friday et al., 2008). Pre-
and post-treatment biopsies showed an 83% reduction in nuclear phospho-ERK 
immunostaining following AZD6244 treatment, showing evidence of significant drug 
activity within tumour tissue. Clinical trials using targeted therapy against the MAPK 
pathway in low-grade astrocytoma, for patients with recurrent or metastatic disease, or 
where surgery is ineffective are likely to start in the near future. 
 
However, a note of caution must be introduced here, remembering that these treatments 
are aimed at paediatric patients. Altering the patterns of activity in the MAPK pathway  212
within the developing brain may have devastating, and entirely unexpected 
consequences, potentially as serious as those left by current treatment modalities. A 
future goal for treatment of low-grade astrocytomas could be to use RNA inhibition to 
specifically target the RAF gene fusions, leaving cells without the fusion unaffected. 
 
 
7.1.2   Lessons from adult glioblastoma studies  
 
The comprehensive genome-wide analyses of copy number and mutations, and the 
recently published study using GWAS to identify novel candidate genes in adult 
glioblastoma show the power of combining research efforts in large collaborative 
studies (CGARN et al., 2008, Parsons et al., 2008, Shete et al., 2009). Paediatric brain 
tumours are rare compared to brain tumours seen in adults, therefore future research 
strategies should include more national and international collaborations to increase the 
power of studies to reveal new insights into these diseases. 
 
A recent paper has indicated that NF1 inactivation may play a more significant role in 
adult glioblastomas than previously thought, and that differences in the method of 
inactivation may affect responses to treatment (McGillicuddy et al., 2009). Two distinct 
mechanisms for NF1 inactivation were identified in GBMs. Firstly, hyperactivation of 
protein kinase C (PKC) triggers proteasomal degradation of neurofibromin, the protein 
encoded by NF1, as a result these tumours show sensitivity to PKC inhibitors. More 
rarely, GBMs may have complete homozygous loss of NF1 with concurrent inactivation 
of p53. These tumours are not sensitive to PKC inhibitors, but homozygous loss of NF1 
confers high sensitivity to mTOR inhibitors.  The same authors have proposed a 
mechanism for the development of pilocytic astrocytomas in neurofibromatosis type 1 
(NF1) (McGillicuddy et al., 2009). Immunohistochemical analysis of two NF1-
associated pilocytic astrocytomas revealed high levels of expression of p15
INK4β, 
p16
INK4α and p53; all three have been described as markers of oncogene-induced 
senescence (Braig et al., 2005, Collado et al., 2005). McGillicuddy et al propose that in 
patients with NF1 the second genetic ‘hit (as outlined in Knudon’s two-hit hypothesis 
(Knudson, 1971)) results in complete inactivation of NF1, or may drive an initial period 
of rapid cellular proliferation, resulting in the development of a pilocytic astrocytoma. 
The p53 pathway is unaffected in these patients, and is subsequently activated to induce  213
senescence, preventing further progression. What triggers tumour progression to occur 
at a later date in these patients is currently unknown. Malignant astrocytoma formation 
occurs with 100% penetrance in mouse models with homozygous loss of function 
mutations in NF1 and concurrent inactivation of the p53 pathway (Zhu et al., 2005). 
Mice with homozygous NF1 loss of function with intact p53 rarely develop tumours, 
implying that the intact p53 pathway prevents the formation of tumours by activation of 
the RAS pathway alone. 
 
7.1.3   Fusion genes in cancer 
 
Numerous karyotypic abnormalities have been identified in cancers, however these do 
not appear to be evenly distributed throughout the genome (Heim et al., 2009). Some 
genomic regions are preferentially involved in rearrangements found in cancer, and 
some of these genetic aberrations appear to be highly specific for particular cancer 
types. 
 
Translocations and their corresponding gene fusions have been implicated in the 
development of cancer for many years (reviewed by Mitelman in 2007) (Mitelman et 
al., 2007). To date, the majority of fusion genes have been found in leukaemias and 
sarcomas, however new techniques including array CGH and SNP arrays have enabled 
fusions to be identified in other solid tumours. Recent studies have identified novel gene 
fusions in solid tumours using entirely new technologies and approaches including 
genome-wide massively parallel paired-end sequencing and integrative transcriptome 
sequencing (Ruan et al., 2007, Campbell et al., 2008, Maher et al., 2009). These studies 
have identified gene fusions in prostate, lung and breast cancers, all of which had 
breakpoints situated so closely together that they could not have been identified by 
previously available cytogenetic techniques (Heim et al., 2009). It is likely that there 
will be an exponential growth in our knowledge of genetic aberrations and gene fusions 
in solid tumours, as these new technologies are exploited further. However, a large 
number of chromosomal abnormalities may not, in themselves, be causative of cancer, 
and may merely reflect an accumulation of aberrations in a cell already displaying 
evidence of neoplastic transformation as reviewed by Stratton (Stratton et al., 2009). 
Distinguishing which aberrations constitute ‘drivers’ of malignant transformation, and 
which are ‘passengers’, conferring no particular advantage to the malignant process,  214
which may have occurred at any time before or after the ‘driver’ mutation arose will be 
particularly important for future studies.  
 
Chromosomal aberrations in themselves may not be sufficient for tumorigenesis to 
occur. Trisomy 8 has been found in both benign and malignant diseases, but has also 
been found in tissue from apparently healthy normal individuals (Heim et al., 2009). 
Fusion genes associated with leukaemias, including BCR-ABL t(9;22)(q34;q11) and 
ETV6/RUNX1 t(12;21)(p13;q22) have been found in the blood of healthy infants, at ~ 
100 fold higher than the rates of childhood leukaemias (Mori et al., 2002, Greaves, 
2006). Only a small proportion of these children will go on to develop leukaemia, which 
suggests that further stimuli in addition to the presence of a fusion gene are necessary to 
drive leukaemic transformation. Numerous epidemiological data, and a recent GWAS 
study which has implicated genes involved in transcriptional regulation and 
differentiation of B-cell progenitors suggest that infections may drive the genesis of 
childhood leukaemias in patients with an underlying genetic predisposition (Greaves, 
2006, Papaemmanuil et al., 2009). Additional stimuli may also be required to drive the 
process of tumorigenesis in solid tumours: their identification must await future studies.  
  215
Chapter 8.  Appendices 
Appendix A   Reagents 
Chemicals 
 
Agarose       (Invitrogen,  Carlsbad,  CA) 
Anti-avidin-FITC       (Roche  Diagnostics) 
Anti-digoxigenin-rhodamine        (Roche  Diagnostics) 
Biotin-14-dATP      (Invitrogen,  Carlsbad,  CA) 
1mM  Cy3  dCTP         (NEN  Life  Science) 
1mM  Cy5  dCTP         (NEN  Life  Science) 
Citifluor  (Glycerol/PBS)     (Citifluor,  Ltd) 
Chloroform        (Sigma) 
C o l c e m i d         ( S i g m a )  
Cot-1  DNA        (Invitrogen,  Carlsbad,  CA) 
DAPI  III        (Invitrogen,  Carlsbad,  CA) 
Dextran  sulphate       (Fisher  Scientific) 
Digoxigenin-11dUTP       (Roche  Diagnostics) 
E4  media        (Invitrogen,  Carlsbad,  CA) 
E D T A          ( S i g m a )  
Ethanol         (Fisher  Scientific) 
Ethidium  bromide       (Sigma) 
F e t a l   c a l f   s e r u m         ( G i b c o )      
Fluoroscein isothiocyanate-12-dUTP (FITC)      (NEN Life Science) 
Formamide        (Applied  Biosystems) 
Formaldehyde        (Fisher  Scientific) 
Glacial  acetic  acid       (Fisher  Scientific) 
L-glutamine        (Fisher  Scientific) 
Glycerol        (Fisher  Scientific) 
Herring  sperm  DNA         (Sigma,  D7290) 
Human  Cot-1  DNA         (Invitrogen,  Carlsbad,  CA) 
Hyperladder  I-II,  DNA  ladders      (Bioline) 
Klenow  fragment       (Applied  Biosystems) 
2-mercaptoethanol       (Sigma) 
Methanol        (Fisher  Scientific) 
NP-40         (Calbiochem) 
Non-essential  amino  acids      (Sigma)  216
O r a n g e - G           ( S i g m a )  
P e p s i n          ( V y s i s )  
Phoshate  buffered  saline  (PBS)      (Fisher  Scientific) 
Potassium  Chloride  (KCl)      (Fisher  Scientific) 
R N a s e          ( S i g m a )  
Salmon  sperm  DNA       (Invitrogen,  Carlsbad,  CA) 
Sodium  dodecyl  sulphate  (SDS)      (Fisher  Scientific) 
20x SSC (0.3M trisodium citrate/3.0M sodium chloride)    (Fisher Scientific)   
Sodium  acetate  (NaAc)       (Fisher  Scientific) 
Sodium  pyruvate       (Fisher  Scientific) 
Texas  Red-5-dUTP  (TR)     (NEN  Life  Science) 
Tris(hydroxymethyl)aminomethane (Tris)    (Fisher  Scientific) 
Trizol         (Invitrogen,  Carlsbad,  CA) 
Tween  20        (Pierce  28320) 
Vysis  SpectraVysion  probe      (Abbot  Laboratories) 
Water (distilled Rnase/Dnase free)        (Sigma) 
Yeast  tRNA          (Invitrogen,  Carlsbad,  CA) 
 
Kits 
 
BigDye Terminator Cycle Sequencing kit version 3.0  (Applied Biosystems) 
Bioprime  labelling  kit       (Invitrogen,  Carlsbad,  CA) 
BioNick  kit        (Invitrogen,  Carlsbad,  CA) 
DyeEx 2.0 spin columns/96-well plates      (Qiagen, Crawley) 
Exosap-IT          (USB,  Affymetrix) 
QIAGEN DNeasy Blood and Tissue Mini Kit     (Qiagen, Crawley) 
QIAGEN RNeasy Cell and Tissue Mini  Kit      (Qiagen,  Crawley) 
QIAGEN®  Fast-cycling  PCR  kit     (Qiagen,  Crawley) 
QIAquick
TM Gel extraction kit        (Qiagen, Crawley) 
QIAGEN  large-construct  kit      (Qiagen,  Crawley) 
Micro-spin  G50  columns        (Pharmacia  Amersham) 
Repli-G  mini  kit       (Qiagen,  Crawley)   
SuperScript First-Strand cDNA synthesis  kit    (Invitrogen,  Carlsbad,  CA) 
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8.1.1  Loading buffer for gel electrophoresis 
Orange G - 1-Phenylazo-2-naphthol-6,8-disulfonic acid disodium salt (Sigma) 
 
2% orange G is made from 0.2g in 10 ml of water.  
 
Glycerol   5  ml 
0.5 M EDTA    1 ml 
2% orange G    1 ml 
10% SDS    0.1 ml 
Distilled water   2.9 ml 
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Appendix B   Reagents prepared for array CGH 
Hybridisation buffer 
 
Dextran  sulphate    2  grams 
De-ionised formamide    10ml 
20  x  SSC       2ml 
1M  Tris     200μl 
10% Tween 20      200μl 
Distilled water       make up final volume to 20mls 
 
Dissolve overnight on shaking platform at room temperature. 
Once made, divide into 800μl aliquots and store at –20
0C. 
 
Array CGH wash 1 
 
20  x  SSC     100ml 
20%  SDS     1.5ml 
Make up to 1 litre with distilled water 
 
 
Array CGH wash 2 
 
20  x  SSC     10ml 
Make up to 1 litre with distilled water 
 
 
Array CGH wash 3 
 
10% Tween 20      10ml 
Make up to 1 litre with distilled water 
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Clone Chr Position  (bp)
bA326G21 1 143533568 
bA5K23 1  159201779.5 
dJ1108M17 1 104815713 
dJ97P20 1  167462445 
bA32C20 2  128082133 
bA400O18 2 184873490 
963K6 4  191632378 
bA94E2 5  18186914.5 
dJ159G19 6 80412976 
dJ93N13 6  32596730.5 
bA350F16 8  46413667 
bB445N5 10 38414815 
bA13E1 10  48233085 
221K18 12  131110572 
bA25J23 13  78143302 
bA279F15 13  55656472 
820M16 14  104124908 
bA2F9 15  18507931 
bA161M6 16  1085464 
dJ843B9 17  43741286 
bA220N20 17 44390565.5 
bA416K7 17  45289524.5 
bA294I20 19  86263 
bA50L23 22  19845427.5 
 
Table 8.1 Array CGH clones known to give unexpected ratios 
The following autosomal clones used on the array slides have been shown to 
display unexpected linear ratios in normal/normal hybridisations by a number of 
independent groups.  220
Appendix C. Primers 
 
Gene cDNA  Primers 
KIAA1549 primer 1 F (exon 2)  5’AGCACAGCAGTCCTCTCCAT3’ 
KIAA1549 primer 2 F (exon 2)  5’CACCTTTCGGTCAGCTTTTC3’ 
KIAA1549 primer 3 F (exon 2)  5’CCTAGCGACTCCAGCAAAAC3’ 
KIAA1549 primer 4 F (exon 2)  5’CACTGCATTTTTCTCGGTCA3’ 
KIAA1549 primer 5 F (exon 2)  5’ACGGTTTCACTGACGGATTC3’ 
KIAA1549 primer 6 F (exon 2)  5’GCCTTCACTCTCGAAGCAAC3’ 
KIAA1549 primer 7 F (exon 6)  5’TTGCGGTTAAAAGCACACAG3’ 
KIAA1549 primer 8 F (exon 9)  5’AAATGGACCTCCAGAGAGCA3’ 
KIAA1549 primer 9 F (exon 12)  5’GAGGGACGCAGGAGATAAGA3’ 
KIAA1549 primer 10 F (exon 14/15)  5’CCAGGAAGAGCTCACGGATA3’ 
KIAA1549 primer 11 F (exon 16)  5’CAGTGGGGGTCCTTCTACAG3’ 
KIAA1549 primer 12 F (exon 20)  5’CTCCACGGAAGACCTCCAG3’ 
BRAF exon 12 R  5’TGCTGAGGTGTAGGTGCTGT3’ 
KIAA1549 nested primer 1 F  5’GAGGGACGCAGGAGATAAGA3’ 
KIAA1549 nested primer 2 F  5’CCAGGAAGAGCTCACGGATA3’ 
BRAF nested primer 1 R  5’AAGTAATCCATGCCCTGTGC3’ 
BRAF nested primer 2 R  5’TGCTGAGGTGTAGGTGCTGT3’ 
Table 8.2 Primers for identification of KIAA1549-BRAF gene fusions in cDNA 
Forward primers (F) and reverse primers (R) are shown. 
 
 
 
 
 
 
 
 
 
Gene  Primers
KIAA1549 DNA 1 F  5’CAGTGGGGGTCCTTCTACAG3’ 221
KIAA1549 DNA 2 F  5’GGGACCAGTAAACGGTCAGA3’
KIAA1549 DNA 3 F  5’GCCAGTCTGTGTGACTCCAA3’
KIAA1549 DNA 4 F  5’ACTCTGTCGGCCTGTGTTTT3’
KIAA1549 DNA 5 F  5’AGGTGAGAGGGAGCAGTTGA3’
KIAA1549 DNA 6 F  5’TGGTGAAACCCCGTCTCTAC3’
KIAA1549 DNA 7 F  5’AACCAGGTGCTTCAAGGATG3’
KIAA1549 DNA 8 F  5’CCAAAGAAAACAGCAGCACA3’
KIAA1549 DNA 9 F  5’GAGTGCAGTGGCACAATGTC3’
KIAA1549 DNA 10 F  5’GCTGGGTTTACCTTCCTTCC3’
KIAA1549 DNA 11 F  5’ACATGAAATTGGGTGGCAAT3’
KIAA1549 DNA 12 F  5’GCAGGAGGACTTTTGCTTTG3’
BRAF DNA 1 R 5’CACCACGAAATCCTTGGTCT3’
BRAF DNA 2 R 5’ATGTCCATTTCAGGCCATTC3’
BRAF DNA 3 R 5’TGAATGGCCCCAAATATCTC3’
BRAF DNA 4 R 5’GCACCCAGCCGATAAGATT3’
BRAF DNA 5 R 5’TCCTTCACAGCCAAGCTTCT3’
BRAF DNA 6 R 5’TAGTCTCCCTCCCCAAAACA3’
BRAF DNA 7 R 5’CCCAACATACCAGGGAACAG3’
BRAF DNA 8 R 5’CATGCATGGCTAATTTGTTTT3’
Table 8.3 Primers for identification of the KIAA1549-BRAF fusion breakpoints 
in genomic DNA 
Forward primers (F) and reverse primers (R) are shown. 
 
Gene Primers 
SRGAP3 1 F (exon 1)  5’ATCTGGGGCAGGTTACTGTG3’ 
SRGAP3 2 F (exon 2)  5’GCTGGTGGAGCAGTTCAAAT3’ 
SRGAP3 3 F (exon 5)  5’GCTGAGAAGCAGGAGGAGAA3’ 
SRGAP3 4 F (exon 7)  5’AGTCTTCTGCCCTCCACTCA3’ 
SRGAP3 5 F (exon 10)  5’TGGCAGTAACCTCATCACCA3’ 
SRGAP3 6 F (exon 14/15)   5’AGAGGTGAAGACCCCCTTGT3’ 
SRGAP3 7 F (exon 18)  5’TTGACCATGACAATGGCACT3’ 
SRGAP3 8 F (exon 21)  5’GCGGTTACGATCTGATGGAG3’ 
SRGAP3 9 F (exon 22)  5’CGAGATGATGACCACCTTCA3’ 
RAF1 1 R (exon 10)  5’AAAAGAGCCTGACCCAATCC3’ 
RAF1 2 R (exon 11)  5’GGTTGGGTCGACAACCTTTA3’ 
RAF1 3 R (exon 12)  5’GCCAGGTTGTCCTTTGTCAT3’ 
Table 8.4 Primers for identification of the SRGAP3-RAF1 fusion breakpoints in 
cDNA 
Forward primers (F) and reverse primers (R) are shown. 
 
 
Exon Primers 
KRAS exon 2 F  5’CCTTTATCTGTATCAAAGAATGGTC3’ 
KRAS exon 2 R  5’TTTGTATTAAAAGGTACTGGTGGAG3’ 
KRAS exon 3 F  5’TGCATGGCATTAGCAAAGAC3’ 
KRAS exon 3 R  5’TCTTTGGAGCAGGAACAATG3’  222
NRAS exon 2 F  5’GAACCAAATGGAAGGTCACA3’ 
NRAS exon 2 R  5’TGGGTAAAGATGATCCGACA3’ 
NRAS exon 3 F  5’TGCCCCCTTACCCTCCACA3’ 
NRAS exon 3 R  5’CCTCATTTCCCCATAAAGATTCAGA3’ 
HRAS exon 2 F  5’CAGGAGACCCTGTAGGAGGA3’ 
HRAS exon 2 R  5’CCTATCCTGGCTGTGTCCTG3’ 
HRAS exon 3 F  5’AGAGGCTGGCTGTGTGAACT3’ 
HRAS exon 3 R  5’TCACGGGGTTCACCTGTACT3’ 
BRAF exon 11 F  5’TTTTCTGTTTGGCTTGACTTGA3’ 
BRAF exon 11 R  5’TGTCACAATGTCACCACATTACA3’ 
BRAF exon 15 F  5’TCATAATGCTTGCTCTGATAGGA3’ 
BRAF exon 15 R  5’GGCCAAAAATTTAATCAGTGGA3’ 
 
Table 8.5  DNA sequencing primers for KRAS, NRAS, HRAS and BRAF 
Forward primers (F) and reverse primers (R) are shown. 
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Exon Primers 
CDKN2A exon 1 F  5’GAAAGAGGAGGGGCTGGCTGGTC3’ 
CDKN2A exon 1 R  5’GCGCTACCTGATTCCAATTCCCCTGC3’ 
CDKN2A exon 2 F  5’GGCTCTACACAAGCTTCCTT3’ 
CDKN2A exon 2 R  5’TGAGCTTTGGAAGCTCTCAG3’ 
CDKN2A exon 3 F  5’CAACAGTGTCAGAAACGATGC3’ 
CDKN2A exon 3 R  5’TGTGCCACACATCTTTGACC3’ 
PTEN exon 1 F  5’TTCCATCCTGCAGAAGAAGC3’ 
PTEN exon 1 R  5’ATCCGTCTACTCCCACGTTC3’ 
PTEN exon 2 F  5’TCCAGCTATAGTGGGGAAAAC3’ 
PTEN exon 2 R  5’AAGTCCATTAGGTACGGTAAGCC3’ 
PTEN exon 3 F  5’AAACCCATAGAAGGGGTATTTG3’ 
PTEN exon 3 R  5’AACAATGCTCTTGGACTTCTTG3’ 
PTEN exon 4 F  5’AAAGATTCAGGCAATGTTTGTTAG3’ 
PTEN exon 4 R  5’TGTATCTCACTCGATAATCTGGATG3’ 
PTEN exon 5 F  5’GGAATCCAGTGTTTCTTTTAAATACC3’ 
PTEN exon 5 R  5’TTTTCCAATAAATTCTCAGATCCAG3’ 
PTEN exon 6 F  5’ATGGCTACGACCCAGTTACC3’ 
PTEN exon 6 R  5’CAAATGCTTCAGAAATATAGTCTCC3’ 
PTEN exon 7 F  5’TGCTTGAGATCAAGATTGCAG3’ 
PTEN exon 7 R  5’CTCACCAATGCCAGAGTAAGC3’ 
PTEN exon 8 F  5’CTCAGATTGCCTTATAATAGTCTTTG3’ 
PTEN exon 8 R  5’TCAAGCAAGTTCTTCATCAGC3’ 
PTEN exon 9 F  5’AGCTTGGCAACAGAGCAAG3’ 
PTEN exon 9 R  5’TAAAACGGGAAAGTGCCATC3’ 
IDH1 exon 4 F  5’GAGCTCTATATGCCATCACTGC3’ 
IDH1 exon 4 R  5’CAAGTTGGAAATTTCTGGGC3’ 
IDH2 exon 4-5 F  5’ATTCTGGTTGAAAGATGGCG3’ 
IDH2 exon 4-5 R  5’CAGAAGAAAGGAAAGCCACG3’ 
Table 8.6 DNA sequencing primers for CDKN2A, PTEN, IDH1 and IDH2 
Forward primers (F) and reverse primers (R) are shown. 
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